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Abstract 
Biliverdin Reductase (BVR) functions downstream of Heme Oxygenase 1 (HO-1) in the 
process of heme degradation and catalyses the reduction of biliverdin to bilirubin. For over 
thirty years, BVR was regarded as rather a trivial enzyme whose only known function was to 
aid heme disposal. Over the last decade however, it has become increasingly clear that BVR 
is pleiotropic in function and for example, functions as a dual-specificity protein kinase and 
also as a transcription factor. The bile pigment bilirubin is now known to possess potent 
anti-inflammatory and antioxidant effects, and this finding is underscored clinically by the 
observation that mild hyperbilirubinemia, due to Gilbert’s syndrome, protects patients 
against cardiovascular diseases associated with atherosclerosis. However a number of 
studies have suggested that BVR, aside from its bilirubin generating capacity, is pro-
inflammatory. In the present study, we show that BVR acts in an anti-inflammatory manner 
in the endothelium; by increasing eNOS activation and nitric oxide release, inducing HO-1 
protein expression and by inhibiting TNFα-induced leukocyte-endothelium interaction. 
These highly novel findings give credence to future therapeutic strategies aiming to 
modulate BVR activity in vivo in the fight against chronic inflammatory diseases such as 
atherosclerosis. 
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Introduction 
Inflammation is the complex reaction of the microcirculation to insult or injury, in which 
leukocytes and various serum proteins transcend the endothelium to the extravascular 
space (Lawrence and Gilroy, 2007). Inflammation can be defined as acute or chronic, and it 
is chronic inflammation that drives the pathophysiology of numerous diseases, from 
rheumatoid arthritis to atherosclerosis. Acute inflammation consists of the recruitment of 
circulating leukocytes and, following successful elimination of the stimulus (e.g. infection); 
the response subsides via a process broadly termed as resolution. However chronic non-
resolving inflammation, in which tissue damage occurs, ensues if the initiating stimulus is 
not neutralised (Lawrence and Gilroy, 2007). 
Biliverdin reductase (BVR) is a component of the HO-1/BVR pathway and it catalyses the 
reduction of biliverdin to bilirubin. Over the last decade, it has become increasingly clear 
that BVR is pleiotropic in function, acting for example as a dual specificity kinase and a 
transcription factor. The bile pigments, biliverdin and bilirubin, have potent anti-
inflammatory and antioxidant effects, and their therapeutic potential has been 
demonstrated in a number of in vivo animal models. Furthermore Gilbert’s syndrome 
patients, who experience mild hyperbilirubinemia, are protected from cardiovascular 
diseases such as atherosclerosis (Schwertner et al, 1994). On the other hand, the non-
canonical activities of BVR are largely pro-inflammatory. For example via its dual-specificity 
kinase activity, BVR potentiates TNFα-induced NFκB activation (Kapitulnik and Maines, 
2009). 
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The function of the non-canonical activities of BVR and the interplay of these with its 
established reductase activity in disease processes has not yet been evaluated, not least 
because the pleiotropic functions of the enzyme were realised only very recently. In this 
regard, no published study has yet evaluated the role of this enzyme in atherosclerosis – the 
leading cause of mortality in most developed nations (Beckman et al, 2002). 
 
History of BVR 
The reduction of biliverdin to bilirubin in animal tissues was first described at the start of the 
20th century, at a time when BVR was yet to be identified (Lemberg and Wyndham, 1936). 
Little was known about the oxidation and reduction of bile pigments and even the premise 
that bilirubin arose from the reduction of the primary product of haem breakdown, 
biliverdin, was dubious. Lemberg and Wyndham showed that most guinea pig tissues could 
reduce biliverdin to bilirubin, in a manner which would suggest that biliverdin was in fact 
the primary product of heme breakdown. Although the corresponding enzyme system was 
yet to be identified (i.e. the HO-1-BVR axis), this study provided a basis for Laster and 
Singleton to identify the enzymatic reducing activity responsible for biliverdin reduction 
nearly three decades later (Laster and Singleton, 1965). Laster and Singleton purified the 
enzyme some 15-fold from guinea pig liver homogenate and showed that NADH or NADP 
was in fact required for the biliverdin reduction.  
Further characterisation of BVR was hampered for over a decade until the enzyme was 
eventually purified sufficiently for accurate analyses. Using a partially purified BVR 
preparation from pig spleen, Noguchi et al demonstrated for the first time that the enzyme 
had markedly different pH optima for the NADH- and NADPH-dependent reactions – the 
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reductase activity is NADH-dependent at acidic pH however, NADPH-dependent at basic pH 
(Noguchi et al, 1979). A couple of years later, BVR was purified to homogeneity from rat 
liver cytosol and further characterised – including relevant Km values and pH optima (Kutty 
and Maines, 1981). During this time, BVR was regarded as rather a trivial enzyme whose 
only known physiological function was purported to be the in utero facilitation of foetal-
maternal biliverdin placental transfer via reduction of water-soluble biliverdin to the 
lipophilic, cell-membrane permeable bilirubin (McDonagh et al, 1981). The human form of 
BVR was first purified from liver tissue in 1993 (Maines and Trakshel, 1993) and this allowed 
further characterisation. 
Amongst the first indications that BVR may be pleiotropic was the observation that BVR was 
an evolutionarily conserved protein found in many non-placental organisms from unicellular 
red algae to puffer fish (Beale and Cornejo, 1984). Furthermore it was later shown that 
bilirubin could in fact function as a physiologically relevant antioxidant (Stocker et al, 1987). 
The recently realised pleiotropic nature of BVR is reflected by a growth in the literature 
(Figure 1.1).   
The first published study (Breimer et al, 1995) to link serum bilirubin levels to cardiovascular 
disease showed that low serum bilirubin levels were predictive of increased ischemic heart 
disease (IHD). This relationship was later conclusively clarified in a study that demonstrated 
low prevalence of IHD in Gilbert’s syndrome patients due to increased serum antioxidant 
capacity (Vitek et al, 2002). 
17 
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Structure of BVR 
Human adult BVR is a 296-residue polypeptide (Yamaguchi et al, 1994). There are actually 
two different forms of human BVR with differing molecular weights; BVR-IXα (isozymes I and 
II) and BVR-IXβ (isozymes III and IV). The reason for the two different forms of BVR is due to 
differences in the isoforms of bile pigments present in foetal and adult life. Adult human bile 
is composed of 95-97% bilirubin-IXα and 3-5% bilirubin-IXβ (Yamaguchi et al, 1994). At 20 
weeks of gestation however, foetal bile is composed of approximately 6% bilirubin-IXα and 
Figure 1.1 Interest in BVR doubled from the '90s to the '00s. Number of publications with a 
PubMed ID that contain the phrase ‘biliverdin reductase’ in the title by decade. There have been 4 
such publications in the first 6 months of 2010, and hence a projection of nearly 80 publications by 
the end of the decade is reasonable.    
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87% bilirubin-IXβ. BVR-IXβ does not reduce biliverdin-IXα at all whereas BVR-IXα can reduce 
biliverdin-IXβ to a small extent. BVR-IXα has a molecular weight of 34kDa (296 amino acids) 
whereas BVR-IXβ (206 amino acids) has a molecular weight of 21kDa. Human BVR-IXα is 
encoded by single copy gene with five exons and four introns (Florczyk et al, 2008).  
 
Biliverdin 
Isomer/Cofactor 
BVR Isozyme Km 
BVR-IXβ BVR-IXα 
I II III IV 
Biliverdin-IXα 
(µM) 
- - 1.0 0.8 
Biliverdin-IXβ 
(µM) 
0.3 0.3 50.0 43.0 
NADPH (µM) 35.9 13.1 10.9 34.1 
NADH (mM) 5.6 8.2 7.9 23.4 
 
 
BVR is a monomeric protein and consists of two structural domains (Whitby et al, 2002), the 
N-terminal ‘catalytic domain’ and the C-terminal ‘regulatory domain’, which form a cleft in 
the middle of the protein that constitutes the active site (Figure 1.2).  The N-terminal 
domain consists of an α/β Rossmann-fold (dinucleotide-binding motif) in which six α-helices 
(turquoise) surround a central parallel β-sheet (pink). The C-terminal domain consists of a 
relatively flat parallel β-sheet (orange) which presents polar/charged residues to solvent at 
one side. On the other side, the β-sheet is flanked by six α-helices (green) which form the 
rest of the C-terminal domain. The majority of these helices interact with the N-terminal 
domain and some also contain residues which form the active site cleft. 
Table 1.1 Km values of BVR isozymes for biliverdin substrates and cofactors. 
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The organisational structure of BVR is generally similar to that of the PKC isozymes (Newton, 
2001). The greatest (tertiary) structural similarity however is with the periplasmic, 
homotetrameric enzyme Glucose-Fructose Oxidoreductase (GFOR) from Zymomonas mobilis 
(Kingston et al, 1996). The primary structure of BVR (Figure 1.3) is similar to the primary 
structures of the kinase domains of the Insulin Receptor (IR) and Insulin Receptor Substrate 
(IRS) proteins (Lerner-Marmarosh et al, 2005).  
NADH 
C 
N 
Figure 1.2 (Left) Ribbon diagram of rat BVR with NADH cofactor at the active site. N-terminal 
domain helices and strands are coloured in turquoise and pink respectively whereas C-terminal 
helices and strands are coloured bright green and orange respectively. The NADH cofactor is 
shown in ball-and-stick form (coloured by atom type – Carbon; yellow, Oxygen; red, Nitrogen; 
blue) and is sitting in the active site, interacting with a number of important highly conserved 
residues. (Right) Ribbon diagram showing BVR active site (turquoise) with NADH cofactor 
(bright purple bonds) and biliverdin (dark green bonds) shown in ball-and-stick form (coloured 
by atom type). The adenine part of the cofactor is omitted for clarity. Highly conserved residues in 
sidechains of the BVR protein active site residues are shown with yellow bonds (coloured by 
atom) in ball-and-stick form. Adapted from Whitby et al, 2002.         
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The non-canonical activities of BVR – i.e. its ability to function as a dual specificity kinase 
and also as a leucine zipper (bZip) transcription factor – are primarily conferred by the C-
terminal domain, which contains various consensus signalling motifs consistent with the 
pleiotropic functions of the protein. The N-terminal domain however is primarily involved in 
catalysis. The C-terminal β-sheet is the putative site for protein-protein interactions. This 
contains two Src Homology 2 (SH2)-binding motifs. Indeed, tyrosine residues (Y198MKM and 
Y228LSF) contained in these two SH2-binding motifs are phosphorylation targets of Insulin 
Receptor Kinase (IRK). The β-sheet also contains a C-box and a D-box, F162GFP and 
K275KRILHCLGL respectively, both of which are consensus MAPK docking motifs. The C- and 
D-boxes are sites for ERK interaction and therefore crucial for BVR-mediated ERK activation 
(Lerner-Marmarosh et al, 2008). The C-box has high affinity for kinases in the MAPK 
pathway whilst the D-box has low affinity (Myers et al, 1996). A leucine-rich motif, 
L176VSLFGELSL, is a characteristic of nuclear export signal (NES) and is also found in the C-
terminal β-sheet. BVR also has a nuclear localisation sequence (NLS). Both the NES and NLS 
are involved in the BVR-facilitated transport of ERK and heme to the nucleus (Maines et al, 
2001 and Ahmad et al, 2002).         
The N-terminal G15XGXXG motif is characteristic of protein kinases and ATP-binding domains. 
In BVR, this motif binds NADH/NADP (for reductase activity) and ATP (for kinase activity). 
Adjacent to this motif is a cluster of four valine residues (V4) which are essentially (due to 
the sidechain) hydrophobic and such a motif is generally found in proteins that interact with 
cell membranes. The Ser/Thr kinase consensus motif, G148(T/S)XX(Y/F)XAPQ, is found within 
the bZip motif (Hunter and Cooper, 1985). The bZip motif interacts with DNA, binding to 
7/9-BP AP-1 sites, and is found in stress-activated transcription factors such as c-Jun (Ahmad 
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et al, 2002). Furthermore, BVR contains a structure similar to the conserved Pleckstrin 
Homology (PH) domain (Lerner-Marmarosh et al, 2005). This would suggest a possible 
scaffolding role for BVR. The cysteine-rich sequence (CC-box) located at the C-terminus of 
BVR is involved in Zn2+ binding (Kapitulnik and Maines, 2009).    
 
 
 
 
 
 
Atherosclerosis 
Atherosclerosis is regarded as a chronic inflammatory condition affecting mainly large and 
medium-sized arterial blood vessels. Its downstream complication, cardiovascular disease 
(CVD), represents the leading cause of mortality in most industrialised nations (Beckman et 
al, 2002). As recently as three decades ago, atherosclerosis was widely regarded as a mere 
arterial proliferative disorder, in which passive lipid deposition on the artery wall results in 
atheroma formation (Ross and Glomset, 1976). Recent studies have elucidated the 
molecular processes underlying the pathophysiology of atherosclerosis and in so doing, the 
importance of inflammation in the conception, progression and eventually rupture of 
atherosclerotic plaques has been demonstrated. More recently, inflammatory processes 
Figure 1.3 Primary structure of BVR showing various conserved regulatory and catalytic motifs 
implicated in the canonical and non-canonical activities of BVR. Adapted from Kapitulnik and 
Maines, 2009.    
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have been identified as a link between the numerous risk factors of atherosclerosis and the 
numerous cardiovascular complications associated with the disease (Corrado et al, 2010).  
Atherosclerosis is characterised by the formation and progression of atherosclerotic plaques, 
which consist of lipid regions, calcified regions, necrotic cores and foam cells, all in an 
inflammatory milieu. Atherosclerosis is a progressive condition, and early forms of 
atherosclerotic plaques, termed ‘fatty streaks’, are evident in young children (Mallika et al, 
2007). Fatty streaks progress to form bona fide atherosclerotic plaques, which then 
generally clinically manifest themselves in middle to late adulthood. The appearance of fatty 
streaks – yellow/white sub-endothelial discoloration – reflects the accumulation of foam 
cells, macrophages which have endocytosed oxidised LDL.       
Fatty streaks progress to atherosclerotic plaques as a result of three fundamental driving 
processes; 1, proliferation and consequent accumulation of intimal smooth muscle cells 
(and also accumulation of macrophages and T cells), 2, secretion, by the smooth muscle cell 
population, of connective tissue matrix and 3, accumulation of intracellular lipids (and also 
extracellularly in the connective tissue). The acute perils of atherosclerotic plaques are 
associated with the degree of arterial stenosis, and also thrombogenic potential (Libby et al, 
2010). Inflammation is an essential process that governs the progression of atherosclerosis, 
from initial endothelial dysfunction to plaque rupture and thrombosis (Corrado et al, 2010).       
On a molecular level, the process of atherosclerosis begins with activation of the 
endothelium, in response to cardiovascular risk factors such as hypertension or obesity. This 
is an early, initiating event that is often termed ‘endothelial dysfunction’. The endothelial 
cells then begin to express adhesion molecules (e.g. ICAM-1, VCAM-1 or E-selectin) on their 
apical surfaces which function to recruit specific leukocytes (Figure 1.4). This recruitment is 
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facilitated by the secretion of chemokines into the arterial lumen. Circulating monocytes are 
the most abundant of the infiltrating leukocytes that populate the forming plaque. Indeed, 
there are two distinct populations of circulating monocytes; Gr1+/Ly6Chigh monocytes and 
Gr1-/Ly6Clow (Woollard and Geissmann, 2010). The monocytes are recruited into the intima 
and sub-intima and, via their scavenger receptors, they internalise oxidised LDL (ox-LDL). 
The monocytes are then activated (to macrophages) and they begin to accumulate. 
Macrophages progressively become foam cells, characterised by a microscopic ‘frothy’ 
appearance due to intracellular accumulation of lipids in cytoplasmic vesicles. This results in 
the formation of ‘fatty streaks’, which progressively develop to form atherosclerotic plaques 
(Libby et al, 2010). 
Ox-LDL has a key role in both the initiation and progression of atherosclerosis. The ox-LDL 
hypothesis of atherosclerosis, in which LDL penetrates the arterial endothelial wall, is 
oxidised, and promotes the formation of lipid-rich foam cells, was originally proposed by 
Steinberg over twenty years ago (Steinberg, 1989). Macrophages and vascular smooth 
muscle cells (VSMCs) are primarily responsible for producing the reactive oxygen species 
(ROS) that oxidise the LDL (Antoniades et al, 2007). 
It is now known that macrophages express several scavenger receptors, responsible for ox-
LDL uptake. A seminal study by Sawamura et al also identified the first endothelial ox-LDL 
receptor, LOX-1 (Sawamura et al, 1997). Ox-LDL is cytotoxic to the vascular endothelium and 
therefore contributes to endothelial dysfunction (Balla et al, 1991). 
The atherosclerotic plaque further develops via accumulation of inflammatory cells and 
extracellular lipid. Arterial stenosis arises because cells in the developing plaque secrete 
cytokines (e.g. TNFα), chemokines (e.g. MCP-1), growth factors, and smooth muscle cells 
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secrete extracellular matrix. This causes smooth muscle cell proliferation and further 
recruitment of inflammatory cells. The central core of the atherosclerotic plaque becomes 
necrotic and consequently, pro-angiogenic mediators are released which leads to 
neovascularisation. The secretion of enzymes that degrade the extracellular matrix, such as 
matrix metalloproteinases (MMPs), may eventually cause plaque rupture. The plaque 
contains pro-thrombotic material and the ensuing thrombus may occlude the lumen of the 
artery, resulting in for example myocardial infarction (Libby et al, 2010). 
 
 
 
 
 
 
 
 
Figure 1.4 Role of monocyte-endothelial interactions in atherosclerosis. Endothelial dysfunction, 
due to smoking, diabetes, etc, results in the activation of endothelial cells. Hence, the endothelial 
cells begin to express adhesion molecules which function to recruit inflammatory cells. Monocytes 
migrate into the intima and this process is driven, at least in part, by the chemokine monocyte 
chemotactic protein-1 (MCP-1). Monocytes differentiate into macrophages, which express 
scavenger receptors. This differentiation may be driven by the cytokine macrophage-colony 
stimulating factor (M-CSF). The macrophages become engorged with lipids thus becoming foam 
cells. The foam cells contribute to the inflammatory process but eventually undergo apoptosis. 
Taken from Libby et al, 2010.      
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HO-1/BVR Axis in Atherosclerosis 
Heme Oxygenase (HO) is the rate-limiting enzyme in the degradation of heme, producing 
the bile pigment biliverdin, carbon monoxide (CO) and iron (Fe2+) in an NADPH-dependent 
manner (Figure 1.5). There are three known isoforms of HO, HO-1, HO-2 and the 
catalytically-inactive HO-3. HO-1 is inducible and responds to stress whereas HO-2 is 
constitutively active. Biliverdin is reduced to bilirubin by the functionally pleiotropic BVR. 
HO-1 is a key vasoprotective mediator and this is largely thought to be conferred by the 
three end-products of the HO-1/BVR axis; CO and the two bile pigments, biliverdin and 
bilirubin. These molecules exhibit anti-inflammatory, antioxidant, anti-mutagenic and anti-
apoptotic effects (Ollinger et al, 2007). The significance of these properties, in terms of CVD, 
is reflected in individuals with Gilbert’s syndrome.  
 
 
 
Figure 1.5 The HO-1/BVR axis. HO degrades free heme in an NADPH-dependent manner, yielding 
CO, Fe2+ and biliverdin. Fe2+, which is cytotoxic, is stored by ferritin. Biliverdin reductase reduces 
biliverdin to bilirubin in an NADPH-dependent manner. Taken from Morita, 2005. 
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Induction of the HO-1/BVR axis with pharmacological mediators and gene delivery 
approaches is therefore likely to be beneficial in atherosclerosis. Numerous studies have 
already evaluated the therapeutic potential of administration of the three end-products of 
the HO-1/BVR axis, in animal models of inflammatory diseases.  
HO-1 degrades heme and this is beneficial, in terms of atherosclerosis, per se. This is 
because heme is both pro-oxidant and cytotoxic, and can catalyse protein peroxidation. 
Jeney et al showed that heme can catalyse LDL oxidation (Jeney et al, 2002). Endothelial 
cells upregulate HO-1 in response to ox-LDL, suggesting that the HO-1/BVR axis is a defence-
mechanism against ox-LDL. Heme also induces the expression of ICAM-1, VCAM-1 and E-
selectin adhesion molecules in endothelial cells (Wagener et al, 1997).  
A study by Nakayama et al showed that HO-1 mRNA and protein is increased in endothelial 
and foam cells, from atherosclerotic plaques, in hypercholesterolemic rabbits (Nakayama et 
al, 2001). Bilirubin was also found to be accumulated in foam cells. Several in vivo studies 
have shown that inhibition of endogenous HO-1 activity, with metalloporphyrins (i.e. tin 
protoporphyrin), exacerbates atherosclerotic lesion formation. For example, Ishikawa et al 
showed that the number of atherosclerotic lesions in HO-1-inhibited hyperlipidemic rabbits 
was elevated compared to controls (Ishikawa et al, 2001). Togane et al showed that 
endothelial denudation resulted in upregulation of HO-1 in a rat model of balloon injury. 
Importantly, HO-1 inhibition in this system promoted neointimal formation whereas a HO-1 
inducer (hemin) had the opposite effect (Togane et al, 2000). 
In summary, hundreds of studies have examined the effect and/or therapeutic potential of 
HO-1 activity modulation, or CO/biliverdin/bilirubin administration, in vivo, in regard to 
atherosclerosis. However, no study has focussed on elucidating the role of BVR specifically 
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in atherosclerosis or other inflammatory conditions and, given the recent realisation of the 
pleiotropic functions of the reductase, this represents an evidence chasm. 
 
Gilbert’s Syndrome 
Gilbert’s syndrome patients are generally asymptomatic and have moderately elevated 
levels of bilirubin, and this confers protection against CVD (Schwertner et al, 1994). The 
syndrome was first clinically described over a century ago by the French gastroenterologist 
Gilbert and his co-worker Lereboullet in 1901. It is characterised by mild unconjugated 
hyperbilirubinemia, not overtly secondary to hemolysis and without hepatic disease (i.e. 
inflammation, fibrosis, etc). Diagnostic criteria for Gilbert’s syndrome include a consistent 
mild elevation of serum bilirubin levels (i.e. 17-102µM or 1-6mg/dL). This elevation in 
bilirubin levels is attributable to an increase in unconjugated bilirubin levels only – 
conjugated bilirubin levels remain within normal limits (i.e. <20% of the total bilirubin). On 
this basis, 3-10% of the general population are thought to have Gilbert’s syndrome with 
men more frequently affected than women (12.4% vs. 4.8% respectively). The mean 
bilirubin concentration is also significantly higher in males than in females (Olsson et al, 
1988). 
The pathogenesis of Gilbert’s syndrome is explained by the approximately 70% reduced 
hepatic glucuronidating activity in such patients (Bosma et al, 1995). Hepatic bilirubin 
conjugation with a polar group – i.e. UDP-glucuronic acid – is essential for the biliary 
excretion of bilirubin because this renders bilirubin water-soluble, which allows it to form 
bile and exit into the duodenum. UDP-glucuronic acid is a ubiquitous intracellular molecule 
is derived from glucose metabolism. Bilirubin conjugation is mediated by the bilirubin 
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uridine diphosphoglucuronate-glucuronosyltransferase 1 (UGT1A1) which, in common with 
other glucuronosyltransferases, is a membrane-bound enzyme found mainly in the smooth 
endoplasmic reticulum. Bosma et al first discovered that the reduced expression of UGT1A1 
in Gilbert’s syndrome patients is accounted for by abnormalities in the promoter region of 
the corresponding gene whereas the coding region of the gene is normal (Figure 1.6). 
Gilbert’s syndrome patients were found to be homozygous for two extra bases in the 5’ 
promoter ‘TATA’ box – [A(TA)7TAA+ in Gilbert’s syndrome patients vs. *A(TA)6TAA] in normal 
subjects – and this abnormal allele had a frequency of 40% amongst normal subjects 
suggesting incomplete penetrance and other precipitating genetic/environmental factors 
(Bosma et al, 1995). The two extra bases substantially reduce the transcriptional activity of 
the promoter. The allele polymorphism with the extra ‘TA’ repeat is also referred to as 
UGT1A1*28. 
This longer ‘TATA’ box – i.e. [A(TA)7TAA] – is almost exclusively associated with Gilbert’s 
syndrome in Caucasians. Other variants – [A(TA)5TAA] and [A(TA)8TAA] – are found 
predominantly in the black population and are also associated with Gilbert’s syndrome 
(Lolascon et al, 1999). 
 
 
 
 
Figure 1.6 Organisation of the UGT1A1 gene. The first exon is variable depending on the isoform 
of the enzyme whereas exons 2-5 remain the same. Solid lines between exons indicate introns. 
Indeed over 100 UGT1A1 variants have been detected (e.g. due to alternative splicing) thus 
leading to a range of serum bilirubin concentrations from low serum bilirubin to life-threatening 
jaundice. Adapted from Radu and Atsmon, 2001.      
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The inverse relationship between serum bilirubin levels and risk of coronary artery disease 
(CAD) was first suggested in 1994 (Schwertner et al, 1994), with the strength of correlation 
being similar to that of low HDL cholesterol levels or high systolic blood pressure. Several 
years later, a prospective study by Vitek et al found that Gilbert’s syndrome patients had an 
approximately six-fold lower risk of developing ischemic heart disease (IHD) compared to 
the general population – prevalence of IHD was 2% in Gilbert’s syndrome patients vs. 12.1% 
in the general population. This study incorporated a small number of females and also older 
(i.e. >40yrs) subjects (Vitek et al, 2002). Importantly, the total serum bilirubin levels were 
found to correlate with total serum antioxidant status, suggesting a likely mechanism of 
action of bilirubin.  
More recently, a retrospective study by Lin et al examined the relationship between the 
UGT1A1*28 allele and three physician-verified cardiovascular endpoints, namely coronary 
heart disease (CHD) (i.e. angina pectoris or coronary insufficiency), CVD (i.e. CHD or death 
thereof, stroke, congestive heart failure, transient ischemic attack or intermittent 
claudication) or MI. Subjects homozygous for the UGT1A1*28 allele had only a 36% and 30% 
risk of CVD and CHD respectively relative to those heterozygous for the UGT1A1*28 allele, 
or to those subjects not in possession of this allele. However, the UGT1A1*28 allele was not 
found to be significantly associated with lower risk of MI. Furthermore, low serum bilirubin 
levels were significantly associated with higher risk of CHD, CVD and MI (Lin et al, 2006).  
In summary, Gilbert’s syndrome affects a large number of the global population (some 5%) 
and this confers protection against CVD. Gilbert’s syndrome arises due to homozygous 
abnormalities in the promoter region of UGT1A1, the enzyme responsible for conjugation 
(and hence clearance) of bilirubin (Figure 1.7). Circulating unconjugated bilirubin levels 
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therefore rise and the protection against CVD may be conferred by increased serum 
antioxidant capacity (Vitek et al, 2002). Recent meta-analyses have confirmed this inverse 
relationship between serum bilirubin and CVD (Schwertner and Vitek, 2008). 
 
 
 
 
 
Bile Pigments 
The bile pigments, biliverdin and bilirubin, are derived primarily from the degradation of 
heme via the heme-bilirubin catabolic pathway. Although both pigments share a common 
porphyrin structure, the pigments have markedly different three-dimensional structures 
(Figure 1.8).  
Historically, both biliverdin and bilirubin were regarded as toxic metabolites with no 
biological function. Recently however, much attention has focussed on the role of these bile 
pigments, particularly bilirubin, in CVD. It has become clear that whilst heme is a pro-
Figure 1.7 Bilirubin conjugation in a liver cell and excretion into the bile duct. Adapted from Radu 
and Atsmon, 2001.   
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oxidative and pro-atherosclerotic molecule, its degradation results in the production of 
biliverdin and bilirubin both of which have anti-atherosclerotic properties.  
It has also been recently found that bile pigments confer regulation of numerous cell 
signalling systems resulting in antioxidant (Stocker et al, 1987), anti-inflammatory (Qin, 
2002), anti-apoptotic (Dudnik et al, 2001), anti-complement (Nakagami et al, 1993), anti-
mutagenic (Tang and Edenharder, 1997), anti-viral (Mori et al, 1991) and anti-proliferative 
(Tell and Gustincich, 2009) effects.  
Both biliverdin and bilirubin possess anti-nitrosative characteristics and have antioxidant 
activity towards peroxynitrite (Kaur et al, 2003); an oxidant derived from the reaction 
between free radical superoxide and free radical nitric oxide.  
Once bilirubin has been formed, it binds serum albumin in the systemic circulation and is 
then delivered to the liver where it is both actively and passively absorbed into hepatocytes 
across the sinusoidal membrane (after albumin has dissociated). Once inside the hepatocyte, 
bilirubin binds to ligandin and Z protein in the cytosol and is carried to the endoplasmic 
reticulum where it is conjugated by UGT1A1 (Kamisako et al, 2000). The catalytic site of 
UGT1A1 is on the lumen side of the endoplasmic reticulum and hence both UDP-glucuronic 
acid and bilirubin must be transported into the lumen. This is thought to occur via a carrier-
mediated and protein-mediated mechanism respectively. Conjugation renders bilirubin 
hydrophilic and allows it to be transported across the canalicular membrane by multidrug 
resistance protein 2 (MRP2). The bile duct directs the bilirubin conjugates into the 
duodenum and as these enter the gastrointestinal tract, bacterial enzymes hydrolyse the 
bilirubin esters to form unconjugated pigment (Kamisako et al, 2000). Approximately 300mg 
of bile pigment is excreted from the human body everyday (Stocker, 2004). 
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Biliverdin in Inflammation 
In recent years, both biliverdin and CO have been the focus of numerous studies seeking to 
elucidate the mechanism of the protective effects of HO-1 in various disease models. 
Several studies have also shown that biliverdin can in fact modulate various intracellular 
Figure 1.8 Two-dimensional (above) and three-dimensional (below) structures of biliverdin (2) 
and bilirubin (1). Nitrogen atoms are coloured blue whilst oxygen atoms are coloured red. 
Adapted from Bulmer et al, 2008. 
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signalling pathways. Investigators have also demonstrated the therapeutic benefit of 
biliverdin administration in animal models of inflammatory diseases.    
Biliverdin has been shown to inhibit the following cell signalling molecules/pathways: (PKCs), 
NFκB, the JNK-SAPK-AP-1 signalling pathway, serum-induced smooth muscle cell 
proliferation via MAPK, and retinoblastoma (Kapitulnik and Maines, 2009). Inhibition of 
these pathways confers anti-inflammatory and anti-proliferative effects. Moreover, 
biliverdin is a feedback inhibitor of BVR (Kutty and Maines, 1981).  
Plasma concentrations of biliverdin can reach as high as 40µM in patients with obstructive 
jaundice (Tickner and Gutteridge, 1978) however, during normal heme metabolism; 
biliverdin is present only in trace amounts. Biliverdin is rapidly reduced by BVR in most 
mammalian tissues and hence some of the effects of biliverdin administration arise due to 
increased bilirubin formation (Deguchi et al, 2008). This is an important consideration when 
interpreting studies in which biliverdin is administered to animal models, and some effect is 
observed over a given period of time. As serum biliverdin enters cells, it is rapidly converted 
to bilirubin by BVR and hence, some (if not all) of the effects of biliverdin administration are 
likely due to increased intracellular bilirubin, as opposed to elevated serum biliverdin or 
bilirubin (Figure 1.9).    
Numerous studies have examined the therapeutic potential of biliverdin (or bilirubin) 
administration in animal models of transplantation. Biliverdin has been specifically 
demonstrated to increase function of liver (Fondevila et al, 2004), lung (Wang et al, 2010), 
intestinal (Nakao et al, 2004) and heart transplants (Yamashita et al, 2004) in animal models, 
via its anti-inflammatory and anti-oxidant capacities. In addition to transplantation however, 
biliverdin has been shown to have therapeutic potential in animal models of cerebral 
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infarction (Deguchi et al, 2008) and also acute lung injury (Nakao et al, 2005). A selection of 
such studies are briefly discussed and summarised below.    
 
 
 
 
 
 
The first study to examine the potential benefit of biliverdin administration in an 
inflammatory context examined the effect of the bile pigment in a hepatic 
ischemia/reperfusion injury (IRI) rat model (Fondevila et al, 2003). Rat livers reperfused with 
Figure 1.9 In vivo (rat) total serum bilirubin levels following intraperitoneal (IP) administration 
of biliverdin-IXα (BV). Serum bilirubin rises dose-dependently and peaks very quickly after 
approximately 30mins before returning to control levels after 3hrs. Taken from Deguchi et al, 
2008.       
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biliverdin-containing perfusate showed significantly higher liver function, as assessed by 
liver enzyme release (i.e. glutamic-oxaloacetic transaminase and glutamic-pyruvic 
transaminase) and histological assessment. Biliverdin-perfused livers also showed greater 
portal vein blood flow and produced more bile. 
Biliverdin administration was subsequently shown to prolong cardiac allograft survival in 
mice via attenuation of alloimmune responses (Yamashita et al, 2004). Biliverdin 
administration (50µmol/kg) almost doubled cardiac graft survival in a major 
histocompatability complex (MHC) class I and class II mismatched transplant model. 
Moreover, this tolerance was donor-specific such that mice accepted a second graft from 
the same donor strain but did not accept a second graft from a third-party donor (in the 
presence of biliverdin). Immunohistochemical analyses showed that biliverdin treatment 
reduced leukocyte infiltration and also inhibited T cell proliferation. Most importantly 
perhaps, this study suggested that at least some of the anti-inflammatory effects of 
biliverdin are related to its ability to inhibit the activation of specific transcription factors, 
namely NFAT and NFκB, as shown by the suppression of nuclear factor-DNA binding in an 
electrophoretic mobility shift assay.  
Another study examined the therapeutic potential of biliverdin administration in syngeneic 
transplants (Nakao et al, 2004) in rats. Biliverdin was shown to increase recipient survival 
following transplant of syngeneic small intestine. Biliverdin treatment also increased 
expression of biliverdin reductase by a small degree in muscularis externa tissue in non-
operated controls. Furthermore, biliverdin exerted its effects via its ant-inflammatory 
capacity – specifically via attenuation of expression of pro-inflammatory NFκB promoter-
driven genes such as ICAM-1 and iNOS. Most importantly however, biliverdin treatment was 
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shown to increase NFκB DNA binding and, pharmacological inhibition of NFκB activity 
resulted in the loss of the ability of biliverdin treatment to prevent graft permeability after 
transplantation. This increased NFκB-DNA binding was shown to be present prior to 
transplantation. 
A more recent study examined the effect of biliverdin treatment in lung graft transplants in 
rats (Wang et al, 2010). Biliverdin was administered intraperitoneally to both brain dead 
donors and recipients after confirmation of brain death and transplantation. Biliverdin 
treatment exerted a number of effects including reduction of the following pro-
inflammatory parameters; wet/dry ratio of lung graft, myeloperoxidase (involved in 
oxidative stress) activity in lung graft and TNFα levels in serum. As one might expect, 
biliverdin also had an anti-oxidative effect – it reduced malanodialdehyde (a reactive species 
involved in oxidative stress) levels in lung graft and increased protein expression of 
superoxide dismutase (an antioxidant enzyme) in lung graft. Histologically, biliverdin 
treatment improved a variety of parameters in lung graft including, leukocyte infiltration. 
Brain death resulted in an increase in protein levels of HO-1, BVR and NFκB in lung graft. In 
the biliverdin treatment group, HO-1 and NFκB expression were reduced whilst BVR 
expression was increased. 
A study examined the effect of biliverdin treatment on NFκB-DNA binding in HEK293 cells 
(Gibbs and Maines, 2007). Biliverdin was shown to suppress the transcriptional activity of 
the nuclear factor in a time- and concentration dependent manner in an electrophoretic 
mobility shift assay, in response to TNFα stimulation. The authors offer two possible 
explanations for this observation – that biliverdin interacts and therefore inhibits NFκB 
directly or, more likely, that biliverdin indirectly exerts an indirect inhibitory effect on NFκB. 
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The latter theory is supported by evidence that biliverdin alters activities of protein kinases 
– i.e. inhibits activity of PKCs (Maines, 2005) – and this may suppress intracellular signalling 
events associated with NFκB activation. Specifically, it has been suggested that biliverdin 
may cause IκB kinase (IKK) inhibition, thus resulting in the inhibition of IκBα degradation and 
sequestration of NFκB in the cytoplasm (Gibbs and Maines, 2007). There is a clear 
discrepancy between this study which reports a decrease in NFκB-DNA activity upon 
biliverdin treatment and the aforementioned studies (Nakao et al, 2004 and Yamashita et al, 
2004) which showed an increase in NFκB-DNA binding. These discrepancies may be 
explained by the different time points, concentrations of biliverdin utilised, cell types, etc. 
The issue is further complicated by the ‘Janus nature’ of NFκB. 
A recent seminal study demonstrated a novel mechanism in which BVR can in fact, at least 
in part, account for some of the anti-inflammatory effects of biliverdin (Wegiel et al, 2009). 
The authors show that functional (i.e. biliverdin-reducing) BVR is expressed on the cell-
surface of RAW 264.7 cells (mouse macrophage cell line). Biliverdin binding to cell-surface 
BVR induces interaction of the BVR with the p85α regulatory subunit of PI3K, and BVR is 
itself phosphorylated on tyrosine residues. This results in downstream Akt phosphorylation 
and activation. The authors show that Akt activation is associated with expression of the 
anti-inflammatory interleukin-10 cytokine and that biliverdin treatment therefore leads to 
interleukin-10 production via the biliverdin-BVRcell-surface-PI3K-Akt pathway in macrophages. 
This mechanism is shown to protect against LPS-induced liver injury (i.e. alanine 
aminotransferase release) in vivo in mice. Importantly, the protective action of biliverdin is 
lost when BVR is knocked down with Ad-siRNA. 
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Although the relationship between hyperbilirubinemia (i.e. due to Gilbert’s syndrome) and 
CVD has now been well established, the potential benefit of hyperbilirubinemia in 
protection against various vascular complications (e.g. due to diabetes) requires further 
investigation. Indeed it has been shown that patients suffering from both diabetes and 
Gilbert’s syndrome have reduced diabetic vascular complications compared to patients 
without hyperbilirubinemia (Inoguchi et al, 2007). Based on these findings, Fujii et al 
examined the effect of biliverdin administration on the severity of diabetic nephropathy in a 
rodent model of type II diabetes – i.e. diabetic db/db mice (Fujii et al, 2010). Uniquely, 
biliverdin was administered orally for a fortnight or more and did not give rise to 
substantively elevated serum bilirubin levels. Importantly, twelve weeks of biliverdin 
treatment reduced mRNA levels of NADPH oxidase 4 (NOX4) in both kidney and glomeruli 
tissue in db/db mice. Indeed, NOX4 is highly expressed in renal tissue and expression is 
elevated in the diabetic kidney (Gorin et al, 2005). NOX4 is a major source of superoxide in 
the kidney. Unsurprisingly therefore, superoxide generation is also reduced by biliverdin 
treatment in db/db mice. This study therefore shows that biliverdin has therapeutic 
potential in the treatment of diabetic nephropathy, partly due to its effects on the 
attenuation of oxidative stress generated via NOX4. 
In summary, biliverdin posseses anti-oxidant, anti-inflammatory, anti-mutagenic, anti-
proliferative and anti-apoptotic properties. Hence, biliverdin is now recognised as a 
potential therapeutic option for the treatment of numerous chronic inflammatory diseases, 
including atherosclerosis (Ollinger et al, 2007). Further animal studies are required however 
before biliverdin can be administered to humans. Biliverdin has also been shown to be able 
to modulate various cell signalling pathways – most relevantly, it can inhibit NFκB activation 
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and also inhibit PKCs. Indeed biliverdin is as effective as a commercially available peptide in 
inhibiting PKC isozymes (Maines, 2005). Whether biliverdin binds to and inhibits NFκB 
directly, or whether biliverdin exerts its inhibitory effect on NFκB by interfering with its 
transduction signals (e.g. via conventional PKC inhibition) is unclear (Gibbs and Maines, 
2007). Biliverdin, in contrast to bilirubin, can also inhibit BVR promoter activity (Gibbs et al, 
2010). Although biliverdin is often investigated in in vivo disease models, it must be 
remembered that its effects may in fact arise due to elevated intracellular bilirubin levels. 
 
Bilirubin in Inflammation 
In common with both the bile pigment from which it is formed and the enzyme which 
catalyses this reaction, bilirubin possesses recently discovered pleiotropic activities. In this 
regard, bilirubin can function in anti-oxidant, anti-inflammatory, anti-apoptotic and anti-
mutagenic capacities, in addition to affecting cell signalling. Interestingly, bilirubin has 
widespread inhibitory effects on protein phosphorylation (Hansen et al, 1996) and this may, 
at least in part, explain some of the non-canonical activities of the pigment.   
Bilirubin has been known to inhibit leukocyte adhesion and rolling to endothelium for over a 
decade. Indeed, an early study showed that bilirubin could inhibit monocyte transmigration 
through human aortic endothelium, in response to mildly oxidised LDL (Ishikawa et al, 1997). 
Prior to this discovery, studies had established that pharmacological HO-1 induction could 
suppress acute inflammation in a variety of systems, including for example LPS-induced 
endotoxemia in rats (Otterbein et al, 1997). This prompted Hayashi et al to elucidate the 
specific downstream mechanism by which HO-1 induction suppressed leukocyte adhesion 
(Hayashi et al, 1999). It was found that exogenously applied bilirubin could dose-
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dependently inhibit both leukocyte rolling and adhesion, as elicited by H2O2 in mesenteric 
venules, in an in vivo intravital assay. Indeed, just 5µM of bilirubin was sufficient to 
attenuate the H2O2-induced adhesion.       
Subsequent studies have found that bilirubin downregulates adhesion molecules. 
Kawamura et al found that bilirubin attenuates TNFα-induced VCAM-1 production in human 
aortic endothelial cells – as evidenced by an ELISA for the soluble VCAM-1 ectodomain 
released into the conditioned medium (Kawamura et al, 2005). Another study showed that 
bilirubin could suppress VCAM-1-associated ROS generation (Keshavan et al, 2005). Low-
level ROS generation by NADPH oxidase is induced upon binding of α4β1 integrin to 
endothelial VCAM-1, and this has the effect of increasing the activities of MMP-2 and -9. In 
turn, the MMPs degrade intercellular tight junctions and therefore facilitate leukocyte 
transmigration. In this regard, bilirubin was also shown to inhibit the activities of MMP-2 
and MMP-9 in murine endothelial cells, downstream of VCAM-1 activation by an anti-
VCAM-1 antibody (Keshavan et al, 2005).  
A recent in vivo study also demonstrated that bilirubin can protect against LPS-induced lung 
injury in rats, at least in part via its ability to inhibit LPS-induced leukocyte-endothelium 
interactions (Kadl et al, 2007). Hence, histological analyses revealed that bilirubin treatment 
suppressed LPS-induced expression of endothelial ICAM-1 and VCAM-1. In addition to this, 
bilirubin treatment could suppress LPS-induced release of TNFα by various cell types, 
including endothelial cells and human PBMCs, in cell culture experiments. 
The mechanism by which bilirubin exerts its anti-inflammatory effects was examined in two 
different studies by Mazzone et al (Mazzone et al, 2009 and Mazzone et al, 2009). The first 
study corroborated previous findings – that bilirubin could attenuate expression of cell-
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surface adhesion molecules (i.e. ICAM-1, VCAM-1 and E-selectin) in response to 
inflammatory cytokines (i.e. TNFα) in endothelial cells. Moreover, this correlated with 
functional analyses showing that bilirubin could inhibit human polymorphonuclear 
leukocyte adherence to TNFα-activated HUVECs.  
In their subsequent study, the authors showed that bilirubin exerted its effects on adhesion 
molecule expression via inhibition of the NFκB signalling pathway (Mazzone et al, 2009). The 
authors showed that bilirubin (30nM) attenuates nuclear translocation of the NFκB p65 
subunit in H5V (murine endothelial) cells. Furthermore, application of an NFκB activation 
inhibitor – pyrridoline dithiocarbamate – additively inhibited the mRNA expression of E-
selectin and VCAM-1 with bilirubin, in response to TNFα stimulation. However, this 
particular aspect of methodology could have been improved by measuring cell-surface 
protein expression of adhesion molecules, as opposed to mRNA levels. 
Another study however, has shown that bilirubin can inhibit NFκB activation in CD4+ T cells 
(Liu et al, 2008). Furthermore, bilirubin was shown to directly inhibit the binding of NFκB to 
DNA in an electrophoretic mobility shift assay (EMSA). Importantly, bilirubin suppressed IκB 
phosphorylation and this is a potential mechanism of inhibition of NFκB activation. 
Interestingly, BVR has completely the opposite effect on NFκB activation (Gibbs and Maines, 
2007). 
Bilirubin is also a potent inhibitor of PKCs (Sano et al, 1985). Importantly, PKCζ is absolutely 
necessary for TNFα-induced NFκB signalling in endothelial cells (Nigro et al, 2010). BVR on 
the other hand activates PKCζ, thus potentiating TNFα-induced NFκB signalling (Lerner-
Marmarosh et al, 2007).  
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In summary, bilirubin has been shown to exert potent anti-inflammatory effects in various 
animal models. Mazzone et al have demonstrated that, in endothelial cells, bilirubin 
downregualtes TNFα-induced adhesion molecule expression via inhibition of NFκB activation 
(Mazzone et al, 2009). Bilirubin is also a potent inhibitor of PKCs (Sano et al, 1985)) and this 
may contribute to the pigment’s anti-inflammatroy properties. BVR has the opposite effect 
on NFκB and PKCs as compared to bilirubin – it activates NFκB (Gibbs and Maines, 2007) and 
PKCζ (Lerner-Marmarosh et al, 2007).  
 
Bilirubin as an Antioxidant 
Reactive oxygen species (ROS) have a key role in the process of atherosclerosis and for 
example, induce macrophage infiltration and inactivate nitric oxide. Bilirubin also has 
indirect antioxidant abilities – i.e. independent of its scavenging activity against reactive 
oxygen and nitrogen species. Of the enzymatic pathways responsible for generating ROS, 
NADPH oxidase, which produces superoxide, is the most important in the vasculature. 
Bilirubin can downregulate NADPH oxidase (Kwak et al, 1991), and in addition to this can 
also inhibit iNOS expression (Lanone et al, 2005). iNOS is associated with several 
inflammatory diseases including atherosclerosis (Kroncke et al, 1998).  
A seminal study by Baranano et al showed that 10nM of bilirubin could protect HeLa cells 
against 10,000-fold molar excesses of H2O2 (Baranano et al, 2002). Novelly, knockdown of 
BVR with siRNA in HeLa cells increased ROS levels and also increased sensitivity to oxidative 
stress. This led the authors to propose a biliverdin-bilirubin antioxidant redox cycle in which 
the linear terapyrrole bile pigment is kept in its reduced (bilirubin) form by BVR. In the 
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putative cycle, bilirubin reduces ROS, itself being specifically oxidised back to biliverdin, 
which is then subsequently reduced back to bilirubin by BVR (Figure 1.10). This model, in 
which bilirubin is recycled in an NADPH-dependent manner, was suggested to explain the 
discrepancy between the antioxidant capacity, and the relatively scarce intracellular 
concentrations of, bilirubin as compared to other established antioxidants. Indeed in 
comparison to glutathione, bilirubin has an intracellular concentration of <0.1% (Baranano 
et al, 2002). 
Sedlak et al have demonstrated that bilirubin is primarily involved in cytoprotection against 
lipid peroxidation (Sedlak et al, 2009). The authors show that knockdown of BVR with siRNA 
in HEK293 cells preferentially increases H2O2-mediated lipid oxidation, as opposed to 
protein oxidation. However, it is suggested that bilirubin may protect against protein 
oxidation in hydrophobic environments (i.e. membrane proteins).      
Although it is well accepted that both biliverdin and CO can function protectively 
downstream of HO, by for example acting as anti-inflammatory compounds, few studies 
have examined to what extent, if any, BVR is required for cellular protection following HO-1 
induction. A recent study examined whether conversion of biliverdin to bilirubin was 
necessary to elicit the protective effects of HO-1 induction (Jansen et al, 2010). It was shown 
that bilirubin is a more potent anti-oxidant than biliverdin, in terms of superoxide 
scavenging ability and also protection against peroxynitrite-mediated protein tyrosine 
nitration, in an in vitro system. BVR knockdown in HUVECs with siRNA resulted in an 
increase in intracellular oxidative stress under basal conditions (as evidenced by 
dihydroethidium staining which specifically detects superoxide). Furthermore, HO-1 and 
BVR knockdown increased protein tyrosine nitration (an indicator of intracellular oxidative 
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stress) by the same amount. The protective effect of hemin on protein tyrosine nitration 
was lost in both HO-1 and BVR silenced cells whereas the protective effect of biliverdin was 
lost only in BVR silenced cells. Bilirubin was also shown to increase the expression of GTP-
cyclohyrolase-1 (GCH-1) in EA.hy 926 (human endothelial) cells. GCH-1 is the rate-limiting 
enzyme in tetrahydrobiopterin (BH4) synthesis, and BH4 prevents eNOS uncoupling and 
subsequent ROS generation (Jansen et al, 2010). These findings indicate an important role 
for BVR in conferring the antioxidant activities of HO-1. 
The existence of any physiologically meaningful biliverdin-bilirubin redox amplification cycle 
is however an ongoing issue of contention (Sedlak and Snyder, 2009). Maghzal et al 
conducted a recent study, the results of which contradict the existence of a biliverdin-
bilirubin redox antioxidant cycle (Maghzal et al, 2009). In contrast to previous studies, the 
authors showed that BVR overexpression in HeLa cells does not affect cell viability in the 
presence of H2O2. In mutant yeast cells which are completely deficient of endogenous heme 
oxygenase and BVR activity, BVR overexpression fails to protect against H2O2-induced cell 
death. Moreover, overexpression of the reductase in HeLa cells does not decrease H2O2-
induced ROS and also, H2O2-mediated bilirubin oxidation yields relatively small amounts of 
biliverdin. However, the central premise of the biliverdin-bilirubin redox cycle is that 
bilirubin oxidation specifically results in the formation of biliverdin. Indeed, Maghzal et al 
argue that biliverdin formation (following oxidant-mediated bilirubin oxidation) is the 
limiting factor in the proposed scheme, preventing the redox cycle from regenerating 
meaningful concentrations of bilirubin. 
Recent in vitro experiments also argue against the putative biliverdin-bilirubin redox 
amplification cycle (Jansen et al, 2010). In this study, HPLC analyses detected no significant 
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conversion of bilirubin to biliverdin by a variety of oxidants, including H2O2. This is in 
agreement with the notion that biliverdin formation is in fact the limiting factor in the 
putative cycle.           
 
 
 
 
 
 
Although further elucidation is required as to the (patho-)physiological relevance of any 
biliverdin-bilirubin cycle, it may be the case that oxidation of intracellular bilirubin does not 
specifically result in biliverdin formation. However, the notion that bilirubin is a 
pathophysiologically important extracellular antioxidant, responsible for the inverse 
correlation between serum bilirubin levels and risk of cardiovascular disease, is well 
accepted. In interpreting studies which aim to raise intracellular bilirubin concentratuions 
via BVR-overexpressing cell culture systems, there are two very important considerations; 
firstly, that HO is rate-limiting for bilirubin formation and secondly, that biliverdin (or heme) 
j 
Figure 1.10 Bilirubin’s antioxidant capacity may be part of a biliverdin-bilirubin redox cycle. In 
this regard, bilirubin is not acting as a solely stoichiometric antioxidant but instead functions in a 
catalytic manner – ROS oxidise bilirubin to biliverdin, after which BVR reduces the newly-formed 
biliverdin back to bilirubin. A cycle of this sort confers amplification such that nanomolar 
concentrations of bilirubin can protect against 10,000-fold greater concentrations of oxidants. 
Adapted from Huffman et al, 2009.  
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substrate may need to be incorporated to generate meaningful levels of bilirubin (Sedlak 
and Snyder, 2009). This may, in part, explain some of the discrepancies between the recent 
findings of Maghzal et al and Jansen et al, which argue against the putative biliverdin-
bilirubin redox cycle, and previous studies. 
 
Bilirubin Inhibits LDL Oxidation 
LDL is highly susceptible to oxidation and the ability of bilirubin to prevent oxidative 
modification of LDL was first demonstrated in vitro by Wu et al (Wu et al, 1994). The authors 
showed that physiological (i.e. <20µM) concentrations of bilirubin could inhibit Cu2+-
mediated LDL oxidation, as evidenced by TBARs assay and agarose gel electrophoresis.    
These findings were corroborated in a study which showed that exogenous bilirubin 
supplementation can suppress oxidation of human blood plasma and also isolated LDL, 
following exposure to a pro-oxidant (Neuzil and Stocker, 1994).  This established the 
potential role of bilirubin as an important antioxidant involved in the prevention of LDL 
oxidation during atherogenesis, and therefore provided the basis for investigations seeking 
to establish a relationship between serum bilirubin levels and cardiovascular risk.  
That bilirubin generation is an important anti-atherogenic defence mechanism, involved in 
suppression of LDL oxidation, is demonstrated by the ability of ox-LDL to induce HO-1 (Siow 
et al, 1995; Siow et al, 1999 and Ishikawa et al, 1997). As HO-1 is the rate-limiting enzyme 
for the formation of bilirubin, its upregualtion is correlated with increased bilirubin 
production. There therefore exists a feedback loop in which elevated ox-LDL levels bring 
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about increases in bilirubin generation, in addition to another important anti-inflammatory 
mediator – CO.  
As previously discussed, bilirubin provides protection against atherosclerosis, coronary 
artery disease and inflammation, at least in part via its potent antioxidant capacity (Gullu et 
al, 2005). However, given the pleiotropic nature of bilirubin, studies have sought to ask what 
contribution, if any, bilirubin’s capacity to specifically inhibit LDL oxidation makes to its 
ability to inhibit atherogenesis. Indeed a recent study found that plasma LDL from Gilbert’s 
syndrome patients is less susceptible to oxidation and that, in these LDL oxidation 
susceptibility experiments, the lag phase was prolonged in Gilbert’s syndrome patients. 
(Yesilova et al, 2008). Interestingly, there was no statistically significant difference between 
TBARS levels in Gilbert’s syndrome patients and healthy controls. This indicates protective 
activities of bilirubin, other than its ability to inhibit LDL oxidation.          
In another study, the antioxidant capacity of Gilbert’s syndrome patients was also not 
significantly different to normal controls (Bulmer et al, 2008). However, a trolox-equivalent 
antioxidant capacity (TEAC) assay did reveal a statistically significant difference between 
Gilbert’s syndrome patients and normal controls, as did a ferric reducing ability of plasma 
(FRAP) assay. As discovered previously by Yesilova et al, the lag phase of serum oxidation 
was demonstrated to be significantly higher in the Gilbert’s syndrome patients. 
In summary, numerous studies have shown the potent anti-inflmmatory and antioxidant 
effects of bilirubin in in vivo models of inflammatory disease. That bilirubin has therapeutic 
potential in the treatment of atherosclerosis is perhaps best demonstrated by Gilbert’s 
syndrome patients, who are protected against CVD. Bilirubin exerts these effects via its well-
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established antioxidant capacity (which may or may not be part of a biliverdin-bilirubin 
redox cycle) and importantly, by also affecting cell signalling (Figure 1.11). 
 
   
 
 
 
 
 
 
Figure 1.11 Bilirubin exerts its antioxidant and anti-inflammatory effects in a pleiotropic 
manner. The pigment inhibits NADPH oxidase, a major source of superoxide in the endothelium 
(Kwak et al 1991). Bilirubin also downregulates TNFα-induced adhesion molecule expression in 
endothelial cells (Mazzone et al, 2009), and this reduces leukocyte adhesion. This is thought to 
occur, at least in part, via bilirubin-mediated inhibition of NFκB (Mazzone et al, 2009). A 
controversial BVR-mediated biliverdin-bilirubin redox cycle has been proposed to explain the 
observation that very low intracellular bilirubin concentrations can have potent antioxidant 
effects (Baranano et al, 2002). Furthermore, bilirubin can directly protect against serum LDL 
oxidation (Yesilova et al, 2008). Bilirubin is a potent inhibitor of PKCs (Sano et al, 1985). Bilirubin 
also protects against eNOS uncoupling (Jansen et al, 2010). Adapted from Abraham and Kappas, 
2008. 
PKCs 
LDL Oxidation 
NFκB 
eNOS Uncoupling 
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NO in Atherosclerosis 
Nitric Oxide (NO), along with CO and hydrogen sulfide (H2S), is one of three endogenously 
generated gaseous signalling molecules implicated in cardiovascular homeostasis. NO is 
produced by three different nitric oxide synthase (NOS) isoforms – neuronal NOS (nNOS), 
inducible NOS (iNOS) and endothelial NOS (eNOS). NO output levels from each of the 
isoforms differ vastly such that iNOS>>nNOS>eNOS (Fleming, 2010).  
Historically, NO was identified as the endothelium-derived relaxing factor (EDRF) due to its 
vasodilatory effects, although it is now known that NO, derived from eNOS, has other anti-
atherosclerotic activities (Chowdhary and Townend, 2001). Amongst these other functions, 
NO is known to mitigate oxidative stress, act as an anti-coagulant, and to inhibit leukocyte-
endothelial adhesion, VSMC proliferation in atherosclerosis and LDL oxidation (Napoli et al, 
2006). Indeed, NO concentrates in the hydrophobic core of LDL where it acts as an 
antioxidant (Denicola et al, 2002).  
Importantly, recent studies from our lab have demonstrated that induction of NO 
production, via eNOS S1177 phosphorylation, attenuates LDL oxidation in both HUVEC-
culture experiments and in vivo, in apoE-/- mice (Ahmed et al, 2009). BVR is not known to 
affect NO generation via eNOS in any cell type. 
NO has a variety of anti-inflammatory effects (Figure 1.12). Indeed, a recently developed 
anti-atherosclerotic drug, chunghyuldan, was shown to exert its effects in VCAM-1 
expression via upregulation of eNOS expression (Park et al, 2005). Chunghyuldan was 
demonstrated to increase mRNA levels NOS, whilst decreasing cell-surface expression of 
VCAM-1 in HUVECs under basal conditions. This was associated with dose-dependent 
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increases in NO production. The compound also inhibited TNFα-induced VCAM-1 mRNA 
levels. Importantly, the effect of chunghyuldan on VCAM-1 expression is lost in the presence 
of an NOS inhibitor, L-NMMA. This demonstrates that the drug exerts its effects on VCAM-1 
expression via NO. Furthermore, inhibition of basal NO generation is associated with 
increased MCP-1 expression in HUVECs (Zeiher et al, 1995). This study also showed that 
inhibition of basal NO production promotes NFκB translocation to the nucleus in HUVECs, in 
a gel mobility shift assay. Moreover, TNFα-induced increases in NFκB activation were 
suppressed by an NO donor.  
A more recent study corroborated these findings and, in addition, showed that NOS 
inhibition increased Ca2+ influx and tissue factor expression in human coronary arterial 
endothelial cells, in the presence of monocyte binding (Sakamoto et al, 2005). Tissue factor 
is involved in coagulation and is therefore pro-thrombogenic. TNFα does not increase NO 
generation when applied to isolated rat hearts (Paz et al, 2003). However, the cytokine does 
downregulate eNOS mRNA. 
NO bioavailability is decreased in atherosclerosis for two reasons – NO inactivation by ROS 
and reduced NO synthesis, due to changes in eNOS activity (Li and Forstermann, 2009). 
Under normal physiological conditions, NO concentrations are in the nM-to-pM range 
(Ignarro et al, 1999). ROS can be generated from a variety of sources however, of the 
enzymatic pathways; specific NAD(P)H oxidase (NOX) isoforms are the most important in 
the vessel wall (Violi et al, 2009). NOXs generate superoxide, which has a short half-life and 
which can readily dismutate to hydrogen peroxide, a species which also contributes to the 
oxidative milieu. In turn, this can lead to eNOS uncoupling thus exacerbating the 
NO/superoxide imbalance (Muller and Morawietz, 2009). NOX activity can be regulated by 
51 
 
cytokines (e.g. TNFα), growth factors, and shear stress (Frey et al, 2009). Indeed, TNFα-
induced ROS generation via NOX requires PKCζ activation, an atypical PKC isoform that is 
highly expressed in endothelial cells (Rahman et al, 2000). Furthermore, increased NOX 
activity by angiotensin II occurs via the ERK1/2 MAPK pathway (Xie et al, 2001). NO has a 
crucial role in the deactivation of ROS, and this contributes to both the antioxidant and anti-
inflammatory effects of NO. Indeed, ROS activate NFκB such that catalase overexpression 
inhibits TNFα-induced NFκB activation in endothelial cells (Schreck et al, 1991). 
 
 
 
 
 
Figure 1.12 The anti-inflammatory role of NO in atherosclerosis. On the right, eNOS generates 
NO. This reaction involves the oxidation of L-arginine to L-citrulline and 2mol of O2 and 1.5mol of 
NADPH are required to produce 1mol of NO. NO is known to inhibit VCAM-1 expression. Loss of 
NO increases TNFα-induced VCAM-1 expression, possibly via a mechanism involving NFκB 
activation (Lazzerini et al, 2009). Loss of NO also leads to an increase in the circulating 
inflammatory marker, C-reactive protein (CRP). On the left, loss of NO increases oxidative stress 
and platelet aggregation. Antioxidants can alleviate oxidative stress. In the centre, asymmetric 
dimethylarginine (ADMA) levels are depicted to have increased. Indeed, ADMA is an endogenous 
competitive inhibitor of nitric oxide synthases, and hence decreases NO generation. Plasma 
ADMA levels are increased in atherosclerosis patients (Cooke, 2004). This perpetuates the 
oxidative milieu, causing LDL oxidation. Taken from Napoli et al, 2006.       
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In summary, NO is critical for endothelial homeostasis and its reduced bioavailability is a 
substantial contributor to the pathophysiology of atherosclerosis. NO is a vasodilator, an 
important antioxidant (preventing for example LDL oxidation) and an inhibitor of TNFα-
induced NFκB activation, and downstream pro-inflammatory signalling. Strategies to 
increase its bioavailability are therefore likely to be beneficial in the treatment of 
atherosclerosis.     
 
Akt in Atherosclerosis 
Akt, a serine/threonine kinase, is activated by phosphatidylinositol 3, 4, 5-trisphosphate 
(PIP3) and also by phosphatidylinositol-dependent protein kinases. PI3K/Akt-dependent 
pathways are critical in endothelial homeostasis and angiogenesis – Akt promotes cell 
survival, improves endothelial function via eNOS activation and NO release, regulates cell 
migration and is involved in neovascularisation in ischemic tissues (Shiojima and Walsh, 
2002). Endothelial cell migration is critical for angiogenesis (Carmeliet, 2000), following 
myocardial infarction for example, and the PI3K/Akt pathway confers the pro-angiogenic 
properties of VEGF in these cells (Morales-Ruiz et al, 2000). Indeed, some of the 
pleiotropism of statins, for example their pro-angiogenic effects, is attributable to activation 
of the PI3K/Akt pathway (Kureishi et al, 2000). In addition, Akt has been demonstrated to 
protect endothelial cells against ox-LDL-induced cytotoxicity (Ou et al, 2010). Other 
pharmacological strategies have also demonstrated that Akt activation is a viable strategy to 
limit atherosclerosis, via improved endothelial function and angiogenesis (Lovren et al, 
2009).  
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On the other hand, there is evidence to suggest that Akt can activate NFκB in endothelial 
cells, via IKK activation (Meng et al, 2002 and Liu et al, 2010). This would lead to the 
transcription of pro-inflammatory genes involved in the initiation and progression of 
atherosclerosis. There is also evidence demonstrating that Akt is activated downstream of 
NFκB activation, suggesting a positive feedback loop (Meng et al, 2002).      
A recent study by Pachori et al suggested that BVR activates Akt in H9c2 cells 
(cardiomyocytes). Co-immunoprecipitation experiments revealed that BVR associates with 
the p85 regulatory subunit of PI3K (Pachori et al, 2007). That BVR activates the PI3K/Akt 
pathway was alluded to in the analyses of the structure of BVR which revealed that the 
reductase has two potential SH2 docking sites, which could interact with the SH2 domains in 
PI3K (Maines, 2005). Zeng et al corroborated these findings in their study which showed 
that BVR-transfected HK-2 (kidney) cells have substantially increased Akt activation, which 
could be reduced with PI3K inhibitors (Zeng et al, 2008). However, studies to date have not 
sought to demonstrate the BVR/PI3K/Akt pathway in endothelial cells.  
 
Regulation of eNOS 
The NO output from eNOS can be regulated via a number of different mechanisms including 
shear stress, phosphorylation, ROS and transcriptional control. Although eNOS was 
historically known as a Ca2+/Calmodulin-dependent enzyme, it is now known that eNOS can 
be activated independent of sustained increases in intracellular calcium levels (Fleming, 
2010). Precise, temporal regulation of eNOS activity is achieved via multi-site 
phosphorylation at specific serine, threonine and tyrosine residues and, various kinases and 
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phosphatases are therefore important in eNOS regulation. eNOS exists as a homodimer that 
is found localised in the plasma membrane caveolae and Golgi apparatus. 
Under basal conditions, eNOS is constitutively phosphorylated on Thr495 by PKC. This 
prevents association with calmodulin. Under conditions of oxidative stress, eNOS 
phosphorylation on Tyr657 by Proline-rich tyrosine Kinase (PYK2) inhibits NO production.  
Upon stimulation, the eNOS signalling complex undergoes structural changes, including the 
dissociation of caveolin-1. Thr495 is dephosphorylated which consequently allows 
calmodulin to bind to and activate the enzyme. Serine residues associated with activation 
(i.e. including Ser1177) are now phosphorylated. Indeed, phosphorylation of Ser1177 
(located at the carboxyl-terminal end of the protein) is absolutely required for eNOS 
activation.        
The phosphorylation of eNOS-Ser1177 involves at least four kinases – Akt, PKA, PKG and 
AMPK and is calcium-independent (Boo and Jo, 2003). Historically, the most salient of these 
was Akt. This was originally demonstrated in a seminal study by Dimmeler et al in which the 
PI3K/Akt pathway was shown to mediate the activation of eNOS (i.e. Ser1177 
phosphorylation) in response to shear stress in HUVECs (Dimmeler et al, 1999). This was 
associated with increased NO generation and inhibition of the PI3K/Akt pathway with 
wortmannin (a PI3K inhibitor) attenuated the shear stress-induced eNOS Ser1177 
phosphorylation.  
Since then, inhibition of the PI3K/Akt pathway has been shown to inhibit eNOS Ser1177 
phosphorylation in response to various other stimuli including VEGF agonist and insulin-like 
growth factor (Boo and Jo, 2003). Moreover a mutant form of eNOS, eNOS S1177D, is 
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utilised experimentally as a constitutively active version of eNOS, which generates 
substantial NO under basal conditions. This mutant is effective because the aspartic acid 
residue serves as a phosphomimetic.  
A recent study examined the mechanism of action of kallistatin in the prevention of TNFα-
induced endothelial cell apoptosis and oxidative stress (Shen et al, 2010). Kallistatin was 
shown to inhibit TNFα-induced endothelial cell apoptosis via the PI3K/Akt/eNOSSer1177 
pathway. This protective effect was lost with L-NAME (a NOS inhibitor) and eNOS 
knockdown (with siRNA) also attenuated kallistatin’s inhibition of TNFα-induced apoptosis. 
Furthermore, TNFα treatment increased NOX activity and intracellular ROS generation – 
kallistatin inhibited this oxidative stress via NO generation, via the PI3K/Akt/eNOS pathway. 
Together, these findings suggest that strategies which aim to increase endothelial 
intracellular NO generation, via upregulation of eNOS Ser1177 phosphorylation, are likely to 
be beneficial in atherosclerosis and CVD. 
Attenuated eNOS activity and consequently, reduced NO bioavailability, is a central feature 
of the pathophysiology of atherosclerosis. In this regard, various therapeutic strategies for 
atherosclerosis, either in use or in development, centre on increasing the bioavailability of 
NO (Li and Forstermann, 2009). 
 
BVR & NO 
At the time of writing, there is no published evidence to suggest that BVR directly influences 
NO release via eNOS. However, because BVR is involved in cell signalling (e.g. via its capacity 
as a dual-specificity kinase) it is possible that it is involved in eNOS regulation in 
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physiological and/or pathophysiological settings. Given the numerous signalling pathways 
that BVR affects – via its dual-specificity kinase activity, its role as a transcription factor, its 
role as an anchor protein or the bilirubin it produces – it is likely that the enzyme has 
multilateral influence on NO generation via eNOS. 
Previous studies have shown that BVR activates the PI3K/Akt pathway in HEK293, HK-2 and 
H9c2 cells (Zeng et al, 2008 and Pachori et al, 2007). It is therefore possible that BVR induces 
NO release via a PI3K/Akt/eNOS pathway in endothelial cells.  
Confounding the situation however, BVR is known to activate both PKCζ and ERK1/2 
(Maines, 2007 and Lerner-Marmarosh et al, 2008). PKCζ is involved in TNFα-induced ROS 
generation via NOX in endothelial cells (Rahman et al, 2000), and also NFκB activation. The 
ERK1/2 pathway is also associated with increased NOX activity (Xie et al, 2001). Hence, one 
might expect that BVR acts to decrease the bioavailability of NO via the increased ROS 
production from NOX. On the other hand, ERK1/2 activation increases NO release via the 
ERK1/2/eNOS/NO pathway in HUVECs (Urano et al, 2008). Moreover, BVR overexpression in 
HEK293A cells increased both basal and TNFα-induced (NFκB-mediated) iNOS expression 
(Gibbs and Maines, 2007).  
PKCζ is activated by BVR and is an important mediator of endothelial dysfunction due to its 
critical role in TNFα-induced inflammation (Nigro et al, 2010). Moreover, PKCζ decreases 
eNOS protein stability in response to TNFα stimulation, via a mechanism involving ERK5 
(Nigro et al, 2010). On the other hand, the bilirubin produced by BVR has potent antioxidant 
and anti-inflammatory effects.  
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In summary, published findings have not yet established a BVR/PI3K/Akt/eNOS/NO pathway 
although one could hypothesise its existence on the established dogma that BVR strongly 
activates Akt. However, BVR also has several other (putative) positive/negative effects on 
NO production, confounding the situation. For this reason it is necessary for investigators to 
establish the dominant effect on NO production, and mechanisms thereof, in specific cell 
types.  
 
Leukocyte-Endothelium Interaction in Atherosclerosis 
During the early phase of atherosclerosis, leukocytes must be recruited from the circulation 
to the vascular endothelium where diapedesis subsequently occurs. Vascular adhesion 
molecules are expressed on both the vascular endothelium and circulating leukocytes in 
response to inflammatory stimuli, and are important in this process. Several different 
classes of adhesion molecule exist including the, integrins, ICAM-1 and VCAM-1, selectins 
and the junctional adhesion molecules (JAMs). The different adhesion molecules serve 
different functions during the process of leukocyte recruitment and transendothelial 
migration. Their importance in atherosclerosis has been demonstrated in numerous in vivo 
functional inactivation studies. For example, atherosclerotic fatty streaks in mice on a high-
fight diet with homozygous mutations in ICAM-1 were substantially reduced compared to 
controls (Nageh et al, 1997). In cell culture experiments, the different adhesion molecules 
have different temporal expression profiles. With the exception of integrins, most of the 
vascular adhesion molecules have soluble forms which can be found in the circulation 
(Blankenberg et al, 2003).    
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The selectins (L-, P- and E-selectin) are C-type lectins that are involved in the initial capture, 
tethering and rolling of leukocytes along the endothelium (McEver, 2002). E-selectin is not 
constitutively expressed rather, only synthesised under inflammatory conditions. VCAM-1 is 
required for the slow rolling of monocytes whereas ICAM-1 is also involved in adhesion 
strengthening (Mestas and Ley, 2008). Augmented expression of these adhesion molecules 
has been observed in atherosclerotic plaques, in numerous in vivo models (Mestas and Ley, 
2008). 
Transcriptional control of the adhesion molecules, ICAM-1, VCAM-1 and E-selectin is largely 
via the NFκB transcription factor in endothelial cells. A study by Chen et al showed that 
inhibitors of IκBα phosphorylation block adhesion molecule expression in HUVECs, in 
response to TNFα (Chen et al, 1995). The authors show that IκBα is almost completely 
degraded after 30mins and that this correlates with NFκB DNA-binding activity, in HUVECs. 
Furthermore, inhibitors of serine proteases attenuated TNFα-induced IκBα degradation and 
consequently, NFκB activation. These inhibitors also blocked the transcription of the 
adhesion molecules.  
A recent study by Zhou et al revealed that TNFα-induced adhesion molecule expression in 
HUVECs was mediated via TNF receptor-1 (TNFR-1) and importantly, they demonstrated 
that this process was completely dependent on NFκB activation (Zhou et al, 2007). Indeed, 
HUVECs express both TNFR-1 and TNFR-2 (at low levels) however the authors demonstrate 
that TNFR-1 is solely responsible for NFκB activation and consequently, downstream mRNA 
and protein expression of ICAM-1 and VCAM-1 (Figure 1.13). In this regard, the ERK1/2, p38 
MAPK and JNK kinase pathways are shown to not contribute to TNFα-induced adhesion 
molecule expression in HUVECs, at the specific time-point studied. Consistent with these 
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findings, Rajan et al utilised a pharmacological inhibitor strategy to show that the p38 
pathway does not contribute to TNFα-induced adhesion molecule expression in endothelial 
cells (Rajan et al, 2008). On the other hand, an earlier study by Read et al showed that 
maximal E-selectin expression in HUVECs depended on both NFκB activation and JNK/p38 
activation (Read et al, 1997). 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Intracellular signalling pathways activated by TNFα. Zhou et al recently showed 
that TNFR-1 was solely associated with NFκB activation in HUVECs. TNFα binding induces 
receptor trimerisation and the recruitment of the TNFR-1-associated death domain (TRADD) 
adaptor protein and in turn, this recruits TNFα Receptor-Associated Factor-2 (TRAF-2). TRAF-2 
activates IκB kinase (IKK) via receptor-interacting protein (RIP). IKK phosphorylates IκBα, 
resulting in IκBα ubiquitination and degradation. This releases NFκB. RIP is essential for TNFα-
induced NFκB activation. Importantly, PKCζ is absolutely necessary for NFκB activation and is 
implicated both upstream and downstream of the IKK complex (Moscat et al, 2006). TRAF-2 also 
activates the ERK1/2, p38 MAPK and JNK kinase pathways. TNFα can also bring about apoptosis 
via degradation of inhibitor of apoptosis proteins (IAPs) and caspase activation via Fas-associated 
protein with death domain (FADD). Taken from Wu and Zhou, 2010. 
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In summary, adhesion molecules are critical in mediating the leukocyte-endothelial 
interactions required in atherosclerotic inflammation. Importantly, studies have shown that 
adhesion molecule expression in response to TNFα is largely via NFκB activation. However, 
the promoter regions of the adhesion molecules (and chemokines such as MCP-1) contain 
other transcription factor binding sites (e.g. AP-1). Hence these other pathways – i.e. ERK1/2, 
p38 MAPK and JNK kinase pathways – may contribute to some extent, depending on the 
system under study.   
 
BVR & Adhesion Molecules 
In short, the cell signalling pathways activated by BVR predominantly terminate on pro-
inflammatory transcription factors, resulting in for example, adhesion molecule expression 
(Figure 1.14). This includes the NFκB, JNK, p38 and and AP-1 pathways (Kapitulnik and 
Maines, 2009). The protective effect of bilirubin, the product of BVR, in downregulating 
adhesion molecule expression, was recently demonstrated (Mazzone et al, 2009). However, 
the dual-specificity kinase activity and phosphorylation targets of BVR are consistent with a 
pro-inflammatory effect.  
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A study by Lerner-Marmarosh et al demonstrated that BVR may function as an essential part 
of the TNFα/PKCζ/NFκB pathway in HEK293A cells (Lerner-Marmarosh et al, 2007). BVR 
achieves this, in part, by reducing biliverdin – a potent inhibitor of PKCs (and PKAs) – to 
bilirubin, therefore increasing PKCζ activity. Also, the authors show that BVR increases PKCζ 
autophosphorylation, therefore increasing PKCζ activity. PKCζ phosphorylates BVR, thus 
increasing its activity. BVR was shown to co-immunoprecipitate with PKCζ, following 
stimulation of HEK293A cells with TNFα. This was not observed under basal conditions. 
Furthermore, TNFα stimulation increased PKCζ activity and BVR overexpression increased 
this effect. Most importantly, TNFα-induced NFκB activation was shown to be mediated by 
Figure 1.14 BVR promotes pro-inflammatory gene transcription. Insulin, cytokines and oxidative 
stress all increase the kinase and reductase activities of BVR. BVR augments the activities of 
PKCs and PI3K, the later via IRS-1. Indeed, BVR competes to be phosphorylated by IRS-1 and in 
return BVR phosphorylates IRS-1. This leads to activation of the PI3K/Akt pathway. BVR also 
activates the ERK1/2, JNK and p38 pathways. Taken from Kapitulnik and Maines, 2009.   
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PKCζ – and crucially, BVR overexpression enhanced this TNFα-induced NFκB activation 
(Figure 1.15). Indeed, BVR overexpression alomost doubled TNFα-induced promoter activity 
from an NFκB promoter-luciferase reporter construct. Interestingly, TNFα stimulation 
increased the reductase (as well as the kinase) activity of BVR such that BVR activity (i.e. 
rate of bilirubin production) doubled 30mins after TNFα was applied. This effect was 
transient and began to decline after 30mins. Moreover, TNFα stimulation altered the 
cellular distribution of BVR from a predominantly cytoplasmic localisation under basal 
conditions to a more nuclear, cell-membrane-associated distribution with TNFα. PKCζ also 
associates with the cell membrane following TNFα stimulation (Lerner-Marmarosh et al, 
2007). 
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TNFα 
PKCζ 
NFκB 
BVR 
INFLAMMATION 
Figure 1.15 The TNFα/BVR/PKCζ/NFκB axis in TNFα-induced inflammation. TNFα increases the 
kinase activity of BVR and induces BVR-PKCζ interaction. In turn BVR increases PKCζ activity and, 
PKCζ increases BVR activity (Lerner-Marmarosh et al, 2007). PKCζ is absolutely necessary in TNFα-
induced NFκB activation (Nigro et al, 2010). On the other hand, bilirubin, produced by BVR, is a 
potent inhibitor of PKCs.     
Biliverdin 
Bilirubin 
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In summary, these findings suggest a critical augmenting role for BVR in TNFα-induced 
inflammation. TNFα signalling is implicated in transducing cardiovascular risk factors into 
endothelial dysfunction (Figure 1.16). BVR affects TNFα-induced inflammation by increasing 
PKCζ activity and consequently, increasing downstream NFκB signalling (Figure 1.15). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16 TNFα has a critical role in mediating cardiovascular inflammation. Lifestyle factors 
determine endothelial dysfunction and the cytokine is crucial in initiating these changes. 
Importantly, TNFα-induced NFκB activation is enhanced by BVR and PKCζ is critical in this process 
(Lerner-Marmarosh et al, 2007). Taken from Zhang et al, 2009.  
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Aims 
It is clear that bilirubin, produced by BVR, functions in an anti-inflammatory and antioxidant 
capacity. However, the dual specificity kinase activity of BVR confers pro-inflammatory 
activities to the HO-1/BVR axis. For example, TNFα increases BVR activity and BVR in turn 
increases PKCζ activity, therefore contributing to NFκB activation. Published studies have 
not yet utilised BVR overexpression strategies in endothelial cells, the site of the initiation of 
atherosclerosis. Whilst BVR-mediated Akt activation has been demonstrated in HK-2 and 
HEK293 cells, endothelial cells have not yet been examined. We aim to demonstrate the 
existence of a BVR/PI3K/Akt/eNOS/NO pathway in HUVECs. A recent study by our group 
(and numerous others) showed that NO release by eNOS can protect against LDL oxidation 
in a cell culture system (Ahmed et al, 2009). We therefore aim to examine whether BVR 
overexpression in HUVECs is associated with reduced LDL oxidation. We also aim to 
investigate the role of BVR in leukocyte-endothelium adherence (i.e. adhesion molecule 
expression and monocyte adherence). This is partly due to a recent study by Mazzone et al 
which showed that bilirubin could attenuate TNFα-induced adhesion molecule expression 
(Mazzone et al, 2009).   
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MATERIALS & METHODS 
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Materials 
Human umbilical vascular endothelial cells (HUVECs) were obtained from umbilical cords, 
from complication-free full-term deliveries. This was courtesy of ethical permission from 
Birmingham Women’s Hospital NHS Trust. The ethical approval reference number for the 
present study was: 09/H1211/83. Umbilical cords remained connected to the placenta and 
were immediately refrigerated at +4°C post-partum in plastic bags, following standard 
clamping and cutting procedures.  
 
Methods 
All tissue culture work, and other work requiring aseptic conditions, was carried out in a 
class II microbiological safety cabinet. Tissue culture media, plastics (e.g. cell culture flasks), 
and supplements were purchased as sterile. Any solutions that were required to be made to 
be sterile (e.g. BSA-PBS solutions) were passed through a syringe-driven sterilizing filter 
(0.22µm pore). Glassware was washed and autoclaved prior to use. Cell culture media was 
stored in accordance with manufacturer guidelines (i.e. at 4°C) and used before the expiry 
date.  
 
Tissue Culture 
Cell cultures were maintained in a humidified incubator at 37°C in an atmosphere of 95% air 
and 5% CO2. Cells were seeded onto T75 flasks which had been pre-incubated with 0.2% 
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gelatin for 5-10mins for adherent cells. Cell monolayer confluence was assessed daily for all 
cell types using a light microscope. Unless stated otherwise, cell culture medium was 
replaced every other day – this involved aspiration of the current medium, two washes with 
PBS and finally the addition of fresh medium. For adherent cells, approximately 11mL of cell 
culture medium was introduced into each T75 flask. Cells were generally passaged once 85-
95% confluence was achieved, using trypsin-EDTA solution.   
 
Isolation of HUVECs 
HUVECs were isolated, characterised and cultured as previously described (Bussolati et al, 
2001). Approximately 15mins prior to requirement, 20mL vials of 0.1% collagenase solution 
(i.e. one vial for each cord) were transferred from the -20°C freezer to the 37°C water bath.  
Excessively hematic cords were discarded due to the inherent difficulties of manipulating 
such tissues. Crucially, each cord was examined for trauma arising from clamping – this 
would indicate possible damage of the endothelial basement membrane and may therefore 
lead to contamination of the isolation with non-endothelial cells (i.e. fibroblasts and VSMCs). 
Following selection of suitable sections of cords, each cord was cut cleanly at either end 
with a scalpel. Cannulae were then introduced at either extremity of the umbilical vein and 
held securely in place with nylon straps. The cannulated umbilical vein was then washed 
with PBS using a 50mL syringe until the effluence was clear and free of hematic 
contamination. Next, 20mL of the 0.1% collagenase solution (per 30-40cm section of cord) 
was injected into the washed umbilical vein with a 20mL syringe and either extremity was 
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then promptly clamped. The cord was then wrapped in clean aluminium foil and placed into 
the 37°C incubator for 20mins.  
After 20mins, the cord was unwrapped in the hood and gently massaged for 1-2mins to 
encourage HUVEC detachment. Detached cells were collected into a 50mL tube by flushing 
the umbilical vein with M199 medium. The cell suspension was then centrifuged at 100g for 
5mins before the supernatant was removed. The cell pellet was resuspended in an 
appropriate volume of complete M199 medium and then seeded into T75 flasks pre-coated 
with 0.2% gelatin before being placed in a 37°C incubator overnight. The following day, non-
adherent cells (e.g. erythrocytes) were removed by washing each flask twice with PBS and 
then adding fresh complete M199. Confluence was generally achieved 4-6 days after 
isolation. Generally, HUVECs arising from three different sections of cord (i.e. from three 
different donors) were pooled and grown to confluence in two T75 flasks. Other lab 
members ensured adequate purity of isolations (at regular intervals) using this method by 
staining for the von Willebrand Factor (vWF), an endothelial cell marker. Experiments were 
performed on second or third passage HUVECs unless stated otherwise.                                  
 
Cell Cryopreservation 
Reserve stocks of each cell line and HUVECs were stored at -80°C and maintained via 
cryopreservation. The controlled-rate freezing method was used to freeze the cells at a rate 
of approximately -1°C/min, using the NALGENE ‘Mr Frosty’ freezing container. This protocol 
(see manufacturer instructions) minimises cell damage due to ice crystal formation and 
osmotic imbalance.  
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Reconstitution of the cryopreserved cells was performed by rapidly warming the cryovials at 
37°C in a water bath. For non-adherent cells (i.e. THP-1 cells), residual DMSO was removed 
prior to seeding by pelleting the cells (via centrifugation at 100g for 5mins), removing the 
supernatant and then adding fresh culture medium. For adherent cells, 12-16hrs was 
allowed for cell attachment before two washes with PBS to remove residual DMSO. 
                        
Adenoviral-mediated Infection 
A number of adenoviruses were utilised during the studies (Table 2.1) and the infection 
protocol used was the same for each of the different cell types that were infected. 
Adenoviruses were propagated in HEK-293 cells, purified in house via a double caesium 
chloride (CsCl) gradient, titred and then stored at -80°C in viral storage buffer as described 
previously (Channon et al, 1996). Unless stated otherwise, viruses were administered to 
cells at a concentration of 50 plaque-forming units (PFU) per cell. The transduction was 
carried out in the same culture medium that was used to grow the cells (e.g. complete 
M199 for HUVECs) and the cells were incubated with the virus for at least 20hrs before the 
experiment commenced.  
Virus Titre (PFU/mL) 
CMV 1.23 x 1010 / 1.73 x 1010 
Adβ-Gal 1.38 x 1011 
AdBVR 5.25 x 109 / 6.14 x 109 / 1.67 x 1011 
AdHO-1 4.32 x 1011 
AdeNOS-WT 7.25 x 109 
AdeNOS-S1177D 7.13 x 109 
 
 
Table 2.1 Viruses utilised during the study and corresponding titres. 
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Western Blotting 
All cell lysates for Western blotting were harvested from 80-100% confluent cell monolayers 
growing in tissue culture plates. One hour prior to requirement RIPA lysis buffer was 
prepared on ice from a 10x RIPA lysis buffer stock, using d.H2O as a diluent. The solution was 
then supplemented with an ‘inhibitor cocktail’ of protease and phosphatase inhibitors at 1% 
(v/v) each, to prevent degradation and dephosphorylation of proteins respectively. This 
solution was left on ice for at least 30mins prior to use and was stored (after wrapping in foil 
to protect from light) for up to one week. For each well of a 6 well plate, approximately 
90µL of the RIPA solution was added.  
To harvest the cell-lysate, culture medium was aspirated from each well before ice cold PBS 
was added to each well. The plate was then left on ice for 2-3mins before this was repeated. 
The ice cold PBS was then aspirated and the RIPA solution was added to the centre of each 
well, before the plate was agitated to ensure complete coverage. The plate was then left on 
ice for at least 20mins before a cell scraper was used to harvest the lysates. The lysates were 
collected into tubes which were subsequently centrifuged at 5000rpm for 5mins to remove 
insoluble cell debris. The supernatant was transferred to fresh tubes and frozen at -20°C 
until required.           
Protein assays were carried out to estimate the total amount of protein present in cell 
lysates (for subsequent SDS-PAGE analysis) and to also estimate the total amount of LDL 
present in solution for our LDL oxidation experiments. The Bio-Rad DC protein assay was 
used for this purpose. The assay is a modification of the Lowry assay and employs 
colorimetric detection. A series of protein standards were prepared from a stock solution of 
20mg/mL of BSA to give a range of concentrations from 0.2-1.4mg/mL. The BSA standards 
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were prepared in duplicate – one set of standards were diluted in PBS (for protein 
estimation of LDL concentration) whilst the other set were diluted in RIPA buffer (for protein 
estimation of cell lysate concentration). The standards were then assayed in triplicate (as 
described below for samples) to generate a standard line graph (BSA standard concentration 
vs. optical density) from which protein concentration of samples were calculated.  
The protein assay was performed in near exact concordance with the manufacturer 
guidelines (the Bio-Rad ‘DC Protein Assay Instruction Manual’ – section 5.2 in this case). The 
plate was read within 1hr using a Multiskan Ascent 96 well plate reader at 690nm as per the 
instruction manual.  
Once the resolving gel had been carefully poured into the plate assembly, avoiding the 
formation of air bubbles, it was immediately overlaid with several millilitres of 50% 
methanol. This prevents gel shrinkage and the formation of a meniscus. The gel was then 
allowed to polymerise for at least 30mins after which the 50% methanol was poured off. 
TEMED was then added to the stacking gel solution and following swift repulsing with a 
pipette, the gel was carefully poured on top of the resolving gel. An appropriate pre-cleaned 
sample loading comb was then inserted into the stacking gel and the gel was allowed to 
polymerise for at least 30mins. 
  
SDS-PAGE: Loading & Running 
Unless stated otherwise, 25µg of protein was loaded per well, in reducing buffer. The 
samples were placed on a heat block for 10mins at approximately 100°C to facilitate the 
reduction of disulfide bonds. Gels were initially electrophoresed at 80V. Once the 
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bromophenol blue dye had completely passed through the stacking gel, the voltage was 
increased to 140V.  
 
SDS-PAGE: Semi-Dry Transfer    
Following complete electrophoresis, the resolving SDS-PAG was separated from the glass 
plates. The gel was measured and then equilibrated in transfer buffer to remove buffer salts 
and detergents. Extra thick filter paper and nitrocellulose/PVDF was cut to the required 
dimensions. Generally, nitrocellulose membrane was used for transfer and the membrane 
was soaked in transfer buffer for 5mins before use. However on a few occasions PVDF was 
used. Unlike nitrocellulose, the PVDF membrane is hydrophobic and must be initially 
activated by incubating in 100% methanol for 5mins before being washed in transfer buffer. 
The extra thick filter paper was also soaked in transfer buffer for 5mins before being 
massaged to ensure complete saturation. The gel was then assembled in the Trans-Blot 
semi-dry electrophoretic transfer cell (Figure 2.1).  
The required current was determined using the following equation: 0.8 x area of the gel (in 
cm2) = required current (mA). All gels were allowed to transfer for 2hrs 30mins.  
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Membrane blocking & 1° Ab. Incubation 
Once transfer was complete, the ‘stack’ was disassembled and the membrane was very 
briefly equilibrated in TBST on a platform rocker. Membranes were blocked for either 1hr at 
room temperature or overnight at +4°C with 5% dried skimmed milk (w/v) in TBST on a 
platform rocker. The membrane was then quickly washed twice with TBST to remove 
residual visible milk before being washed for a further 45mins on the rocker platform. The 
TBST was changed every 15mins.  
After washing the membrane, the primary antibody solution was added (Table 2.2). 
Manufacturer time and temperature incubation guidelines for each antibody were adhered 
to. Each antibody was diluted in a 1% BSA-TBST (w/v) solution. To allow reuse of stored 
antibody dilutions, sodium azide (NaN3) was added at 0.02% (w/v) to prevent microbial 
contamination.      
 
Figure 2.1 Assembly of the Trans-Blot semi-dry 
electrophoretic transfer cell. Firstly, pre-soaked extra 
thick filter paper is placed on the platinum anode. A 
pipette tip is then gently rolled along the filter paper to 
remove air bubbles. The membrane is overlaid and 
rolled to remove air bubbles. The equilibrated gel is 
placed on top and air bubbles are rolled out before the 
other piece of filter paper is placed on top. Again, air 
bubbles must be rolled out and then any excess transfer 
buffer surrounding the ‘stack’ is soaked up with paper 
towels, to prevent short-circuiting. The cathode is then 
placed on top, being careful to avoid lateral movement 
which would disturb the stack, before being covered 
with the safety cover.   
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Antibody Manufacturer Description Recognition Optimal Dilution 
BVR Abcam Rabbit polyclonal Human 1/5000 
HO-1 Abcam Rabbit polyclonal Human 1/5000 
Akt Cell Signaling Rabbit polyclonal Human 1/1000 
p-Akt (S473) Cell Signaling Rabbit polyclonal Human 1/1000 
eNOS Cell Signaling Rabbit polyclonal Human 1/1000 
p-eNOS 
(S1177) 
Cell Signaling Rabbit polyclonal Human 1/1000 
IκBα 
BD Transduction 
Labs 
Mouse monoclonal Human 1/500 
β-actin Sigma Mouse monoclonal Human 1/15000 
  
 
 
2° Ab. Incubation & ECL Detection 
After primary antibody incubation, the membrane was thoroughly washed as previously 
described. The secondary antibodies (Table 2.3) were diluted in 5% skimmed milk-TBST (w/v) 
solution pro re nata and were disposed of after usage. As an exception, when detecting β-
actin a secondary antibody concentration of 1/20000 was always used due to the high 
abundance of this protein in cell lysates. 
 
Antibody Manufacturer Description Recognition 
Optimal 
Dilution 
Peroxidase Anti-Rabbit IgG 
(H+L) 
Vector Labs Goat polyclonal Rabbit 1/10000 
Peroxidase Anti-Mouse IgG 
(H+L) 
Vector Labs Horse polyclonal Mouse 1/10000 
Peroxidase Anti-Biotin Vector Labs Goat polyclonal (Biotin) 1/5000 
 
 
 
Table 2.2 Optimal dilutions of primary (1°) antibodies utilised during Western blotting. 
Table 2.3 Secondary (2°) antibodies and relevant optimal dilutions utilised during Western 
blotting.   
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Following 1hr incubation with the secondary antibody (or 30mins when detecting β-actin) 
on a platform rocker, the membrane was washed as previously described. The TBST was 
then drained from the membrane and ECL detection fluid was added. We utilised the EZ-ECL 
(Biological Industries) detection system in accordance with manufacturer instructions. 
 
Quantitative NO Analysis  
The Sievers nitric oxide analyzer (NOA) was used to indirectly measure the NO content of 
cell culture conditioned medium. The method is suitable for measuring low nanomolar to 
millimolar levels of NO in liquid samples. The underlying principle of the method is that the 
vast majority of NO in the liquid sample is oxidized to nitrite (NO2
-) by dissolved oxygen, in 
the absence of oxyhemoglobin or superoxide. The NOA was therefore setup to measure 
nitrite via its reduction to NO by iodide. This reaction occurs in the purge vessel of the 
machine which contains the reducing agent, 1% sodium iodide (w/v) in glacial acetic acid: 
I- + NO2
- + 2H+                   NO + 0.5I2 + H2O  
The amount of NO formed by this reaction is therefore directly proportional to the amount 
of nitrite in the sample which is in turn dependent on the amount of NO originally present. 
The NO enters the NOA (Figure 2.2) where it is detected by chemiluminescence. The 
detector relies on the reaction between NO and ozone (generated from an oxygen supply): 
NO + O3            NO2* + O2 
NO2*               NO2 + hf 
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The nitrogen dioxide produced in this reaction is in an excited state and decay of this species 
results in infrared photon emission (>600nm) in accordance with E = hf. Photon emission is 
therefore proportional to the NO content of the sample. Photon emission from this reaction 
is measured with a red-sensitive photomultiplier tube (PMT). To increase sensitivity, the 
PMT is cooled to <-12°C. The PMT amplifier processes the signal from the PMT and this was 
used in high gain mode (linear response up to approximately 400pmol nitrite). The PMT 
signal is represented in mV and changes in the PMT signal with time can be seen in real-time 
onscreen. Software was used to calculate the NO concentration in each sample by firstly 
finding the area under each sample peak. The NO concentration was then calculated by 
comparison with a standard graph, which was generated from the analysis of a set of serial 
dilutions of sodium nitrite. 100µL of each sample was injected into the centre of the purge 
vessel through the septum in the injection port with a syringe (Figure 2.2). The iodide 
reducing agent becomes more yellow as the reagent is depleted due to I3
- formation and 
this can be used as an indication of when to change the solution.    
 
 
Figure 2.2 Purge vessel apparatus used 
for nitrite reduction. Generally, about 5mL 
of the reducing agent was added to the 
purge vessel. The solution is simply 
discarded via the drain stopcock and 
replenished via the injection port. The 
inert gas that was used was nitrogen and 
this functions to purge the NO generated 
by the reduction reaction from the liquid 
phase. The NO is then drawn under 
vacuum to the NOA unit. The needle valve 
is used to adjust the flow of nitrogen such 
that the cell pressure is within a 
reasonable range. The polypropylene filter  
(IFD) protects the chemiluminescence reaction cell from liquid damage. Adapted from 
www.geinstruments.com.        
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Conditioned medium samples (0.5mL/well) for NO analysis were collected from confluent 
quiescent cells growing in 24 well plates. NO release was measured over the indicated times 
and ‘stimulation’ was therefore initiated by adding fresh culture medium. Fluid shear stress 
can activate eNOS and hence care was taken to prevent unnecessary movements. RPMI 
1640 supplemented with 0.2% BSA was used for stimulation unless indicated otherwise. To 
control for background nitrite/NO inherently present in the culture medium, medium-only 
(cell-free) controls were incubated under the same experimental conditions. NO levels from 
these medium-only controls were subtracted from samples. All samples were collected into 
tubes and then stored at -80°C until analysis. Samples were analysed in triplicate.     
       
Flow Cytometric Analyses 
Flow cytometry was used to assess HUVEC-surface expression of adhesion molecules, 
specifically ICAM-1, VCAM-1 and E-selectin. The following antibodies were utilised: 
 
Antibody Manufacturer Description Recognition 
Optimal 
Dilution 
ICAM-1 Dako Mouse monoclonal Human 1/100 
VCAM-1 Dako Mouse monoclonal Human 1/100 
E-Selectin-
Fluorescein 
R & D Systems 
Fluorescein-conjugated Mouse 
monoclonal 
Human 1/25 
IgG1 Dako 
Mouse monoclonal (negative 
control Antibody) 
- 1/100 
Anti-mouse IgG-
FITC 
Sigma 
FITC-conjugated Goat 
polyclonal (2° Antibody) 
Mouse 1/100 
     
 
 
Table 2.4 Primary antibodies and relevant optimal dilutions utilised during flow cytometric 
analyses.  
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Human recombinant TNFα cytokine composed of 157 amino acids, corresponding to the C-
terminal extracellular domain of the full length transmembrane protein, was utilised at a 
working concentration of 10ng/mL, in order to induce cell-surface expression of the 
aforementioned adhesion molecules. Unless stated otherwise, stimulation with this 
cytokine was carried out for 6hrs (excluding any pre-incubation times with inhibitors) in 12 
well plates (0.5mL/well). HUVECs were used in all experiments and were not pre-starved to 
quiescence. All stimulations were carried out in ‘HUVEC starvation medium’ (containing 5% 
FCS and no supplemental growth factors). If inhibitors were used in the experiment, cells 
were pre-incubated for one hour in the starvation medium with the inhibitors. The medium 
was then changed and fresh medium containing inhibitor and/or cytokine was added and 
incubated for 6hrs. 
Antibodies were prepared at the indicated concentrations in 1% BSA (w/v) PBS solution. The 
cell culture plates were removed from the incubator and checked under the microscope for 
cytotoxicity. Each well was then washed twice with warm (i.e. 37°C) PBS before 60µL of 
trypsin-EDTA solution was added to each well. The plate was then jolted from side-to-side to 
ensure complete coverage before being placed in the incubator for 2-3mins. Cell 
detachment was then confirmed under the microscope before approximately 0.5mL of fresh 
starvation medium (at room temperature) was promptly added to each well. The contents 
of each well were transferred into a FACS tube on ice before approximately 2mL of ice cold 
PBS was added to each tube to remove medium/trypsin solution. The tubes were spun at 
1200rpm for 6mins at +4°C before supernatant was discarded.  
Primary antibodies were then added to the cell pellets. The Dako antibodies were added in a 
volume of 100µL/tube whereas the E-selectin antibody was added in a volume of 15µL/tube 
81 
 
in accordance with manufacturer guidelines in either case. Gentle vortexing and tapping of 
the tubes ensured thorough mixing and the tubes were left on ice for 30-45mins. Ice cold 
PBS was then added to each tube to wash off unbound antibody and the tubes were spun as 
previously described. Supernatant was discarded and 100µL/tube of secondary antibody 
was added and mixed, and left on ice for approximately 30mins. Tubes containing E-selectin 
antibody were omitted and left on ice because this antibody is already conjugated and so 
does not require the secondary antibody step. All tubes were then washed with ice cold PBS 
to remove unbound antibody, spun down and supernatant was discarded as previously 
described. The cell-antibody complexes were then fixed by the addition of 0.4mL of 2% 
paraformaldehyde (w/v) in PBS to each tube. Crucially, each tube was vortexed immediately 
after adding the fixative to prevent cell clumps being fixed. The tubes were sealed and 
stored at +4°C for up to three days before analysis. Prior to analysis, cells were pelleted and 
supernatant discarded as described previously and 0.3mL 1% BSA (w/v) PBS solution was 
added to each tube. This is to prevent the fixative from damaging the flow cytometer. 
A ‘BD FACSCalibur’ flow cytometer was used to analyse the samples whilst a ‘Summit’ 
software package was used to view the results. Ten thousand events per tube were 
measured and median fluorescence was graphed.        
 
Isolation of PBMs 
Peripheral blood monocytes (PBMs) were isolated from whole human blood for the 
monocyte adhesion assays, using Ficoll and Percoll gradients. Healthy donors were asked to 
sign a consent form and were notified of how much blood was to be taken. Venipuncture 
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was performed (courtesy of Dr Kequing Wang) and blood was taken from the median cubital 
vein of the anterior forearm. The blood was then gently injected into a 50mL tube 
containing 100µL of 0.5M EDTA/50mL blood. The tube was inverted several times and either 
left at +4°C for no longer than 2hrs or processed immediately.  
Peripheral blood mononuclear cells (PBMCs) must first be isolated, from which monocytes 
can be subsequently isolated. For every 50mL of whole blood, three 20mL tubes were 
prepared, each containing 8mL of the sterile density medium ‘Ficoll-Paque PLUS’. Equal 
volumes of whole blood were carefully overlaid onto the gradients in each tube and spun at 
400g for 30mins at room temperature. Crucially, the break setting was adjusted to zero to 
prevent disruption of the separation when the centrifuge is decelerating. The PBMCs 
present themselves as a ‘buffy coat’ – a white interphase ring. A Pasteur pipette was used to 
remove the PBMCs to a fresh 50mL tube, and care was taken to not disturb the layer of 
erythrocytes beneath. The PBMCs were then washed with PBS-citrate solution three times, 
with centrifugation at 150g for 8mins. The citrate in the solution prevents platelet 
contamination. If PBMCs were required for the experiment they were utilised at this stage.  
If monocytes were required, the PBMCs were suspended in HUVEC starvation medium 
(15mL/50mL blood). Percoll gradients were prepared from a solution of isotonic Percoll. The 
isotonic Percoll is a solution of 90% Percoll (d = 1.130 g/mL) and 10% (v/v) 1.5M NaCl. From 
this isotonic Percoll solution, two solutions were prepared: a 1:1 solution (v/v) of isotonic 
Percoll and PBS-citrate and, an 11:9 solution (v/v) of isotonic Percoll and PBS-citrate 
respectively. Percoll gradients were made by carefully overlaying 4mL of the 11:9 Percoll 
solution with 4mL of the 1:1 Percoll solution. This was prepared three times in three 
different tubes and then 5mL of the PBMC suspension was carefully overlaid onto each 
83 
 
gradient. The tubes were then centrifuged at 400g for 30mins, with the break setting at zero. 
The lymphocytes are pelleted at the bottom of the tube whilst the monocytes are found 
dispersed in the upper two thirds of the gradient. The whole of the upper two thirds of the 
gradient was therefore transferred to a fresh 50mL tube before washing with PBS-citrate 
solution as previously described. The monocytes were then diluted in HUVEC starvation 
medium to the required concentration, after counting with a hemocytometer. Care was 
taken to avoid fluid shear stress during all steps because this can affect monocyte adhesion. 
The purity of monocyte isolation using this method was checked at regular intervals by 
other lab members, by staining for the monocyte-specific membrane marker CD14, which 
was typically 80-90%.         
 
Static Monocyte Adhesion Assay 
All monocyte adhesion assays were conducted on confluent HUVEC monolayers in 24 well 
plates under static conditions, with TNFα cytokine used to induce adhesion molecule 
expression. HUVECs were pre-incubated with inhibitors for one hour in HUVEC starvation 
medium in a volume of 250µL/well. After one hour the culture medium was aspirated from 
the wells and fresh starvation medium containing the inhibitor and/or TNFα at 10ng/mL was 
added. The stimulation was carried out for six hours, during which time monocytes were 
isolated from whole blood. 2 X 105 monocytes/well were then added in a volume of 400µL 
of HUVEC starvation medium – the culture medium already present (containing TNFα 
and/or inhibitor) was not aspirated. The monocytes were then allowed to adhere to the 
monolayer for one hour before non-adherent monocytes were washed off by washing the 
HUVEC monolayers once with PBS. Crucially, the culture medium was aspirated very gently 
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at this stage and the PBS was added with a Gilson pipette to avoid shearing off of bound 
monocytes. The PBS was then gently aspirated and 0.4mL/well of 1% glutaraldehyde (v/v) in 
PBS was added for fixation. The culture plate was then left at room temperature for 5mins 
before being stored at +4°C for up to one week for subsequent analysis. 
The glutaraldehyde solution was aspirated and wells were washed twice with d.H20. 0.4mL 
of Mayer’s hematoxylin solution was then added to each well at a concentration of 4% (v/v), 
diluted in d.H20. The plate was left at room temperature for 10-15mins before the 
hematoxylin solution was aspirated. Wells were then washed twice with 0.5mL of tap water. 
A further 0.5mL of tap water was subsequently added to prevent desiccation. 
Images of adherent cells were captured using a confocal microscope. No fewer than five 
fields of view were imaged per well using a 10x lens. Fields of view were randomly selected 
from different quadrants of the well. ‘Image-Pro Plus’ software (Media Cybernetics) was 
used to count stained cells (i.e. adherent monocytes). The software can be programmed to 
count objects that have a relatively high optical density and can also discriminate on the 
basis of size (i.e. objects too large to be monocytes such as HUVEC nuclei can be excluded). 
This method proved to be highly accurate, as evidenced by concordance with results from 
human-counted images, and also very time-efficient. 
 
ELISA for Human MCP-1 
HUVECs were grown in 24 well plates. Cells were pre-incubated for one hour with inhibitors 
in HUVEC complete medium. The wells were then aspirated and fresh medium containing 
inhibitor and/or 10ng/mL of TNFα was added in HUVEC complete medium. The stimulation 
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was carried out in 0.5mL of the medium/well for 24hrs. The conditioned medium was then 
collected into tubes and centrifuged at 5000rpm for 5mins to remove detached cells. The 
supernatant was then transferred to fresh tubes and stored at -80°C for up to one month 
before analysis. 
The ‘Human CCL2/MCP-1 DuoSet’ sandwich ELISA kit (R & D Systems) was used to measure 
the concentration of MCP-1 in the conditioned media, in complete accordance with the 
manufacturer instructions. Optical density was measured with a microplate reader at 
450nm, with correction at 540nm. A standard curve was created from the optical densities 
of the recombinant MCP-1 standards and this was used to calculate MCP-1 concentration in 
the samples. Medium-only blanks were incorporated in the experiments and results were 
subtracted from the samples. 
 
LDL Oxidation & TBARs Assay 
The effect of BVR on lipid peroxidation was assessed via the thiobarbituric acid reactive 
substances (TBARs) assay. Native LDL isolated from human plasma was purchased from 
‘Sigma’ and ‘Sunnylab’. This native LDL solution contains EDTA and other small molecular 
weight contaminants which must be removed prior to the experiment by passing an 
appropriate volume of the native LDL solution through a Sephadex G25-M PD-10 size-
exclusion column (Amersham Biosciences). The column was equilibrated with 50mL of 
sterile PBS (pre-filtered to 0.22µm) before the native LDL was applied to the column. Sterile 
PBS was also used for elution and approximately twelve 0.5mL fractions were collected into 
sterile tubes. The LDL fractions were then assayed for protein content as described 
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previously before fractions containing the highest concentrations of LDL (generally fractions 
5-8) were pooled in serum-free Ham’s F-10 medium containing 0.2% BSA to give a final LDL 
concentration of 100µg/mL (unless stated otherwise). Care was taken when handling the 
LDL solutions because fluid shear stress can cause LDL denaturation. 
LDL oxidation experiments were conducted on confluent cell monolayers (not pre-starved to 
quiescence) in 12 well plates. 0.5mL of Ham’s F-10 LDL solution was applied to each well, 
after washing each well with (LDL-free) Ham’s F-10 to remove growth factors. The 
stimulation was conducted for 18hrs and cells were viewed under a light microscope at the 
end of the stimulation to check for cytotoxicity. Conditioned media were collected and 
centrifuged at 2200rpm for 10mins at +4°C to pellet detached cells. Supernatants were 
transferred to fresh tubes and EDTA and butylated hydroxytoluene (BHT) were added to 
give final concentrations of 2mM and 20µM respectively. EDTA and BHT prevent further LDL 
oxidation. Samples were frozen at -80°C for up to 2 weeks before analysis. 
LDL oxidation was determined by measuring TBARs in the samples. Malondialdehyde (MDA) 
standards were prepared from an MDA stock of 500µM. The MDA stock was prepared by 
adding 4.17µL of MDA to 1mL of ethanol, before this solution was added to 49mL of d.H20. 
A serial dilution was then performed to give a range of MDA concentrations from 0-100µM. 
These dilutions were prepared in the stimulating medium (i.e. Ham’s F-10) for comparability. 
Essentially, this assay expresses TBARs in terms of MDA equivalents. 
 
                  
Figure 2.3 MDA. MDA is the central three-
carbon molecule and this is shown to have 
formed a 1:2 adduct with thiobarbituric acid 
in this diagram. This molecule can then be 
quantified using spectrophotometry.   
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200µL of TBARS reagent was added to 200µL of samples or MDA standards. The tubes were 
then heated at 100°C for 5mins prior to being centrifuged at 13000rpm for 6mins. Crucially, 
tubes were pierced approximately four times to prevent pressure build up and consequent 
sample loss. 150µL of sample/standard supernatant was then added in duplicate to a 96 
well microplate. Absorbance was read immediately at 540nm in a microplate reader. Results 
were calculated by subtracting a blank (i.e. 0µM MDA) from readings before a standard 
curve was plotted ([MDA] vs. optical density). Mean MDA-equivalents in the samples were 
then calculated from the standard curve graph.  
A positive control was incorporated into the experiments by using CuSO4 as an oxidant – 
0.5mL of the Ham’s F-10 medium (containing 100µg/mL LDL) was placed into a well 
(containing no cells) and sterile CuSO4 solution was added at a final working concentration 
of 60µM. 
 
In-Cell ELISA 
An in-cell ELISA colorimetric system was optimised de novo for specific antibodies, for the 
quantification of intracellular proteins in whole cells (Figure 2.4). This method is both cost- 
and time-efficient. The protocol was modelled on the ‘In-Cell ELISA Colorimetric Detection 
Kit’ (Thermoscientific). Cells were plated at a density of 1 X 104/well in a 96 well culture 
plate. At the end of the experiment, the culture medium was removed and 100µL of 4% 
formaldehyde was added to each well for fixation and the plate was incubated for 15mins in 
the fume hood. The formaldehyde solution was aspirated and the plate was washed twice 
with 100µL/well of TBS. The plate was then left at room temperature for 15mins with 
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100µL/well of permeabilization buffer. The plate was washed with 100µL/well of TBS before 
100µL/well of quenching solution was added. The plate was left for 20mins before the plate 
was washed once with 100µL/well of TBS. 100µL/well of blocking buffer was then added 
and the plate was incubated for 30mins at room temperature. The blocking buffer was 
removed and 50µL/well of primary antibody was added before the plate was sealed and 
incubated overnight at +4°C. 
The primary antibody was then removed and the plate was washed three times with 
100µL/well of wash buffer. 100µL of biotinylated secondary antibodies were added at 0.002% 
(v/v) in blocking buffer. Incubation was carried out for 1hr at room temperature. The 
primary and secondary antibodies utilised in the in-cell ELISA system and optimal dilutions 
were as follows: 
  
Antibody Manufacturer Description Recognition 
Optimal 
Dilution 
BVR Abcam Rabbit polyclonal Human 1/5000 
HO-1 Abcam Rabbit polyclonal Human 1/10000 
Akt Cell Signalling Rabbit polyclonal Human 1/1000 
p-Akt (S473) Cell Signalling Rabbit polyclonal Human 1/500 
eNOS Cell Signalling Rabbit polyclonal Human 1/10000 
p-eNOS (S1177) Cell Signalling Rabbit polyclonal Human 1/10000 
β-actin Sigma Mouse monoclonal Human 1/40000 
Biotinylated Anti-
rabbit IgG (H+L) 
Vector Labs Goat polyclonal Rabbit 1/500 
Biotinylated Anti-
mouse IgG (H+L) 
Vector Labs Horse polyclonal Mouse 1/500 
  
 
After incubation with secondary antibody, the plate was washed with wash buffer three 
times. 100µL/well of 0.005% (v/v) HRP conjugate was added before incubation for 30mins. 
The plate was washed three times with wash buffer and then 100µL/well of TMB substrate 
Table 2.5 Primary antibodies and relevant dilutions utilised for in-cell ELISAs. 
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was added.  The plate was protected from light and incubated for 10mins before the 
reaction was stopped by adding 50µL of 1M H2SO4. The absorbance was measured with a 
microplate reader at 450nm with correction at 540nm. ‘No primary antibody’ controls were 
always incorporated into the experiment and these readings were subtracted from the 
results.  
 
 
 
 
In some experiments, whole-cell staining was then performed to control against varying 
inter- and intra-experiment cell densities. In this case, plate contents were discarded and 
wells were washed three times with 200µL/well of ultrapure water (filtered at 18.2 
MOhm.cm). Water was removed and 50µl/well of Janus green whole-cell stain was added 
and incubated for 10mins at room temperature. The stain was discarded and the plate was 
washed 3-6 times with 200µL/well of ultrapure water until all excess stain had been 
 
Figure 2.4 Schematic overview of the in-cell ELISA colorimetric detection system. Adapted from 
Thermoscientific (www.piercenet.com).  
d 
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removed. 100µL/well of elution buffer (i.e. 0.5M HCL) was then added, the plate was 
incubated for 10mins and the absorbance was measured at 615nm.         
 
Pharmacological Inhibitors 
Several pharmacological inhibitors were utilised during the study. The table below shows 
working concentrations of all inhibitors used (Table 2.6). The inhibitors were pre-incubated 
with cells for one hour (unless stated otherwise) before addition of TNFα as required. 
 
Inhibitor Manufacturer Description 
Working 
Concentration 
Tin protoporphyrin-IX (SnPP) 
Alexis 
biochemicals 
HO competitive inhibitor 20µM 
LY294002 Calbiochem PI3K competitive inhibitor 10µM 
NG-Nitro-L-arginine (L-NNA) 
Alexis 
biochemicals 
NOS competitive inhibitor 500µM 
Ro-31-8220 Calbiochem PKC competitive inhibitor 1µM 
6-Amino-4-(4-
phenoxyphenylethylamino) 
quinazoline 
Calbiochem NFκB Activation Inhibitor 10µM 
Diphenyleneiodonium (DPI) Sigma 
Flavoenzyme competitive 
inhibitor 
10µM 
SP600125 Calbiochem JNK competitive inhibitor 10µM 
PD98059 Calbiochem 
MEK competitive 
inhibitor 
10µM 
    
 
 
Statistical Analyses 
Data were analysed and graphed using GraphPad Prism 4 software. Generally, a one-way 
ANOVA was performed followed by a post-hoc Newmann-Keuls multiple comparison test to 
evaluate statistical significance. A t-test was performed when comparing just two groups.   
Table 2.6 Pharmacological inhibitors utilised during the study and relevant working 
concentrations.   
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Validation 
Optimal Adenoviral MOIs 
Our study utilised biliverdin reductase adenovirus (AdBVR), as a strategy to elucidate the 
intracellular functions of the protein via its overexpression. Our preliminary experiments 
sought to ask two fundamental questions; 1, does AdBVR transduction correlate with 
protein expression and 2, what multiplicity of infection (MOI) should be utilised in 
experiments. In asking our two fundamental questions, we confirmed that the protein is 
overexpressed using this method and that our chosen MOI – the lowest possible MOI that 
confers mild, reproducible protein overexpression – is not cytotoxic to the cells. Similarly, a 
number of early studies involved the use of a HO-1 adenovirus (AdHO-1). The AdHO-1 is a 
well-established construct and its optimal MOI, for HUVECs, had been determined by 
previous studies conducted in our lab (Cudmore et al, 2007). However, we thought it 
prudent to revaluate its terms of usage.      
Before using these adenoviruses in experiments, we sought to confirm protein expression. 
HUVECs were transduced at varying MOIs in cell culture experiments and cell-lysate was 
collected and analysed by Western blotting for BVR or HO-1. This experiment was repeated 
a number of times during the course of the study to ensure that different batches of 
adenovirus were consistent in their protein expression. The MOI administered to the cells 
correlated with protein expression; in such a way that MOI is proportional, prima facie at 
least, to its protein expression (Figure 3.1). Importantly, BVR protein was not detected in 
none-transduced HUVECs (Figure 3.1, A). We inferred that an MOI of 50 (i.e. 50 viral 
particles/cell) for both constructs would yield sufficient protein overexpression, would not 
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be cytotoxic (or cause changes in visible phenotype), and would be practical and 
reproducible. 
 
    
 
 
 
 
 
 
 
In addition to allowing us to determine optimal MOIs for these constructs, we also 
confirmed that BVR protein expression in HUVECs is undetectable. Importantly, we 
substantially increased autoradiographic exposure time and BVR remained undetectable 
(not shown).   
 
In-Cell ELISA  
An in-cell enzyme-linked immunosorbent assay (ELISA) was developed and optimal 
conditions were determined. Although cell density is controlled for when cells are plated – 
i.e. because approximately equal numbers of cells are dispensed into each well – we 
thought it prudent to use a Janus green whole-cell stain. Indeed, although the cells are fixed 
Figure 3.1 Correlation between MOI and protein expression in HUVECs. Cells were plated into 6 
well dishes in complete M199 medium and allowed to adhere overnight. The following 
afternoon, the HUVECs were transduced in complete M199 medium. After 24hrs, cell lysates 
were collected and analysed via Western blotting. Autoradiographic exposure time was no 
longer than 1min. (A), Of particular interest is the clear absence of BVR expression in non-
infected cells. (B), In contrast, HO-1 is detectable in none-infected cells.      
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using formaldehyde, cells may become detached during the numerous washing steps and 
hence, whole-cell staining can control for such phenomena. As expected, the greater the 
number of cells plated, the greater the optical density read-out (Figure 3.2). A Newman-
Keuls multiple comparison test was performed in order to determine the sensitivity of this 
methodology that is, the degree to which the stain can significantly detect small differences 
in HUVEC density. We inferred that the Janus green whole-cell stain is only suitable for 
detecting differences of >2500 HUVECs.       
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Figure 3.2 HUVEC density validation using Janus green whole-cell stain in an in-cell ELISA. Early 
passage HUVECs were plated at the indicated densities and allowed to adhere overnight in M199 
complete medium. Staining was performed using the Thermoscientific Janus green whole-cell 
stain. The results represent the mean of 6 wells ± SEM in one experiment. A one-way ANOVA was 
performed to assess the variance between the means vs. the variance within the samples. There 
is a statistically significant difference (p<0.0001), F ratio = 22.04, R2 = 0.992. A Newman-Keuls 
multiple comparison test was used to assess the difference in the means.   
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Next, we sought to determine the sensitivity of our new assay, because our primary 
antibodies had been previously used only for Western blotting. We were therefore 
conscious that there would be differences in the ability of these antibodies to recognise 
reduced and denatured proteins, compared to proteins in native form. Hence, we first 
determined the optimal concentrations of the BVR and HO-1 primary antibodies (Figure 3.3). 
This is important in terms of maximising the sensitivity of the assay whilst ensuring that it is 
cost-effective. The optimal concentrations of other primary antibodies used in our analyses 
had been previously determined by another member of our lab. 
The small increase in HO-1 protein due to BVR overexpression is detectable at a dilution 
factor of 1/10000 (Figure 3.3, A). Hence, because the antibody was primarily used to 
evaluate increases in HO-1 due to AdBVR, we were satisfied that 1/10000 would be optimal. 
We decided to use an anti-BVR concentration of 1/3000 (Figure 3.3, B). This is because this 
antibody was primarily going to be used to confirm BVR overexpression. We were unlikely 
to encounter a situation where BVR protein levels would be higher than those elicited by 50 
MOI of AdBVR. 
We proceeded to evaluate whether our chosen antibody concentrations could detect 
changes in protein expression associated with varying MOIs of Adβ-Gal, AdHO-1 and AdBVR 
(Figure 3.4). We expected that the Adβ-Gal construct would not affect HO-1 or BVR 
expression (Figure 3.4, A). However, there is a statistically significant difference between 50 
and 100 MOI as indicated, in terms of HO-1 expression. This may be an artifact of the in-cell 
ELISA methodology. The sensitivity of the anti-HO-1 antibody is low because the signal 
saturates at 50 MOI AdHO-1 – i.e. there is not a statistically significant difference between 
50 and 100 MOI, in terms of HO-1 protein expression (Figure 3.4 B). HO-1 overexpression 
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does not appear to alter BVR protein expression. The sensitivity of the anti-BVR antibody is 
also low – the signal appears to saturate at 50 MOI (Figure 3.4, C). In this regard, there is no 
statistically significant difference in BVR (or indeed HO-1) expression between 50 and 100 
MOI. 
 
 
10000 5000
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Ad-Gal
AdBVR
*
*
p<0.01
p<0.001
Anti-HO-1 Dilution Factor
O
p
ti
c
a
l 
D
e
n
s
it
y
(4
5
0
-5
4
0
n
m
)
 
20000 10000 5000
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
Ad-Gal
AdBVR
p<0.01
p<0.01
*
*
*
Anti-BVR Dilution Factor
O
p
ti
c
a
l 
D
e
n
s
it
y
(4
5
0
-5
4
0
n
m
)
 
 
Figure 3.3 In-cell ELISA to 
determine the optimal 
concentrations of the 
anti-BVR and anti-HO-1 
antibodies. (A), A dilution 
factor of 10000 is optimal 
for the anti-HO-1 
antibody. The optimal 
concentration of the anti-
HO-1 antibody is 1/10000. 
(B), The anti-BVR 
antibody must be present 
at a dilution factor of less 
than 5000 for optimality. 
We decided that a 
concentration of 1/3000 
for the Anti-BVR antibody 
would be optimal. * 
p<0.001 vs. lowest 
concentration of 
antibody. These data 
represent the mean ± 
SEM of 1 experiment 
performed in triplicate. 
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Figure 3.4 Protein Expression of 
HO-1 and BVR in Adβ-Gal- AdHO-
1- and AdBVR-infected cells. 
HUVECs were plated in 96 well 
plates and allowed to adhere 
overnight in M199 complete 
medium. The following day, the 
cells were transduced at the 
indicated MOIs. Approximately 
24hrs later, levels of HO-1 and BVR 
protein were assessed in an in-cell 
ELISA. (A), BVR and HO-1 protein 
expression in Adβ-Gal-infected 
HUVECs. In any case, an MOI of 50 
was used for the Adβ-Gal 
construct. (B), BVR and HO-1 
protein expression in AdHO-1-
infected HUVECs. As expected, 
higher MOIs of the AdHO-1 
construct led to higher protein 
expression of HO-1. (C), BVR and 
HO-1 protein expression in 
AdBVR-infected HUVECs. 
Interestingly however, we see that 
BVR overexpression appears to 
increase HO-1 protein levels. * 
p<0.05 vs. 0 MOI. OD was adjusted 
for cell-density. These data 
represent the mean ± SEM of 1 
experiment performed in 
duplicate. 
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SnPP inhibits Bilirubin Generation  
In order to distinguish between the effect of the reductase activity (i.e. bilirubin) and other 
non-canonical activities of BVR in an inflammatory context, we utilized SnPP to block 
bilirubin production. We sought to ensure that the inhibitor was having the desired effect 
on bilirubin production in both control and AdBVR-transduced cells. Prof Libor Vitek (Charles 
University, Czech Republic) kindly analyzed our samples for intracellular unconjugated 
bilirubin concentration using high-performance liquid chromatography (Figure 3.5).    
We asked a number of questions; 1, does BVR overexpression alter intracellular bilirubin 
concentration, 2, what is the effect, if any, of TNFα on bilirubin production, and 3, what 
effect does SnPP have in these different contexts. We measured bilirubin at two different 
time-points; 1hr, and 6hrs (excluding 1hr pre-treatment). This is because our assays pre-
incubated with SnPP for 1hr followed by addition of TNFα for a further 6hrs as appropriate. 
After the 1hr pre-treatment phase, the levels of bilirubin are marginally lower in the SnPP 
group compared to the control (Figure 3.5, A). Interestingly, we also see that bilirubin levels 
are slightly lower in the BVR overexpressing cells as compared to the control (CMV) cells. 
After 6hrs however, we see that the BVR overexpressing cells have substantially reduced 
(>50%) bilirubin levels as compared to the control (Figure 3.5, B). In the presence of TNFα 
only, this is reversed – CMV and AdBVR treatment groups have similar bilirubin levels. 
However when HO-1 is inhibited in the presence of TNFα, AdBVR-infected cells have 50% 
lower bilirubin levels compared to CMV-transduced cells. In the presence of HO-1 inhibitor 
only, bilirubin levels are substantially reduced compared to control. 
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In summary, these data have allowed us to confirm that SnPP is effective in suppressing 
intracellular bilirubin levels, including in the presence of TNFα. Surprisingly and importantly 
however, overexpression of BVR is not associated with increases in intracellular bilirubin. In 
control cells, TNFα reduces bilirubin levels whilst the opposite effect is seen in AdBVR-
infected cells. 
Figure 3.5 HPLC analysis of 
intracellular unconjugated 
bilirubin levels in CMV- and 
AdBVR-infected HUVECs. 
(A), BVR overexpression 
reduces intracellular 
bilirubin in HO-1-inhibited 
HUVECs. At 1hr, bilirubin 
levels are lower with BVR 
overexpression, in both 
control and SnPP groups. 
(B), HO-1-inhibition reduces 
intracellular bilirubin in BVR 
overexpressing HUVECs. 
After 6hrs, the unstimulated 
treatment groups (i.e. 
‘control’ and ‘SnPP’) have 
lower bilirubin levels when 
BVR is being overexpressed. 
The experiment was 
performed in single wells 
and hence this precluded 
statistical analysis, although 
we are assured of the 
accuracy of the results. 
Samples were collected and 
then sent to Prof Libor Vitek 
for the HPLC analysis.                
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Results 
BVR Activates Akt 
Akt is a downstream effector of PI3K and is involved in various cellular processes including 
for example, the promotion of cell survival. In endothelial cells, Akt is part of the 
PI3K/Akt/eNOS/NO pathway (Fulton et al, 1999). This pathway is important in 
atherosclerosis – its downregulation is implicated in diabetes-related vascular dysfunction 
and atherosclerosis (Du et al, 2001 and Okon et al, 2005). The importance of the 
PI3K/Akt/eNOS/NO pathway in atherosclerosis is further demonstrated by the finding that 
ellagic acid attenuates ox-LDL-induced cytotoxicity in HUVECs via this pathway (Ou et al, 
2010). 
BVR has been shown to activate Akt in H9c2 and HK-2 cells (Pachori et al, 2007 and Zeng et 
al, 2008). However, this has not been demonstrated in endothelial cells. We therefore 
evaluated this in HUVECs using an adenoviral-mediated overexpression strategy (Figure 4.1).  
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Figure 4.1 BVR activates Akt in HUVECs. The experiment was conducted 24hrs post-infection in 
HUVEC starvation medium. P-Akt levels were normalized to total Akt levels. (A), BVR induces Akt 
S473 phosphorylation in a Western blot densitometric analysis. PI3K inhibition with an inhibitor 
(i.e. LY294002) precipitates BVR-induced Akt activation. (B), BVR overexpression induces Akt 
S473 phosphorylation in HUVECs in an in-cell ELISA. BVR activates Akt under basal conditions. * 
p < 0.0001 vs. CMV control. These data represent the mean ± SEM of three independent 
experiments, conducted in at least duplicate wells.        
A 
B 
102 
 
Our Western blot analyses show that under conditions of PI3K inhibition, BVR 
overexpression substantially increases Akt activation. There is no difference in Akt activation 
between CMV and BVR infected cells under basal conditions (Figure 4.1, A). However in the 
in-cell ELISA (Figure 4.1, B), BVR overexpression does indeed increase Akt activation under 
basal conditions (i.e. in the absence of PI3K inhibition). These findings are novel, suggesting 
that BVR is a strong activator of Akt in endothelial cells.  
 
BVR Activates eNOS & Induces NO Release 
Encouraged by our early finding that BVR activates Akt in endothelial cells, we proceeded to 
evaluate the next downstream component in the BVR/PI3K/Akt/eNOS/NO pathway; eNOS 
(Figure 4.2).  
Our highly novel findings clearly demonstrate that BVR induces eNOS activation via S1177 
phosphorylation in HUVECs. As this effect was lost in the presence of the PI3K inhibitor, 
LY294002, BVR activates eNOS via PI3K. Published studies have not yet demonstrated BVR-
induced eNOS activation in any cell type. 
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Given that eNOS S1177 phosphorylation is associated with activation of the enzyme and NO 
release, we sought to demonstrate that BVR overexpression induces NO release (Figure 4.3). 
Our preliminary experiments with HUVECs were inconclusive. Undeterred, we decided to 
conduct the same experiment in another related cell type, porcine aortic endothelial cells 
(PAECs). Given the aortic (vs. umbilical) origins of these cells, we reasoned that the 
‘eNOS/NO system’ would be of greater similarity to endothelial cells from atherosclerotic-
susceptible arteries. 
Figure 4.2 BVR induces eNOS S1177 phosphorylation in a PI3K-dependent manner in a Western 
blot densitometric analysis. HUVECs were infected as indicated and the experiment was 
conducted 24hrs later in HUVEC starvation medium. Due to the unavailability of a total eNOS 
antibody, p-eNOS levels were normalized to β-actin. * p < 0.05 vs. CMV. These data represent the 
mean ± SEM of three independent experiments conducted in duplicate wells.  
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BVR overexpression induces NO release in PAECs (Figure 4.3). This is a highly novel finding, 
especially in regard to our previous finding that BVR activates eNOS via S1177 
phosphorylation.  
 
 
 
Figure 4.3 BVR doubles nitric oxide release in PAECs during a 30min stimulation. Cell-free 
medium was incubated alongside the samples to correct for NO indigenous to the medium itself. 
PAECs were infected as indicated in RPMI 1640 (+ 0.2% BSA) medium. Approximately 24hrs later, 
fresh RPMI 1640 medium was gently added to each well, being careful to avoid shear stress. The 
cells were incubated for 30mins before medium was removed into tubes and frozen at -80°C until 
analysis. * p < 0.01 vs. CMV. These data represent the mean ± SEM of three independent 
experiments conducted in at least duplicate wells.        
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BVR Induces HO-1 Expression 
Given the well-documented protective actions of HO-1 in atherosclerosis (Hoekstra et al, 
2004), we sought to determine whether BVR can induce HO-1 expression in endothelial cells 
(Figure 4.4). We utilised both Western blotting and the in-cell ELISA. 
   
 
 
 
 
Figure 4.4 BVR induces HO-1 protein expression in HUVECs in an in-cell ELISA. HUVECs were 
infected in HUVEC complete medium as indicated and the experiment commenced 24hrs later. 
Inset, a representative Western blot demonstrating that the magnitude of BVR overexpression 
(i.e. AdBVR MOI) correlates with HO-1 protein expression. * p < 0.01 vs. CMV with same antibody. 
These data represent the mean ± SEM of three independent experiments conducted in at least 
duplicate wells.        
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BVR overexpression almost doubles HO-1 protein expression in HUVECs. Furthermore, the 
extent to which HO-1 expression is increased appears to correlate linearly with the degree 
to which BVR is overexpressed (Figure 4.4, inset). Published studies have not yet 
demonstrated this effect in endothelial cells. 
 
LDL Oxidation 
We examined whether BVR overexpression would have any effect on LDL oxidation 
independent of its bilirubin-producing capacity (Figure 4.5), especially given that the enzyme 
appears to induce NO release (Figure 4.3). We also examined the effect of HO-1 
overexpression on LDL oxidation; this enzyme is upregulated in response to ox-LDL (Siow et 
al, 199) and so may participate in a defence mechanism against LDL oxidation. However CO, 
a product of HO-1, is known to increase ROS generation (Piantadosi, 2008) and Fe2+, also a 
HO-1 product, is a potent oxidising agent capable of oxidising LDL (Kapiotis et al, 2005).  
The results show that BVR overexpression in HUVECs does not significantly reduce LDL 
oxidation. It is curious that HO-1 overexpression has a significantly opposite effect on LDL 
oxidation than BVR, not least because BVR induces HO-1 expression. Possible explanations 
for this are discussed later. 
 
 
 
 
107 
 
     
 
 
 
 
 
 
 
 
 
Figure 4.5 BVR and HO-1 have opposite effects on LDL oxidation in a TBARs Assay. A TBARs assay 
and inset, a representative electrophoretic mobility shift assay (EMSA). HUVECs were infected as 
stated. 100µg/mL of LDL was exogenously applied to fresh cell culture medium (Ham’s F-10) and 
the stimulation was conducted for 18hrs before the medium was assayed for TBARs. Cell-free 
controls were incorporated – i.e. a negative control consisting of native LDL and, a positive control 
consisting of native LDL in the presence of 60µM CuSO4, which acts as an oxidizing agent. Whilst 
HO-1 overexpression appears to increase LDL oxidation (none-significantly), BVR appears to 
reduce LDL oxidation (none-significantly). This is also demonstrated in the EMSA – the upper 
bands represent LDL. Oxidised LDL migrates quicker across the gel compared to none-oxidised 
LDL. These data represent the mean ± SEM of 3 independent experiments conducted in at least 
duplicate. * p > 0.05 compared to CMV control.     
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BVR Attenuates TNFα-Induced MCP-1 Release 
Our experiments aimed to address the apparent discrepancy between the canonical (i.e. 
bilirubin production) and non-canonical activities of BVR in terms of inflammation. We 
evaluated the effect of adenoviral-mediated BVR overexpression on TNFα-induced NFκB 
pro-inflammatory gene expression (i.e. MCP-1 and adhesion molecules) in HUVECs. We 
were therefore keen to evaluate the relative contributions of the reductase and kinase 
activities of BVR to these end-points.  
We initially assessed the effect of BVR overexpression in HUVECs on TNFα-induced MCP-1 
release (Figure 4.6). As discussed previously, MCP-1 is a chemokine involved in leukocyte 
recruitment and has an important role in atherosclerosis. 
Our findings are highly novel, demonstrating that BVR inhibits TNFα-induced MCP-1 release 
in endothelial cells. When HO-1 is inhibited, BVR overexpression continues to suppress 
MCP-1 release, suggesting that its mechanism of action is independent of bilirubin 
production. In control (CMV) cells, we see that HO-1 inhibition reduces MCP-1 release. The 
NFκB activation inhibitor (NAI) reduces TNFα-induced MCP-1 release by a small extent in 
control cells. BVR overexpression continues to inhibit MCP-1 release by the same amount in 
the presence of the NAI, as compared to without the NAI.            
 
109 
 
- - SnPP SnPP NAI NAI
0
5000
10000
15000
20000
25000
30000
CMV
AdBVR
TNF +- - + - +
* *
#
p < 0.001 p < 0.01
[M
C
P
-1
]
(p
g
/m
L
)
 
          
 
 
 
 
 
BVR Attenuates TNFα-Induced Leukocyte-Endothelium Adherence  
Given that adhesion molecule expression is broadly regulated by the same intracellular 
signaling pathways as MCP-1 expression in endothelial cells (i.e. NFκB, JNK and p38), we 
proceeded to evaluate the effect of BVR overexpression on adhesion molecule expression. 
Figure 4.6 BVR attenuates TNFa-induced MCP-1 release in a bilirubin-independent manner in 
HUVECs. An ELISA for MCP-1 released into cell culture medium by HUVECs, following a 24hr 
stimulation with TNFα. HUVECs were treated with two different inhibitors as indicated – 20µM 
SnPP (a HO-1 inhibitor) and 10µM NAI (NFκB activation inhibitor). TNFα was applied at a 
concentration of 10ng/mL, in HUVEC complete medium. The NAI was incorporated in order to 
assess the component of TNFα-induced MCP-1 release that is NFκB-dependent. * p < 0.001 vs. 
CMV with same treatment . # p < 0.01 vs. CMV with same treatment. These data represent the 
mean ± SEM of three independent experiments conducted in duplicate wells.    
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As previously discussed, endothelial expression of adhesion molecules is an early marker of 
endothelial dysfunction. Adhesion molecules function to recruit leukocytes from the 
circulation across the endothelium. We decided to assay for ICAM-1, VCAM-1 and E-selectin 
expression using flow cytometry. These adhesion molecules have subtlety distinct functions 
in the process of leukocyte recruitment. Hence assaying for all three of these adhesion 
molecules is advantageous because, collectively, the adhesion molecule expression data is 
likely to correlate with functional (i.e. monocyte binding) data.  
In tandem with our flow cytometric analyses, we decided to conduct monocyte adhesion 
assays to ascertain the functional relevance of changes in cell-surface expression levels of 
ICAM-1, VCAM-1 and E-selectin. The monocyte adhesion assay consisted of applying 
monocytes to a HUVEC monolayer in the presence/absence of TNFα (and any inhibitors) and 
then subsequently counting the adhered monocytes. Although initial, preliminary 
experiments were conducted with THP-1 cells (supplementary results); we decided to use 
freshly isolated monocytes from human blood for our subsequent experiments.      
Mazzone et al showed that bilirubin, in its unconjugated form, could attenuate TNFα-
induced adhesion molecule expression in HUVECs (Mazzone et al, 2009). Furthermore, the 
authors demonstrated that bilirubin exerts its effects on adhesion molecule expression via 
inhibition of TNFα-induced NFκB activation. Although we had previously established that 
BVR overexpression is not associated with bilirubin generation (Figure 3.5), indeed at the 
same time-point and with the same stimulation (TNFα) as in our adhesion molecule 
experiments, we were keen to rule out any bilirubin-dependent effect. This was especially 
important because we had only analysed a single set of samples for bilirubin. In addition to 
this, we have previously shown that BVR overexpression induces HO-1 protein expression 
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(Figure 4.4). For this reason, it was important to distinguish between BVR-mediated effects 
and HO-1-mediated effects. Our early experiments therefore incorporated SnPP, a HO-1 
inhibitor (Figures 4.7 and 4.8). 
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Figure 4.7 BVR attenuates TNFα-induced cell-surface adhesion molecule expression in a 
bilirubin-independent manner. Flow cytometric analyses utilizing anti-ICAM-1, anti-VCAM-1 
and anti-E-Selectin antibodies and, inset, a representative overlay. HUVECs were grown in 12-
well plates and infected as indicated. Approximately 24hrs later, HUVECs were pre-treated as 
indicated with SnPP for 1hr in HUVEC starvation medium. Then, TNFα was applied for 6hrs in 
fresh medium as indicated. The cells were then harvested and subsequently analyzed. The 
results clearly demonstrate that inhibition of bilirubin production (via inhibition of HO-1 with 
SnPP) does not affect the ability of BVR to attenuate TNFα-induced ICAM-1, VCAM-1 and E-
Selectin expression. * p < 0.01 vs. CMV with identical treatment. ** p < 0.001 vs. CMV with 
identical treatment. These results represent the mean ± SEM of three independent experiments 
performed in duplicate.             
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Taken together, our highly novel flow cytometric and monocyte adhesion data show that 
BVR is capable of attenuating TNFα-induced monocyte-endothelium adherence 
independently of its bilirubin generating capacity. This is in agreement with our earlier 
demonstration that BVR attenuates TNFα-induced MCP-1 secretion independently of 
bilirubin production.  
Figure 4.8 BVR attenuates TNFα-induced monocyte adhesion in a bilirubin-independent manner. 
HUVECs were grown in 24 well plates and infected. Approximately 24hrs later, the cells were pre-
treated for 1hr with 20µM SnPP in HUVEC starvation medium as indicated. 10ng/mL TNFα was 
then applied as indicated for 6hrs. Then, freshly isolated human monocytes were applied to each 
well (2 X 105/well) and allowed to adhere for 1hr. The HUVEC monolayer was then washed, fixed 
and analysed. Inhibition of bilirubin production (with SnPP) has no effect on the ability of BVR to 
attenuate TNFα-induced monocyte adhesion. ** p < 0.001 vs. CMV with identical treatment. 
These results represent the mean ± SEM of four independent experiments performed in singlet or 
duplicate. A minimum of five randomly chosen fields of view per well were analysed.          
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As Figure 4.7 shows, BVR attenuates TNFα-induced leukocyte-endothelium interactions via, 
at least in part, downregulation of cell-surface ICAM-1, VCAM-1 and E-selectin. Our flow 
cytometric experiments also suggest that BVR is most potent in attenuating TNFα-induced 
VCAM-1 cell-surface expression and least potent in regard to ICAM-1. This flow cytometric 
data is in concordance with our monocyte adhesion data (Figure 4.8) in that addition of 
SnPP does not affect BVR-mediated attenuation of TNFα-induced leukocyte-endothelium 
interaction. 
Next, we sought to determine the relevance of BVR’s ability to activate Akt via PI3K, to its 
capacity to inhibit TNFα-induced leukocyte-endothelium adherence. Our rationale stemmed 
from the fact that the PI3K/Akt axis has multilateral effects in atherosclerosis. On the one 
hand, Akt activates eNOS and this correlates with NO production in endothelial cells (Figure 
3.8). NO inhibits adhesion molecule expression (Park et al, 2005). NO also inhibits NFκB 
activation (Zeiher et al, 1995). A recent in vivo study showed that upregulation of the 
PI3K/Akt pathway, with angiotensin-converting enzyme II, has anti-atherosclerotic effects 
(Zhang et al, 2010). On the other hand, there is strong evidence that Akt activates IKK, and 
consequently NFκB, in various cell types (Meng et al, 2002; Narayan et al, 2006). Akt 
activation has also been shown to be increased in atherosclerotic lesions in humans and 
animal models (Miyauchi et al, 2004). 
In order to investigate the role of the BVR/PI3K/Akt pathway in monocyte-endothelium 
adherence we utilized LY294002 (LY), a PI3K inhibitor (Figures 4.9 and 4.10).  
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Figure 4.9 BVR attenuates TNFα-induced cell-surface adhesion molecule expression in a PI3K-
independent manner. Flow cytometric analyses utilizing anti-ICAM-1, anti-VCAM-1 and anti-E-
Selectin antibodies. HUVECs were grown in 12 well plates and infected as indicated. 
Approximately 24hrs later, HUVECs were pre-treated as indicated with 10µM LY294002 (LY) for 
1hr in HUVEC starvation medium. Then, TNFα was applied for 6hrs in fresh medium as indicated. 
The cells were then harvested and subsequently analyzed. The results indicate that BVR 
attenuates TNFα-induced adhesion molecule expression in a manner that is independent of the 
BVR/PI3K/Akt/eNOS/NO pathway. # p < 0.05 vs. CMV with identical treatment. * p < 0.01 vs. CMV 
with identical treatment. ** p < 0.001 vs. CMV with identical treatment. These results represent 
the mean ± SEM of three independent experiments performed in duplicate.             
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Taken together, these results suggest that the BVR/PI3K/Akt pathway has no functional net 
effect in terms of monocyte adhesion. As shown in Figure 4.10, inhibition of PI3K reduces 
TNFα-induced monocyte adhesion in CMV control cells. This indicates that the net effect of 
the PI3K/Akt pathway is to increase TNFα-induced adhesion. Importantly, Figure 4.9 would 
Figure 4.10 BVR attenuates TNFα-induced monocyte adhesion in a PI3K-independent manner. 
HUVECs were grown in 24 well plates and infected. Approximately 24hrs later, the cells were 
pre-treated for 1hr with 10µM LY294002 (LY) in HUVEC starvation medium as indicated. 
10ng/mL TNFα was then applied as indicated for 6hrs. Then, freshly isolated human monocytes 
were applied to each well (2 X 105/well) and allowed to adhere for 1hr. The HUVEC monolayer 
was then washed, fixed and analysed. Inhibition of PI3K in has no effect on the ability of BVR to 
attenuate TNFα-induced monocyte adhesion. ** p < 0.001 vs. CMV with identical treatment. 
These results represent the mean ± SEM of three independent experiments performed in singlet 
or duplicate. A minimum of five randomly chosen fields of view per well were analyzed.          
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suggest that this is specifically due to upregulation of VCAM-1, as opposed to the other 
adhesion molecules.  
Next, we sought to examine the role of NFκB activation in relation to BVR’s ability to 
attenuate adhesion molecule expression (Figure 4.11). Previous analyses of TNFα-induced 
MCP-1 release (Figure 4.6) showed that whilst our NFκB activation inhibitor (NAI) 
significantly reduced MCP-1 release, it did not do so substantially. A number of 
considerations are relevant; 1, that both BVR’s kinase and reductase activities are increased 
by TNFα (Lerner-Marmarosh et al, 2007), 2, that bilirubin may attenuate adhesion molecule 
expression via inhibition of NFκB activation (Mazzone et al, 2007), 3, that BVR may increase 
NFκB activation via PKCζ  (Lerner-Marmarosh et al, 2007), 4, that BVR may activate IKK via 
Akt (i.e. BVR/PI3K/Akt/IKK/NFκB pathway) and 5, that BVR may attenuate NFκB activation 
via the BVR/PI3K/Akt/eNOS/NO pathway.   
117 
 
   
None TNF NAI TNF+NAI None TNF NAI TNF+NAI None TNF NAI TNF+NAI
0
10
20
30
40
50
60
70
80
90
100
CMV
AdBVR
** ** ** **
ICAM-1 VCAM-1 E-Selectin
**
**
P<0.001
P<0.001
 CMV
AdBVRTNF + NAI
 
ICAM-1
Treatment (6hrs)
M
e
d
ia
n
-F
IT
C
 
 
 
 
 
 
Our results are in broad agreement with Mazzone et al, 2009. In their study, Mazzone et al 
showed that exogenously applied bilirubin, together with an NFκB activation inhibitor, could 
suppress adhesion molecule expression – i.e. E-Selectin – in endothelial cells to a greater 
extent than the inhibitor alone (i.e. without bilirubin). Our results show that this additive 
Figure 4.11 BVR additively attenuates TNFα-induced cell-surface ICAM-1 expression in the 
presence of NFκB activation inhibitor. Flow cytometric analyses utilizing anti-ICAM-1, anti-VCAM-1 
and anti-E-Selectin antibodies and, inset, a representative overlay. HUVECs were grown in 12-well 
plates and infected as indicated. Approximately 24hrs later, HUVECs were pre-treated as indicated 
with 10µM NFκB Activation Inhibitor (NAI) for 1hr in HUVEC starvation medium. Then, TNFα was 
applied for 6hrs in fresh medium as indicated. The cells were then harvested and subsequently 
analyzed. The results indicate that BVR and NAI, additively, attenuate ICAM-1 expression. ** p < 
0.001 vs. CMV with identical treatment. These results represent the mean ± SEM of three 
independent experiments performed in duplicate.             
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effect is only evident in regard to ICAM-1. Importantly however, our experiments utilize a 
method of BVR overexpression (as opposed to application of bilirubin) and we have 
previously shown that AdBVR is not associated with increased intracellular bilirubin. The NAI 
attenuates only TNFα-induced ICAM-1 expression by a small degree, and does not seem to 
attenuate TNFα-induced VCAM-1 or E-Selectin expression.  
Next, we sought to probe the role of the BVR/PKCζ axis in leukocyte-endothelium adherence 
(Figures 4.12 and 4.13). A number of considerations are important; 1, that both BVR’s kinase 
and reductase activities are increased by TNFα (Lerner-Marmarosh et al, 2007), 2, that both 
biliverdin and bilirubin are potent inhibitors of PKCs (biliverdin to a greater extent than 
bilirubin), 3, that BVR increases PKCζ activity and vice versa  (Lerner-Marmarosh et al, 2007), 
and 4, that PKCζ has been shown to be essential in TNFα-induced NFκB activation (Nigro et 
al, 2010). Our experiments utilized RO-31-8220 (RO31), a pan-PKC inhibitor with well-
established efficacy in the inhibition of the atypical PKCζ.   
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Figure 4.12 BVR has a limited role in inducing adhesion molecule expression via the 
TNFα/BVR/PKCζ/NFκB pathway. Flow cytometric analyses utilizing anti-ICAM-1, anti-VCAM-1 
and anti-E-Selectin antibodies and, inset, a representative overlay. HUVECs were grown in 12-well 
plates and infected as indicated. Approximately 24hrs later, HUVECs were pre-treated as 
indicated with 5µM RO-31-8220 (RO31) for 1hr in HUVEC starvation medium. Then, TNFα was 
applied for 6hrs in fresh medium as indicated. The cells were then harvested and subsequently 
analyzed. The results indicate that BVR does not increase adhesion molecule expression via PKCζ. 
# p < 0.05. ** p < 0.001 vs. CMV with identical treatment. These results represent the mean ± 
SEM of three independent experiments performed in duplicate.             
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The results indicate that, in our system, BVR does not increase adhesion molecule 
expression via PKCζ. It is important to note that whilst RO-31-8220 was used at a 
concentration of 5µM in flow cytometric analyses, only 1µM was used in the monocyte 
adhesion assays. This is because 5µM of the compound reduced TNFα-induced adhesion 
molecule expression to below basal, unstimulated levels and indeed to a level that was 
Figure 4.13 BVR does not increase monocyte adhesion via the TNFα/BVR/PKCζ/NFκB pathway. 
HUVECs were grown in 24 well plates and infected. Approximately 24hrs later, the cells were pre-
treated for 1hr with 1µM RO-31-8220 (RO31) in HUVEC starvation medium as indicated. 10ng/mL 
TNFα was then applied as indicated for 6hrs. Then, freshly isolated human monocytes were 
applied to each well (2 X 105/well) and allowed to adhere for 1hr. The HUVEC monolayer was 
then washed, fixed and analysed. BVR overexpression attenuates TNFα-induced monocyte 
adhesion. Inhibition of PKCζ reduces this adhesion to the same level in both CMV control and 
AdBVR cells. ** p < 0.001 vs. CMV with identical treatment. These results represent the mean ± 
SEM of three independent experiments performed in singlet or duplicate. A minimum of five 
randomly chosen fields of view per well were analyzed.          
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almost undetectable – particularly with regard to VCAM-1 and E-Selectin. We therefore 
decided to utilize 1µM of the compound in the monocyte adhesion analyses because we felt 
that 5µM would inhibit PKCζ to such an extent that it would be impossible for BVR to 
activate NFκB via this pathway. 
It was our aim to test the notion that BVR may activate PKCζ and therefore increase 
adhesion molecule expression via this pathway. In a sense, we utilized the same strategy as 
for our earlier demonstration that BVR activates Akt via PI3K (cf. Figure 4.1, A) – an inhibitor 
was used in both experiments to try and precipitate a particular downstream event (i.e. Akt 
activation or adhesion molecule expression/monocyte adherence). Our results demonstrate 
that, even under conditions of PKCζ inhibition, BVR does not increase monocyte adherence 
via this pathway. This is an important finding that gives credence to our view that 
modulation of BVR activity in vivo may have therapeutic potential in chronic inflammatory 
diseases such as atherosclerosis. 
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Supplementary Results 
Leukocyte-Endothelium Adherence 
The flavin enzymes include the nitric oxide synthases, such as eNOS, and also the NADPH 
oxidases (NOXs). The different flavin enzymes have different effects on adhesion molecule 
expression; eNOS produces NO which has the effect of reducing monocyte adhesion whilst 
NOXs generate superoxide which increases adhesion molecule expression via NFκB in 
response to TNFα stimulation (Ray and Shah, 2005). BVR produces bilirubin which inhibits 
NOX, and also activates eNOS. Biliverdin also inhibits NOX (Fujii et al, 2010). As previously 
demonstrated BVR activates eNOS and increases NO generation (Figure 4.3).  In an early 
experiment utilising THP-1 cells, we were keen to study the interplay between BVR, flavin 
enzymes and monocyte adhesion, with a view to establish the mechanism by which the 
reductase inhibits monocyte adhesion (Figure 5.1). We utilised diphenyliodonium (DPI), an 
established inhibitor of flavin enzymes. 
BVR overexpression is associated with atennuation of TNFα-induced monocyte (i.e. THP-1) 
adherence. When flavin enzymes are inhibited in the presence of TNFα, BVR overexpression 
continues to suppress monocyte adherence, indeed to a greater extent than with TNFα 
alone. In control (CMV) cells, we also see that TNFα-induced monocyte adherence is lower 
with flavin enzyme inhibition.  
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Another one of our early experiments incorporated SnPP (a HO-1 inhibitor) in order to 
determine whether BVR reduces monocyte (THP-1) adhesion via bilirubin generation (Figure 
5.2).  
 
Figure 5.1 BVR inhibits TNFα-induced monocyte adhesion independently of flavin enzymes. 
HUVECs were grown in 24 well plates and infected. Approximately 24hrs later, the cells were pre-
treated for 1hr with 10µM diphenyliodonium (DPI) in HUVEC starvation medium as indicated. 
10ng/mL TNFα was then applied as indicated for 6hrs. Then, THP-1 cells were applied to each 
well (2 X 105/well) and allowed to adhere for 1hr. The HUVEC monolayer was then washed, fixed 
and analysed. ** p < 0.001 vs. CMV with identical treatment. These results represent the mean ± 
SEM of one experiment performed in triplicate. Six randomly chosen fields of view per well were 
analyzed.          
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The results indicate that BVR is able to inhibit TNFα-induced monocyte adhesion 
independently of bilirubin generation. Interestingly, TNFα-induced monocyte adhesion 
appeared to increase in the presence of HO-1 inhibitor.  
Figure 5.2 BVR inhibits TNFα-induced monocyte adhesion independently of bilirubin production. 
HUVECs were grown in 24 well plates and infected. Approximately 24hrs later, the cells were 
pre-treated for 1hr with 20µM SnPP in HUVEC starvation medium as indicated. 10ng/mL TNFα 
was then applied as indicated for 6hrs. Then, THP-1 cells were applied to each well (2 X 105/well) 
and allowed to adhere for 1hr. The HUVEC monolayer was then washed, fixed and analysed. ** p 
< 0.001 vs. CMV with identical treatment. “ p < 0.001 vs. AdBVR with TNFα treatment only. These 
results represent the mean ± SEM of one experiment performed in triplicate. Five randomly 
chosen fields of view per well were analyzed.          
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Before repeating this experiment with monocytes, we conducted a number of experiments 
with peripheral blood mononuclear cells (PBMCs). This allowed us to perfect and optimize 
our isolation method (Figure 5.3). PBMCs include lymphocytes in addition to monocytes.   
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Figure 5.3 BVR inhibits TNFα-induced monocyte adhesion independently of bilirubin 
production. HUVECs were grown in 24 well plates and infected. Approximately 24hrs later, the 
cells were pre-treated for 1hr with 20µM SnPP in HUVEC starvation medium as indicated. 
10ng/mL TNFα was then applied as indicated for 6hrs. Then, THP-1 cells were applied to each 
well (2 X 105/well) and allowed to adhere for 1hr. The HUVEC monolayer was then washed, fixed 
and analysed. ** p < 0.001 vs. CMV with identical treatment.* p < 0.01 vs. CMV with same 
identical treatment. These results represent the mean ± SEM of three independent experiments 
performed in duplicate. Five randomly chosen fields of view per well were analyzed.          
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As with THP-1 cells, the results are consistent with a bilirubin-independent mechanism of 
action. Interestingly, HO-1 inhibition consistently resulted in lower TNFα-induced monocyte 
adhesion (Figure 5.3). This is in contrast to our earlier experiment with THP-1 cells which 
demonstrated the opposite effect (Figure 5.2).  
THP-1 cells were also utilized in our initial experiments examining the role of the PI3K/Akt 
axis in the ability of BVR to attenuate TNFα-induced monocyte adhesion (Figure 5.4). The 
PI3K/Akt axis has an important role in atherosclerosis. For example, PI3K/Akt activation 
correlates with eNOS activation and NO production, and NO inhibits adhesion molecule 
expression.  
The results of this experiment suggest that BVR does not inhibit TNFα-induced monocyte 
adhesion via the PI3K/Akt/eNOS/NO pathway. Moreover, we actually see a decrease in 
TNFα-induced monocyte adhesion with PI3K inhibition in both control and BVR 
overexpressing cells, suggesting that the PI3K/Akt axis is pro-inflammatory in our system. 
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We evaluated the roles of the p38 MAPK, ERK1/2 and JNK pathways in the modulation of 
TNFα-induced monocyte adhesion by BVR (Figures 5.5, 5.6 and 5.7 respectively). Indeed, 
previous studies have suggested that BVR activates these pathways (Kapitulnik and Maines, 
2009). A number of studies have shown that these three pathways, in addition to the NFκB 
pathway, are activated by TNFα and are involved in adhesion molecule expression (Paul et al, 
1997 and Schmitz et al, 2001). We therefore wondered whether BVR was exerting its effects 
Figure 5.4 BVR inhibits TNFα-induced monocyte adhesion independently of PI3K/Akt activation. 
HUVECs were grown in 24 well plates and infected. Approximately 24hrs later, the cells were pre-
treated for 1hr with 10µM LY294002 (LY) in HUVEC starvation medium as indicated. 10ng/mL 
TNFα was then applied as indicated for 6hrs. Then, THP-1 cells were applied to each well (2 X 
105/well) and allowed to adhere for 1hr. The HUVEC monolayer was then washed, fixed and 
analysed. ** p < 0.001 vs. CMV with identical treatment. These results represent the mean ± SEM 
of one experiment performed in triplicate. Five randomly chosen fields of view per well were 
analyzed.          
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on adhesion molecule expression by inhibiting one, or a combination of these pathways, or 
indeed whether these pathways made any contribution to adhesion molecule expression. 
We utilized a pharmacological strategy; SB203580 (SB) to inhibit p38, SP600125 (SP) to 
inhibit JNK and PD98059 (PD) to inhibit MEK1 (and therefore ERK1/2).  
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Figure 5.5 BVR inhibits TNFα-induced adhesion molecule expression independently of the p38 
pathway. Flow cytometric analyses utilizing anti-ICAM-1, anti-VCAM-1 and anti-E-Selectin 
antibodies. HUVECs were grown in 12-well plates and infected as indicated. Approximately 24hrs 
later, HUVECs were pre-treated as indicated with 5µM SB203580 (SB) for 1hr in HUVEC starvation 
medium. Then, TNFα was applied for 6hrs in fresh medium as indicated. The cells were then 
harvested and subsequently analyzed. The results indicate that the p38 pathway has a limited 
role in TNFα-induced adhesion molecule expression in our system. These results represent the 
mean ± SEM of one experiment performed in single wells.             
 
129 
 
None TNF SP TNF+SP None TNF SP TNF+SP None TNF SP TNF+SP
0
5
10
15
20
25
30
35
40
45
50
55
60
65
CMV
AdBVR
ICAM-1 VCAM-1 E-Selectin
Treatment (6hrs)
M
e
d
ia
n
-F
IT
C
 
 
 
 
 
 
 
 
Figure 5.6 BVR inhibits TNFα-induced adhesion molecule expression independently of the JNK 
pathway. Flow cytometric analyses utilizing anti-ICAM-1, anti-VCAM-1 and anti-E-Selectin 
antibodies. HUVECs were grown in 12-well plates and infected as indicated. Approximately 24hrs 
later, HUVECs were pre-treated as indicated with 30µM SP600125 (SP) for 1hr in HUVEC 
starvation medium. Then, TNFα was applied for 6hrs in fresh medium as indicated. The cells were 
then harvested and subsequently analyzed. The results indicate that the JNK pathway has a 
limited role in TNFα-induced adhesion molecule expression in our system. These results 
represent the mean ± SEM of one experiment performed in single wells.             
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The results indicate that p38, JNK and ERK1/2 are not involved in TNFα-induced ICAM-1 and 
VCAM-1 expression in our system. To a small extent, p38 appears to contribute to TNFα-
induced E-Selectin expression. However, we can safely conclude that BVR does not inhibit 
adhesion molecule expression by inhibiting these pathways.  
 
Figure 5.7 BVR inhibits TNFα-induced adhesion molecule expression independently of ERK1/2. 
Flow cytometric analyses utilizing anti-ICAM-1, anti-VCAM-1 and anti-E-Selectin antibodies. 
HUVECs were grown in 12-well plates and infected as indicated. Approximately 24hrs later, 
HUVECs were pre-treated as indicated with 30µM PD98059 (PD) for 1hr in HUVEC starvation 
medium. Then, TNFα was applied for 6hrs in fresh medium as indicated. The cells were then 
harvested and subsequently analyzed. The results indicate that ERK1/2 is not involved in TNFα-
induced adhesion molecule expression in our system. These results represent the mean ± SEM of 
one experiment performed in single wells.             
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Cytotoxicity 
We sought to determine whether BVR could protect HUVECs against oxidative stress – as 
associated with hydrogen peroxide and ox-LDL (Figures 5.8, 5.9 and 5.10). BVR produces 
bilirubin which protects against oxidative stress, possibly via a biliverdin-bilirubin redox 
cycle (Sedlak and Snyder, 2009). Furthermore, we have demonstrated that BVR increases 
NO production (Figure 4.3), and NO is involved in protection against oxidative stress (Napoli 
et al, 2006). 
We incorporated hemin, the substrate for biliverdin (and hence bilirubin) synthesis. Ox-LDL 
was generated from native LDL using a well-established method of CuSO4-mediated 
oxidation (Esterbauer et al, 1992). A TBARs assay was then conducted to ensure that the LDL 
had indeed been oxidized (not shown).  
We conducted MTT assays to assess HUVEC viability under these conditions, and at various 
time-points, with or without BVR overexpression.  
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Figure 5.8 BVR is not cytoprotective against oxidative stresss in a MTT assay. MTT assay 
conducted following 2hrs exposure to cytotoxic agents. HUVECs were grown in 96-well plates 
and infected as indicated. Approximately 24hrs later, HUVECs were pre-treated with 5µM hemin 
for 1hr. Then, treatments were applied as indicated in HUVEC starvation medium for 2hrs. MTT 
was then added in serum-free medium and incubated for 4hrs, after which the solution was 
aspirated and DMSO applied. The results indicate that BVR overexpression does not protect 
against cytotoxicity associated with oxidative stress. ** p < 0.05 vs. same virus, no treatment 
control. These results represent the mean ± SEM of one experiment performed in duplicate 
wells.             
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Figure 5.9 BVR is not cytoprotective against oxidative stress in a MTT assay. MTT assay 
conducted following 4hrs exposure to cytotoxic agents. HUVECs were grown in 96-well plates and 
infected as indicated. Approximately 24hrs later, HUVECs were pre-treated with 5µM hemin for 
1hr. Then, treatments were applied as indicated in HUVEC starvation medium for 4hrs. MTT was 
then added in serum-free medium and incubated for 4hrs, after which the solution was aspirated 
and DMSO applied. The results indicate that BVR overexpression does not protect against 
cytotoxicity associated with oxidative stress. ** p < 0.05 vs. same virus, no treatment control. 
These results represent the mean ± SEM of one experiment performed in duplicate wells.             
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The results suggest that BVR overexpression in HUVECs does not protect against H2O2-
associated oxidative stress. We found that although the LDL had been significantly oxidized, 
the ox-LDL was not cytotoxic to the HUVECs in our system. Hemin was generally ineffective 
in protecting against H2O2-associated cytotoxicity and had only a small (insignificant) effect 
on increasing viability at the 4hr time-point. 
 
Figure 5.10 BVR is not cytoprotective against oxidative stress in a MTT assay. MTT assay 
conducted following 6hrs exposure to cytotoxic agents. HUVECs were grown in 96-well plates and 
infected as indicated. Approximately 24hrs later, HUVECs were pre-treated with 5µM hemin for 
1hr. Then, treatments were applied as indicated in HUVEC starvation medium for 6hrs. MTT was 
then added in serum-free medium and incubated for 4hrs, after which the solution was aspirated 
and DMSO applied. The results indicate that BVR overexpression does not protect against 
cytotoxicity associated with oxidative stress. ** p < 0.05 vs. same virus, no treatment control. 
These results represent the mean ± SEM of one experiment performed in duplicate wells.             
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Nitric Oxide 
We examined the effect of BVR overexpression on NO release in a number of different cell-
types. Amongst these, we tested human aortic endothelial cells (HAECs). Due to the aortic 
origin of this cell line, the ‘eNOS/NO system’ is of greater similarity to endothelial cells from 
atherosclerosis-susceptible arteries (Figure 5.11). 
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Figure 5.11 BVR and HO-1 have opposing effects on nitric oxide release in HAECs during a 30min 
stimulation. Cell-free medium was incubated alongside the samples to correct for NO indigenous 
to the medium itself. HAECs were infected as indicated in RPMI 1640 (+ 0.2% BSA) medium. 
Approximately 24hrs later, fresh RPMI 1640 medium was gently added to each well, being careful 
to avoid shear stress. The cells were incubated for 30mins before medium was removed into 
tubes and frozen at -80°C until analysis. These data represent the mean ± SEM of one experiment 
conducted in triplicate wells.        
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The results from this experiment were not conclusive. BVR overexpression did not 
significantly alter NO release (compared to CMV control), whilst HO-1 overexpression 
reduced NO release. Interestingly, BVR overexpression had a significantly opposite effect to 
HO-1 overexpression. 
In another experiment, we attempted to evaluate the optimal duration of stimulation for 
NO release in HUVECs, the time-point at which BVR overexpression would have the largest 
impact on NO generation (Figure 5.12). We tested three different time-points; 30mins, 
60mins and 90mins. 
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Figure 5.12 Measured NO release decreases with duration of stimulation in HUVECs. Cell-free 
medium was incubated alongside the samples to correct for NO indigenous to the medium itself. 
HUVECs were infected as indicated in RPMI 1640 (+ 0.2% BSA) medium. Approximately 24hrs 
later, fresh RPMI 1640 medium was gently added to each well, being careful to avoid shear 
stress. The cells were incubated for 30, 60 and 90mins before medium was removed into tubes 
and frozen at -80°C until analysis. These data represent the mean ± SEM of one experiment 
conducted in triplicate wells.        
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The results from this experiment were inconclusive. We found that BVR overexpression 
actually slightly (insignificantly) decreased NO release at all three time-points, the opposite 
of what we expected. Interestingly, the measured NO release decreased with the duration 
of stimulation.   
 
NFκB Activation 
Many of our experiments centered on evaluating the ability of BVR to suppress the TNFα-
induced expression of (largely) NFκB-dependent genes (i.e. adhesion molecules and MCP-1). 
NFκB activation is dependent on the degradation of IκBα (Figure 1.13). IκBα effectively 
sequesters inactive NFκB in the cytoplasm. Upon stimulation (i.e. TNFα), IKK phosphorylates 
IκBα thus marking it for degradation via the ubiquitin-proteasome pathway. IκBα levels can 
therefore indicate the extent of NFκB activation. We decided to conduct a Western blot for 
intracellular IκBα levels in the presence/absence of AdBVR, TNFα, and various inhibitors, at 
two different time-points (Figure 5.13).     
The first lane for each treatment represents CMV-infected cells whilst the second lane for 
each treatment represents AdBVR-infected cells (Figure 5.13). If we consider just the TNFα 
treatment, we see that BVR overexpression decreases IκBα degradation 1hr post TNFα 
stimulation. Surprisingly however, BVR overexpression is associated with increased IκBα 
degradation at 6hrs post-stimulation. SnPP appears to inhibit TNFα-induced IκBα 
degradation. At 1hr and 6hrs post-stimulation (with TNFα and SnPP) however, BVR still 
appears to marginally inhibit IκBα degradation.  
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PI3K inhibition appears to substantially reduce TNFα-induced IκBα degradation at both time-
points. BVR overexpression in the presence of TNFα and LY appears to slightly increase IκBα 
levels at both time-points. 
Although some of our experiments suggested that the NFκB activation inhibitor (NAI) was 
ineffectual, it clearly inhibits IκBα degradation at both 1hr and 6hrs post-stimulation. The 
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Figure 5.13 Western blots for IκBα at 1- and 6hrs post-stimulation in the presence/absence of 
various inhibitors and AdBVR in HUVECs. Importantly, the first lane for each treatment is CMV-
infected cells whilst the second lane for each treatment represents AdBVR-infected cells. 
HUVECs were grown in 12 well plates and infected. Approximately 24hrs later, the cells were 
pre-treated for 1hr with inhibitors (i.e. 20µM SnPP, 10µM LY, 10µM NAI and 1µM RO31) in 
HUVEC starvation medium as indicated. 10ng/mL TNFα was then applied as indicated for 1hr 
(top) or 6hrs (bottom). Cell lysates were then harvested and analyzed via SDS-PAGE. 
Unfortunately, the poor quality of the β-actin blot precluded quantification. These results are 
representative of one experiment.  
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RO31 inhibitor was utilized at a concentration of 1µM. It does not appear to completely 
attenuate TNFα-induced IκBα degradation at either time-point. In comparison to TNFα 
treatment only however, RO31 does appear to reduce TNFα-induced IκBα degradation, 
particularly at the 6hr time-point. In the presence of RO31, BVR overexpression is associated 
with greater TNFα-induced IκBα degradation at the 6hr time-point – as is the case at the 6hr 
time-point with TNFα only.  
The results from this experiment are of great significance, and highly relevant to many of 
our earlier experiments, and therefore certainly merit repetition to ensure accuracy and 
reliability, and to allow quantification.  
Below, representative monocyte adhesion assay images are shown: 
  
 
 
 
 
 
CMV AdBVR 
 
+TNFα 
Figure 5.14 Representative 10X monocyte adhesion assay images. HUVECs were grown in 24 well 
plates and infected. 24hrs later, pre-treatments with inhibitors were carried out as required for 
1hr in HUVEC starvation medium. Then, 10ng/mL TNFα was applied for 6hrs before the monolayer 
was washed fixed and stained. Monocytes (small dark circles) were counted using Image-Pro Plus 
software.      
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Validation 
Although previous studies have transduced AdBVR constructs into HEK293A cells, and 
therefore independently validated that BVR overexpression is a suitable method in terms of 
characterising the enzyme (Kravets et al, 2004), investigators have not yet published 
findings involving AdBVR-transduced endothelial cells. 
In our preliminary experiments, very high MOIs (i.e. >400) of AdBVR were found to induce 
cell death – as evidenced by microscopic examination of cell structure and, the substantially 
lower protein yields from these wells. In addition to allowing us to determine optimal MOIs 
for these constructs, these experiments also confirmed that native BVR protein expression 
in endothelial cells (i.e. in HUVECs) is undetectable (Figure 3.1, A). Importantly, we 
substantially increased autoradiographic exposure time (1hr) and BVR remained 
undetectable. 
An in-cell ELISA system was optimised for the present study. This required optimal antibody 
concentrations to be detertmined (Figure 3.3). Although we found the in-cell ELISA system 
to be more time-efficient and more economical than Western blotting, the sensitivity of this 
method was low. Hence, when BVR was overexpressed using AdBVR, the signal increased by 
approximately sevenfold only, in comparison to non-transduced cells (Figure 3.3, B). 
However, Western blotting reveals a much larger (essentially unquantifiable) discrepancy 
between BVR protein levels in non-transduced and transduced cells, also at 50 MOI (Figure 
3.1, A). The different spatial expression profile of different proteins is one factor likely to 
affect the sensitivity of this assay – i.e. because the proteins are fixed in situ. Hence, whilst 
this assay is preferable to traditional Western blotting when large differences in expression 
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are expected and require confirmation; it is not suitable for detecting small changes in 
expression. However, higher sensitivities may have been achieved with other antibodies.  
Many of our experiments utilised SnPP, a HO-1 inhibitor, to inhibit bilirubin production such 
that the reductase properties of BVR could be distinguished from its other non-canonical 
functions. HO-1 inhibition deprives BVR of its substrate, biliverdin. This has the effect of 
reducing bilirubin production because HO-1 is rate-limiting for its formation. However TNFα, 
an important mediator of the chronic inflammatory milieu, has the effect of increasing both 
the reductase and kinase activities of BVR (Lerner-Marmarosh et al, 2007). We were 
therefore keen to evaluate the effects of our inhibitor on intracellular unconjugated 
bilirubin levels under various experimental conditions (Figure 3.5). 
Although HO-1 activity (i.e. rate of bilirubin production) has been measured for a number of 
decades, the HPLC methodology used to analyse levels of intracellular unconjugated 
bilirubin in our samples was only recently developed (Zelenka et al, 2008). Unfortunately 
therefore, comparative data are not available. It is advantageous to measure intracellular 
unconjugated bilirubin because this is the active version of bilirubin (Mazzone et al, 2009). 
HO-1 activity assays on the other hand measure both conjugated (no relevant biological 
activity) and unconjugated bilirubin. Samples were collected and then sent to Prof Libor 
Vitek (Charles University, Czech Republic) to be assayed for intracellular bilirubin using HPLC. 
A number of considerations are important before our results (Figure 3.5) can be interpreted. 
First, HO-1 activity in HUVECs is approximately 0.6nmol bilirubin produced/mg protein/hr 
(Wagener et al, 1999) and unconjugated bilirubin concentration in tissues is approximately 
10nM (Malik et al, 2010). Second, we must remember that BVR is known to induce 
expression of the rate-limiting enzyme for bilirubin formation, HO-1 (Figure 4.4 and Tudor et 
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al, 2008). Third, that HO-1 substrate (i.e. heme) depletion may be occurring as a result of 
BVR overexpression (Sedlak and Snyder, 2009). In this regard, one could imagine that BVR 
overexpression depletes heme before the experiment has begun. This would lead to lower 
unconjugated bilirubin levels in AdBVR-transduced cells. Finally, that the experiment begins 
with a change of medium – from 20% FCS HUVEC complete medium to 5% HUVEC starvation 
medium. This could potentially affect HO-1 activity.       
Given that HO-1 activity in HUVECs under basal conditions is approximately 0.6nmol 
bilirubin produced/mg protein/hr (Wagener et al, 1999 and others), it is dubious that 
unconjugated bilirubin levels increase from approximately 6nmol/mg protein to 21nmol/mg 
protein in CMV-infected cells, in just 6hrs. It would have been useful to compare this to a 
none-infected control, in order to rule out a CMV non-specific effect. 
The reduced bilirubin levels seen for TNFα-treated (Figure 3.5, B), CMV-infected cells may be 
due to ROS-mediated oxidation of bilirubin (to species other than biliverdin). It is well 
established that TNFα induces intracellular ROS generation in HUVECs (Lee et al, 2010). It is 
also known that TNFα induces HO-1 gene expression (Terry et al, 1999). Interestingly, the 
opposite effect is seen for TNFα-treated, AdBVR-infected cells – bilirubin increases 
compared to the control. This may be due to the increased reductase activity of BVR in 
response to TNFα (Lerner-Marmarosh et al, 2007). It is also likely due to the higher HO-1 
activity in the AdBVR-infected cells (because BVR upregulates HO-1 expression) and this 
would explain the relatively large reduction in bilirubin seen when SnPP is added. 
It is important to note that SnPP is a widely used inhibitor of bilirubin production (i.e. HO-1 
activity). Indeed Pae et al utilised the same concentration (20µM) of SnPP, and found that a 
6hr incubation reduced bilirubin production in HUVECs to below basal levels, even in the 
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presence of a compound which induces HO-1 activity (Pae et al, 2005). This is therefore 
compelling evidence that our methodology – i.e. using SnPP to attenuate the reductase 
activity of BVR – is indeed valid. Also, given that the investigators demonstrate a nearly 5-
fold increase in bilirubin production following pharmacological induction of HO-1 (i.e. 
increased HO-1 protein expression) over 6hrs; it is unlikely that heme depletion is occurring 
at this time point.  
In summary, we have validated our utilisation of SnPP to prevent increases in bilirubin 
production associated with BVR overexpression; even in the presence of TNFα, which 
increases the reductase activity of BVR. Athough we would have ideally repeated our SnPP 
validation experiment at least three times, we can be confident of our methodology 
because SnPP is a ubiquitously used inhibitor of bilirubin production.           
 
Results 
BVR Activates the PI3K/Akt/eNOS/NO Pathway 
BVR possesses a dual-specificity kinase activity and several studies have already examined 
the contributions of the enzyme to inflammatory signaling. However, no such study has 
addressed this issue in endothelial cells, the site at which atherosclerosis first develops in 
the form of endothelial dysfunction. Whilst the protein expression levels of BVR in 
endothelial cells is known to be very low, knockdown studies have confirmed the 
significance of this low-level expression in such cells (Jansen et al, 2010). Furthermore TNFα, 
an important cytokine involved in atherosclerosis, upregulates both the reductase and 
kinase activities of BVR (Lerner-Marmarosh et al, 2007), further increasing the significance 
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of any cell signaling contribution. Previous studies have shown that BVR activates Akt in 
HEK293, HK-2 and H9c2 cells (Zeng et al, 2008 and Pachori et al, 2007); there is no published 
evidence demonstrating this in endothelial cells. 
We utilised a PI3K inhibitor to precipitate the phenomena of BVR-induced Akt activation 
(Figure 4.1, A). The Western blot analysis reveals that in the presence of PI3K inhibition, BVR 
activates Akt. However, we do not see higher Akt activation in the BVR overexpressing cells 
under basal conditions (i.e. in the absence of the PI3K inhibitor), perhaps because Akt 
activation is already high under these conditions. However the in-cell ELISA reveals that 
even under basal conditions, BVR overexpression is associated with increased Akt activation 
(Figure 4.1, B). 
Although our focus was to demonstrate BVR-mediated Akt activation and downstream 
eNOS activation, we must also remember that Akt serves numerous other functions in 
endothelial cells unrelated to eNOS activation. For example Akt promotes cell survival and 
angiogenesis, and in this regard is important in protecting against atherosclerosis and 
consequences thereof (Shiojima and Walsh, 2002). Our experiments have demonstrated 
that BVR strongly activates Akt in endothelial cells (i.e. HUVECs). We can be particularly 
confident of this finding because we utilized two different methods; traditional Western 
blotting and an in-cell ELISA. 
Given the association of Akt activation with eNOS activation in endothelial cells (Fulton et al, 
1999), we also sought to demonstrate that BVR could induce NO release via this pathway. 
This is important because deficiency of NO is characteristic of endothelial dysfunction and, 
numerous therapies for atherosclerosis (either already in use or in development) act to 
increase NO bioavailability (Li and Forstermann, 2009). We demonstrated that BVR 
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overexpression was associated with eNOS S1177 phosphorylation (Figure 4.2). 
Phosphorylation of this residue is a marker of eNOS activation and is indicative of 
downstream NO release.  
Unfortunately, we were unable to demonstrate increased NO release in AdBVR-infected 
HUVECs. We believe that the reasons for this are technical, and related to the abnormal 
temperature-regulation of our Sievers NOA machine. Although we were aware of other 
methods by which NO could be analyzed in cell culture medium, we decided that the costs 
involved in changing strategy were prohibitive. We therefore improvised a cooling 
mechanism for our machine and proceeded to use PAECs instead of HUVECs. As a stable cell 
line, we felt that the PAECs would give us consistent and reproducible results and that their 
aortic origin (as opposed to umbilical) would be conducive to the extrapolation of our 
findings to in vivo atherosclerotic scenarios. We demonstrated that BVR overexpression was 
associated with an approximately two-fold increase in NO release over 30mins (Figure 4.3).  
However, we cannot decipher whether the NO released into the medium is eNOS-derived or 
iNOS-derived. This is of relevance because BVR has been shown to induce iNOS gene 
expression in HEK293A cells via NFκB activation (Gibbs and Maines, 2007). Incorporation of 
an eNOS selective inhibitor (e.g. L-NNA) into our experiments would have allowed us to 
determine the relative contributions of eNOS and iNOS to BVR-mediated NO release. 
Importantly, iNOS is implicated in pathological inflammatory processes. For example, 
Detmers et al found that ApoE-/- iNOS-/- mice had substantially reduced atherosclerotic 
lesion sizes compared to ApoE-/- iNOS+/+ mice (Detmers et al, 2000). However given the 
strong degree of BVR-induced eNOS activation (i.e. S1177 phosphorylation), it is likely that 
at least some of the NO release is attributable to eNOS. 
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In summary, we have demonstrated the existence of a BVR/PI3K/Akt/eNOS/NO pathway in 
endothelial cells. This finding is highly novel and published studies have not yet 
demonstrated the existence of this pathway in any cell type. The importance of NO in 
suppressing the initiation and progression of atherosclerosis is well established. Given that 
TNFα, a prominent cytokine in atherosclerosis, increases both the reductase and kinase 
activities of BVR, it is tempting to speculate the existence of an anti-atherosclerotic defense 
mechanism in which TNFα induces NO release via BVR. However, knockout/knockdown 
studies are required to elucidate the pathophysiological significance of such a mechanism. 
We believe that the signaling activities of BVR in endothelial cells, which are as yet wholly 
unaddressed by published studies, are likely to be of significance in atherosclerosis (and 
other chronic inflammatory diseases). Positive modulators of BVR activity in the 
endothelium may be found and developed, in addition to gene therapy approaches. 
 
BVR Induces HO-1 Expression 
HO-1 is the rate-limiting enzyme in bilirubin production and for this reason, increased BVR 
activity may not correlate with increased bilirubin production. However if BVR were to 
increase HO-1 activity (i.e. by increasing its protein expression) we could then assume that 
BVR overexpression does indeed increase bilirubin production if substrate availability is not 
limiting.  
That BVR is directly involved in gene expression, as a transcription factor, is suggested by its 
possession of a bZip domain. Indeed the association of BVR with induction of HO-1 
expression is certainly not novel. Ahmad et al first demonstrated that BVR was involved in 
oxidative stress-induced HO-1 expression in COS cells (Ahmad et al, 2002). Subsequently, 
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the ability of the reductase to induce HO-1 expression in HEK293A cells was demonstrated 
(Kravets et al, 2004). BVR binds as a homodimer to various regulatory elements in the HO-1 
promoter, including for example the antioxidant response element (Tudor et al, 2008). Aside 
from its own transcription factor capacity, BVR influences the activities of transcription 
factors involved in HO-1 expression. Most notable amongst these is NFκB; BVR increases 
NFκB activation (Gibbs and Maines, 2007) and this, theoretically at least, leads to HO-1 
expression. This is because the link between NFκB activation and HO-1 gene expression is 
well-established, in numerous cell-types (Alam and Cook, 2007). 
We have shown that BVR does indeed increase HO-1 protein expression in HUVECs (Figure 
4.3). However, our findings do not reveal the mechanism by which BVR induces HO-1 
expression. This may occur directly via BVR’s transcription factor activity or indirectly, for 
example through BVR-mediated NFκB activation and subsequent HO-1 expression.   
In summary, we have demonstrated that therapeutic strategies aiming to upregulate BVR in 
the endothelium will have the secondary benefit of increasing HO-1 expression. This confers 
greater substrate flux through the HO-1/BVR axis and also therefore increases levels of CO, 
a powerful anti-inflammatory molecule which protects against atherosclerosis (Durante et al, 
2006). However our experiments do not reveal the mechanism by which BVR induces HO-1 
gene expression; whether via direct DNA binding via its transcription factor capacity or, via 
modulation of NFκB activity. Nonetheless, this finding has important implications in terms of 
determining flux through the HO-1/BVR axis, because HO-1 is rate-limiting. In this regard, it 
might have been argued that therapeutic strategies aiming to induce BVR in the 
endothelium will not lead to bilirubin production, because HO-1 is rate-limiting. Our finding 
suggests that this is not the case because BVR induces HO-1 protein expression. 
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BVR & Ox-LDL 
Our preliminary studies suggested that BVR overexpression in HUVECs does not result in 
increased bilirubin levels (Figure 3.5). As discussed previously, bilirubin has a well-
established antioxidant effect, which protects against LDL oxidation in Gilbert’s syndrome 
patients. However, our earlier experiments had demonstrated that BVR could 
phosphorylate eNOS S1177 and in so doing increase NO production (Figure 4.3). Reduced 
NO bioavailability is a characteristic feature of atherosclerosis and previous studies 
conducted in our lab have demonstrated that increased NO release is the mechanism by 
which angiopoietin-2 confers reduced LDL oxidation in the atherosclerotic plaques of apoE-/- 
mice. This was shown to correlate with reduced atherosclerotic plaque size (Ahmed et al, 
2009).  
Our findings indicate that BVR overexpression is not significantly associated with reduced 
LDL oxidation (Figure 4.5), independently of bilirubin production via the 
BVR/PI3K/Akt/eNOS/NO pathway, or otherwise. In our preliminary experiments, we showed 
that BVR overexpression was not associated with increased unconjugated bilirubin 
production (Figure 3.5). This may, in part, explain why BVR overexpression does not reduce 
LDL oxidation in our system. Given that increased bilirubin is associated with reduced LDL 
oxidation, we could have incorporated heme (the ultimate substrate for bilirubin production) 
into the experiment. However this would have confounded the experiment because heme 
strongly induces HO-1. That bilirubin production by BVR is important in protection against 
oxidative stress was demonstrated in a recent study utilising a siRNA-mediated BVR 
knockdown strategy (Jansen et al, 2010). 
150 
 
HO-1 overexpression had a significantly opposite effect to BVR overexpression, and was 
therefore associated (non-significantly) with increased LDL oxidation relative to the CMV 
controls. This may be attributable to increased Fe2+ (although this would induce ferritin 
synthesis and sequestration) or increased CO, which may be acting in a pro-oxidant manner 
(Piantadosi, 2008). Also, heme depletion (in AdHO-1 cells) may reduce flux through the HO-1 
pathway such that the reduction in bile pigment generation results in increased LDL 
oxidation in AdHO-1 cells. 
In summary, BVR does not appear to significantly reduce LDL oxidation via the 
BVR/PI3K/Akt/eNOS/NO pathway. Given that BVR induces HO-1 protein synthesis, it may be 
the case that BVR overexpression does increase bilirubin production if substrate availability 
is not limiting and this may or may not correlate with reduced LDL oxidation.     
 
BVR Attenuates TNFα-Induced Leukocyte-Endothelium Adherence 
In short, we have shown that BVR substantially attenuates endothelial TNFα-induced MCP-1 
release, adhesion molecule expression (i.e. ICAM-1, VCAM-1 and E-Selectin) and monocyte 
adherence. These findings are highly novel and indeed highly surprising in regard to a 
previous study by Lerner-Marmarosh et al (Lerner-Marmarosh et al, 2007). In this study, the 
authors demonstrated that BVR induces the TNFα/PKCζ/NFκB pathway in HEK293 cells – 
suggesting that BVR increases TNFα-induced NFκB activation. Our experiments, in 
endothelial cells, are not in agreement with this model. 
TNFα is an inflammatory cytokine and serves a critical role in chronic inflammatory diseases 
such as atherosclerosis (Figure 1.16). Most relevantly to our studies, the cytokine induces 
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ROS generation and also various pro-inflammatory genes, including MCP-1 and adhesion 
molecules, via NFκB activation (Zhang et al, 2009). The current consensus in the literature is 
that the dual-specificity kinase activities of BVR are almost completely associated with 
induction of inflammation, especially via NFκB (and to a lesser extent, JNK and p38) 
activation and subsequent pro-inflammatory gene expression (Kapitulnik and Maines, 2009). 
Indeed, BVR potentiates TNFα-induced inflammatory gene induction, via PKCζ activation in 
HEK293 cells (Lerner-Marmarosh et al, 2007). This would suggest that BVR is in fact pro-
inflammatory. On the other hand, BVR generates bilirubin which is a potent antioxidant, and 
anti-inflammatory molecule. Bilirubin has been shown to inhibit NFκB activation (Liu et al, 
2008) and in this regard, low nanomolar concentrations can attenuate TNFα-induced 
adhesion molecule expression (Mazzone et al, 2009). Bilirubin also attenuates increases in 
ROS levels associated with TNFα stimulation (Basuroy et al, 2009).    
Our experiments suggest that BVR attenuates TNFα-induced MCP-1 release, adhesion 
molecule expression and monocyte adherence independently of bilirubin production. 
Bilirubin production was inhibited using SnPP. A recent study showed that SnPP (used at the 
same concentration and over the same time-point as in our experiments) does indeed 
attenuate bilirubin production to below basal levels in HUVECs (Pae et al, 2006). In addition 
we had previously shown that BVR overexpression in our system was not associated with 
increased intracellular unconjugated bilirubin levels (Figure 3.5). Taken together therefore, 
our experiments suggest that BVR is capable of attenuating TNFα-induced leukocyte-
endothelium adherence independently of its bilirubin-generating capacity. 
The results of our MCP-1 ELISA (Figure 4.6) are in agreement with our previous finding that 
BVR overexpression does not increase intracellular bilirubin levels. Inhibition of NFκB 
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activation does not appear to completely suppress TNFα-induced MCP-1 release in the 
control. This may indicate that our inhibitor is ineffective. 
The MCP-1 ELISA results are remarkable for two reasons; 1, BVR continues to inhibit MCP-1 
when bilirubin production is blocked with SnPP and 2, the aforementioned (Figure 1.15) 
TNFα/PKCζ/NFκB activation pathway – of which BVR is a potentiator – is not evident, or at 
least does not dominate, in our system. With regard to the former, bilirubin has been 
associated with attenuation of NFκB activation, and consequently reduced pro-
inflammatory gene expression (Mazzone et al, 2009). In regard to the latter, BVR is either 
not a significant participant in this pathway in our system or, some component of MCP-1 
release occurs via a mechanism not involving NFκB (e.g. p38 pathway). 
We also examined the role of the BVR/PI3K/Akt axis in TNFα-induced leukocyte-
endothelium adherence. Whilst we have demonstrated that this pathway may lead to NO 
generation (Figure 4.2), which may in turn inhibit NFκB activation (Zeiher et al, 1995), there 
is also strong evidence that Akt activates IKK, and consequently NFκB (Meng et al, 2002). 
Taken together, our results show that the BVR/PI3K/Akt/eNOS/NO pathway has no 
dominant effect (positive or negative) on TNFα-induced monocyte adherence. We can 
therefore conclude that BVR does not reduce adhesion molecule expression or monocyte 
adherence via this pathway. However, inhibition of PI3K reduces TNFα-induced monocyte 
adhesion in CMV control cells (Figure 4.10). This indicates that the net effect of the PI3K/Akt 
pathway is to increase TNFα-induced monocyte adhesion, possibly via the 
PI3K/Akt/IKK/NFκB pathway. Specifically this appears to be attributable, at least in part, to 
VCAM-1 upregulation (Figure 4.9). The upregulation of VCAM-1 may occur via the 
aforementioned PI3K/Akt/IKK/NFκB pathway. 
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In this set of experiments (utilising LY), our flow cytometric analyses show that BVR does not 
significantly attenuate TNFα-induced E-Selectin expression (Figure 4.9). However, the other 
sets of flow cytometric analyses prove otherwise and we conclude that this is due to 
experimental variability. Experimental variability is also likely responsible for the none-
significant difference between TNFα-induced, PI3K-inhibited, VCAM-1 expression in CMV vs. 
AdBVR cells. 
Our studies on leukocyte-endothelium adherence incorporated an NFκB Activation Inhibitor 
(NAI). We expected that this inhibitor would completely attenuate TNFα-induced increases 
in MCP-1 and adhesion molecule expression. However, the NAI appeared to have little or no 
effect. It reduced TNFα-induced MCP-1 release by less than 30% (Figure 4.6) and had no 
effect on VCAM-1 or E-Selectin expression (Figure 4.11). TNFα-induced ICAM-1 was reduced 
by less than 25%. This may indicate that our inhibitor is ineffective or that TNFα-induced 
expression of these adhesion molecules occurs, to some extent, independently of NFκB 
activation or indeed independently of transcription altogether, in this system. However, we 
also examined the roles of the p38, JNK and ERK1/2 in TNFα-induced adhesion molecule 
expression and found these pathways to make little or no contribution (supplementary 
results). It is therefore tempting to conclude that our inhibitor is ineffective however, our 
Western blots for IκBα show that the NAI does indeed have some effect (supplementary 
results). 
We also examined the role of the BVR/PKCζ axis in leukocyte-endothelium adherence. Both 
the kinase and reductase activities of BVR are increased by TNFα, and PKCζ is essential in 
TNFα-induced NFκB activation (Nigro et al, 2010). Importantly, BVR increases PKCζ activity 
and vice versa. One could therefore postulate the existence of a TNFα/BVR/PKCζ/NFκB 
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pathway in which BVR is acting in a pro-inflammatory manner (Lerner-Marmarosh et al, 
2007). Our flow cytometric analyses utilised RO31, an inhibitor of PKCζ, and confirmed the 
essentiality of PKCζ in TNFα-induced adhesion molecule expression. More importantly, we 
demonstrated that BVR does not increase monocyte adhesion via the TNFα/BVR/PKCζ/NFκB 
pathway. 
In summary, we have demonstrated that positive modulation of BVR activity is likely 
associated with attenuation of leukocyte-endothelium adherence in the inflammatory 
milleu of atherosclerosis. Specifically, BVR was found to reduce TNFα-induced expression of 
endothelial MCP-1 and adhesion molecules (i.e. VCAM-1, ICAM-1 and E-selectin), in a 
manner that is independent of bilirubin production and the PI3K/Akt axis. Although previous 
studies (Lerner-Marmarosh et al, 2007 and Gibbs and Maines, 2007) have suggested that 
BVR increases NFκB activation, partly via increased PKCζ activation, our study strongly 
suggests that in endothelial cells at least, BVR has an anti-inflammatory effect.          
 
Supplemetary Results 
Leukocyte-Endothelium Adherence 
Our preliminary experiments examining how BVR overexpression affects leukocyte-
endothelium adherence utilised both THP-1 and PBMCs. PBMCs include both lymphocytes 
and monocytes whilst THP-1 cells are derived from a monocytic cell line. 
BVR has multilateral effects on the flavin enzymes (e.g. the NOSs and NOXs) and we 
therefore utilised DPI, an inhibitor of flavin enzymes, to clarify the interplay between BVR, 
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the flavin enzymes and THP-1 adherence in HUVECs (Figure 5.1). DPI reduces TNFα-induced 
THP-1 adherence in both CMV and AdBVR infected cells. The results therefore indicate that 
the net, combined effect of flavin enzymes (including for example eNOS and NOXs) is to 
increase monocyte adhesion. Also, we can infer that the BVR/PI3K/Akt/eNOS/NO pathway is 
not responsible for the attenuation of TNFα-induced THP-1 adherence in BVR 
overexpressing cells. 
We utilised both THP-1 and PBMCs in preliminary experiments to examine how SnPP affects 
BVR’s ability to attenuate TNFα-induced adherence. Whilst SnPP significantly increased 
TNFα-induced THP-1 adherence (Figure 5.2), the opposite effect was observed with PBMCs 
– SnPP significantly reduced PBMC adherence (Figure 5.3). The former is consistent with the 
notion that HO-1-derived products (e.g. bilirubin) inhibit monocyte adhesion whilst the 
latter indicates that HO-1 has some pro-inflammatory component. However neither effect 
was observed when the same experiment was conducted with pure human monocytes 
(Figure 4.8). 
PI3K inhibition reduced TNFα-induced THP-1 adhesion in both control and BVR 
overexpressing cells (Figure 5.4). However, when this experiment was repeated with 
monocytes isolated from human whole blood, we found that PI3K inhibition was only 
associated with reduced TNFα-induced monocyte adhesion in the control cells (Figure 4.10). 
It is likely that this is reflective of experimental variability – the experiment which utilised 
THP-1 cells was only conducted once. The results are consistent with the notion that the 
PI3K/Akt axis is pro-inflammatory in our system.      
We used flow cytometry to assess TNFα-induced adhesion molecule expression in the 
presence of various pharmacological inhibitors – i.e. inhibitors of p38 MAPK, JNK and MEK1 
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(Figures 5.5, 5.6 and 5.7 respectively). The results indicate that BVR has little, if any effect on 
these pathways, positive or negative. However, previous studies have shown that BVR 
activates p38 MAPK, JNK and ERK1/2 (Kapitulnik and Maines, 2009). The results would 
therefore suggest that BVR does not activate these pathways in our system – we would 
expect to observe a decrease in TNFα-induced adhesion molecule expression in the BVR 
overexpressing cells in the presence of inhibitor if this were the case. To a small extent, p38 
does appear to contribute to TNFα-induced E-selectin expression (Figure 5.5). 
 
Cytotoxicity 
Our MTT assays suggest that BVR overexpression does not protect against oxidative stress, 
as elicited by ox-LDL and H2O2 (Figure 5.8, 5.9 and 5.10). This was surprising, especially given 
that we incorporated hemin into the experiment. An effect may have been precipitated if 
we had utilised a different substance to create the oxidative stress. Indeed, a previous study 
demonstrated the importance of BVR in protecting against arsenic-mediated oxidative 
stress (Miralem et al, 2005). However, our results are in agreement with those of Maghzal et 
al. In this study, the authors showed that BVR overexpression in HeLa fails to protect against 
H2O2-mediated cell death (despite the addition of biliverdin or bilirubin), and that BVR 
overexpression does not decrease H2O2-induced ROS levels. Furthermore, BVR knockdown 
in these cells did not increase susceptibility to H2O2-mediated cell death (Maghzal et al, 
2009). 
 
 
157 
 
Nitric Oxide 
We attempted to evaluate the optimal duration of stimulation for NO release in HUVECs, 
and therefore tested three different time-points; 30mins, 60mins and 90mins (Figure 5.12). 
NO release appeared to decrease as the duration of stimulation increased. One might have 
expected the opposite – that NO release would cumulatively increase with duration of 
stimulation. These results may therefore be indicative of some degree of NO degradation, 
and so we decided to employ the 30 mins time-point in future NO release experiments. 
 
NFκB Activation 
NFκB activation is dependent on the degradation of the cytosolic IκBα and hence protein 
levels of IκBα can be assessed in order to determine the extent of NFκB activation. We 
conducted a Western blot for intracellular IκBα levels in the presence/absence of AdBVR, 
TNFα and inhibitors (i.e. SnPP, LY, NAI and RO31), at two different time-points (Figure 5.13). 
This experiment was designed so that the results would be comparable with our other 
endothelial-leukocyte interaction experiments, in terms of time-points. Unfortunately, the 
experiment was only conducted once and the poor quality of the β-actin blot precluded 
quantification.  
In the presence of TNFα alone, BVR overexpression accelerates IκBα degradation at the 6hr 
time-point. This is surprising and would suggest that whilst BVR overexpression reduces 
IκBα degradation at 1hr with TNFα (as might be expected); it increases NFκB activation at 
6hrs. This may involve the BVR/PI3K/Akt/IKK and/or the TNFα/BVR/PKCζ/NFκB pathway. We 
must also remember that IκBα may be resynthesized during the 6hrs stimulation period. 
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Whilst most of the functional assays used a 6hr time-point (i.e. monocyte adhesion assays 
and adhesion molecule expression experiments) we must remember that our MCP-1 ELISA 
was performed over 24hrs – sufficient time to allow for the transcription of any MCP-1 that 
may arise from this additional IκBα degradation in BVR overexpressing cells.    
Interestingly, SnPP appeared to inhibit TNFα-induced IκBα degradation in both CMV and 
AdBVR infected cells. This may suggest that some product of HO-1 accelerates IκBα 
degradation. Consistent with this, CO has been shown to activate NFκB via a 
CO/PI3K/Akt/IKK pathway in hepatocytes (Kim et al, 2008).    
PI3K inhibition appears to substantially reduce TNFα-induced IκBα degradation in both CMV 
and AdBVR infected cells, at both time-points. This would indicate some involvement of the 
PI3K/Akt pathway in TNFα-induced IκBα degradation, possibly via the aforementioned 
PI3K/Akt/IKK pathway. The presence of BVR overexpression (with TNFα + LY) appears to 
slightly increase IκBα levels at both time-points, although the significance of this remains to 
be determined when this experiment is repeated. 
In the presence of RO31, BVR overexpression is still associated with greater TNFα-induced 
IκBα degradation at the 6hr time-point. This would suggest that BVR accelerates TNFα-
induced IκBα degradation independently of the aforementioned TNFα/BVR/PKCζ/NFκB 
pathway. 
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Limitations & Future Studies 
Many of our experiments utilized a BVR overexpression strategy, conferred by AdBVR, and 
sought to differentiate between bilirubin-mediated and kinase-mediated functions, using 
SnPP to inhibit bilirubin generation. However given that the X-ray structure of BVR has been 
solved one could, theoretically at least, develop a variant of AdBVR that is devoid of 
reductase activity. Such a construct would retain its capacity to function as a dual-specificity 
kinase and transcription factor however; the reductase active site would have been mutated 
such that bilirubin cannot be produced. Alternatively, one could mutate the kinase active 
site to produce a BVR mutant which is capable of producing bilirubin but which does not 
have a kinase capacity. Such mutational methodologies are preferable to using SnPP 
because it is more direct and avoids off-target effects associated with pharmacological 
inhibitors. For example, our studies utilised RO-31-8220 (RO31) as an inhibitor of PKCζ. 
However, this inhibitor has been shown to also inhibit Rsk-2 and p70 S6 kinase (Alessi, 1997). 
Overexpression strategies using adenoviruses also have other disadvantages. Whilst such 
experiments potentially provide useful information regarding situations in which BVR 
activity is dramatically increased, it is dubious to extend these findings to physiological 
settings in which BVR activity is not increased. For example, one might argue that whilst 
eNOS activation and NO release are indeed substantially increased with BVR overexpression, 
BVR does not make a significant contribution to eNOS activation and NO release under 
physiological conditions (where BVR levels are extremely low in comparison to those 
achieved with 50MOI of AdBVR). Clearly, such arguments could be addressed by knocking 
down BVR in cells with siRNA and then measuring eNOS activation and NO release. This 
method was recently used in HUVECs to demonstrate the contribution of the low-level 
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expression of BVR to protection against oxidative stress (Jansen et al, 2010). We must also 
remember that it is unlikely that a pharmacological modulator would be developed that 
would be capable of elevating BVR expression levels to those achieved with 50MOI AdBVR. 
In this regard, it may have been preferable to have used an even lower MOI of AdBVR. Also, 
many of our experiments, for reasons of cost and practicality, did not incorporate a no-virus 
control. Ideally, such a control would have been included in every experiment that involved 
an adenovirus. Although we used CMV as a control for AdBVR, it might be argued that Adβ-
Gal would have been more appropriate. This is because whilst CMV controls for viral 
infection, it does not control for the high protein expression associated with AdBVR. 
We ascertained the purity of our endothelial cell preparations (i.e. HUVECs and PAECs) by 
staining for the von Willebrand Factor (vWF). This is a widely used endothelial cell marker 
(for example, Au-Yeung et al, 2004). HUVEC purity was checked by staining for vWF at 
regular intervals and in addition to this, we ensured that the cells displayed the 
characteristic endothelial cobblestone phenotype before utilising these cells in 
experiements. With hindsight, it would have been prudent to have also utilised CD31 IgG 
(anti-PECAM-1) to determine the endothelial cell nature of the cells. If the purity of the 
isolation is not adequate, anti-CD31 magnetic beads can be used. 
Our results suggested that BVR overexpression was associated with PI3K-dependent eNOS 
S1177 phosphoryaltion in HUVECs. Whilst we were unable to demonstrate that BVR 
increases NO release in HUVECs, we showed this to be the case in PAECs. To rule out the 
possibility that BVR overexpression does not induce NO release in HUVECs because the 
enzyme phosphorylates eNOS at Thr495 as well as S1177, it would have been prudent to 
have assessed eNOS Thr495 phosphorylation. As discussed previously, Thr495 
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phosphorylation is inhibitory in terms of NO production. Interestingly, this residue is 
phosphorylated by PKCs (Fleming, 2010). It is therefore tempting to hypothesise that BVR 
indirectly induces eNOS Thr495 phosphorylation via PKCζ activation. It would have also been 
prudent to have utilised L-NNA in our demonstration that BVR increases NO release in 
PAECs, to rule out an iNOS-dependent effect. 
In our preliminary experiments, we showed that BVR overexpression did not result in 
increased intracellular unconjugated bilirubin levels. Ideally, we would have repeated our 
measurements and to then have conducted statistical analyses. With hindsight, it would 
have also been prudent to have included hemin as a substrate for bilirubin production, to 
rule out the possibility that AdBVR is not associated with increased bilirubin levels due to 
lack of substrate. This would have informed our choice about whether to incorporate hemin 
into our LDL oxidation experiments. 
We were unable to conclude precisely how BVR inhibits TNFα-induced leukocyte-
endothelium interactions (i.e. MCP-1 release, adhesion molecule expression and monocyte 
adhesion). To strengthen the reliability of our conclusions, it would have been prudent to 
have repeated our Western blots for IκBα (supplementary results) and to then have 
conducted densitometric and statistical analyses. Furthermore, rather than using the extent 
of IκBα degradation as an indirect measure of NFκB activation, it would have been better to 
have used a more direct method. For example, an NFκB nuclear translocation assay may 
have been performed. This assay compares (inactive) cytosolic and (active) nuclear levels of 
NFκB.  
Whilst we believe that our cell culture experiments provide strong evidence that BVR is in 
fact anti-inflammatory in the endothelium (even independent of its bilirubin generating 
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capacity), it remains to be seen whether these findings will agree with in vivo animal models. 
Indeed, these cell culture studies have led us to generate a ubiquitous BVR overexpressing 
mouse which will be utilised in experiments. To date, there are no published studies which 
have utilised such an animal model. We believe that our BVR overexpressing mouse will 
serve to evolve the in vivo literature surrounding the HO-1/BVR axis from its current focus 
on (administration of) bile pigments to one that also addresses the in vivo significance of the 
non-canonical activities of BVR. In this regard, it would be interesting to administer UGT1A1 
adenovirus to BVR overexpressing ApoE-/- mice and to then examine atherosclerotic lesions. 
The UGT1A1 adenovirus, which is very well established, would serve to conjugate and 
remove serum bilirubin. This would allow us to examine the in vivo effects of BVR, 
independent of its bilirubin generating capacity. 
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Chemical Reagents & Suppliers 
30% (w/v) Acrylamide solution:   National Diagnostics Protogel, UK. 
PVDF:       Millipore, UK. 
Paraformaldehyde:     Sigma, UK. 
Percoll:      Sigma, UK. 
Saran wrap:      Dow, UK. 
2-Thiobarbituric acid (98%):    Sigma, UK. 
Extra thick blot paper:    Bio-Rad, UK. 
NaH2PO4:      BDH, UK. 
NaH2PO4.2H2O:     BDH, UK. 
Na2HPO4:      BDH, UK. 
CuSO4.5H2O:      Sigma, UK. 
Agarose (molecular grade):    Bioline, UK. 
Sodium Citrate:     Sigma, UK. 
Citric Acid:      Sigma, UK. 
NaOH pellets:      Sigma, UK. 
EDTA:       BDH, UK. 
EZ-ECL:      Geneflow, UK. 
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Janus green whole-cell stain:   Thermoscientific, UK. 
LDL:       Sigma, UK and Sunnylab, USA. 
Glacial acetic acid:     Sigma UK. 
Ammonium persulphate:    Sigma, UK. 
Biotin protein ladder:    Cell signaling technology, UK. 
Goat Serum:      Sigma, UK. 
RIPA:       Upstate, UK. 
Glutaraldehyde:     Sigma, UK. 
DMSO:       Sigma, UK. 
M199 medium:     Sigma, UK. 
H2O2 (30%):      Sigma, UK. 
RPMI-1640:      Sigma, UK. 
Gelatin:      Sigma, UK. 
Ham’s F-10:      Sigma, UK. 
Ham’ F-12:      Lonza, UK. 
L-glutamine:      Sigma, UK. 
Ficoll-Paque Plus:     Amersham biosciences, UK. 
Trypan blue:      Sigma, UK. 
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Hydrocortisone:     Sigma, UK. 
Anti-von Willebrand Factor:    Sigma, UK. 
BSA (for ELISAs):     Sigma, UK. 
BSA (for tissue culture):    Melford, UK. 
Glycine:      CN Biosciences, UK. 
Kaleidoscope protein ladder:   Bio-Rad, UK. 
Glycerol:      Sigma, UK. 
Penicillin:      GibcoBRL life technologies, Scotland 
Bromophenol blue:     Sigma, UK. 
Hybond ECL nitrocellulose membrane:  Amersham International, UK. 
Marvel dried skimmed milk:    Sainsbury's, UK. 
Sodium chloride:     Sigma, UK. 
Methanol:      BDH, UK. 
Bio-Rad protein estimation:    Bio-Rad, UK. 
Fetal calf serum:     GibcoBRL life technologies, Scotland. 
Goat serum:      Sigma, UK. 
Phosphate buffered saline tablets (PBS):  Sigma, UK. 
Tris:       CN Biosciences, UK. 
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Streptomycin:      GibcoBRL Life Technologies, Scotland. 
Isopropanol:      Sigma, UK. 
Mayer's Haematoxylin:    Sigma, UK. 
Trypsin-EDTA:      Sigma, UK. 
Sodium nitrite:     Sigma, UK. 
TEMED:      Sigma, UK. 
Collagenase A:     Boehringer Mannheim, UK. 
Phosphatase Inhibitor Cocktail I:   Sigma, UK. 
Phosphatase Inhibitor Cocktail II:   Sigma, UK. 
Protease inhibitor cocktail:    Sigma, UK. 
SDS:       Sigma UK. 
Sodium hydroxide:     Sigma, UK. 
Triton X-100:      Sigma, UK. 
Potassium chloride:     Sigma, UK. 
Proteinase K:      Sigma, UK. 
Ethanol (99.7-100%):     BDH, UK. 
DMSO:       Sigma, UK. 
Kodak, Biomax MR film:    Anachem, UK. 
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Sodium iodide:     Sigma, UK. 
Tween-20:      Sigma, UK. 
β-mercaptoethanol:     Sigma, UK. 
TNFα:       PeproTech, UK 
16% Formaldehyde (methanol-free):  Thermoscientific, UK. 
TMB substrate:     R & D systems, UK. 
HRP conjugate:     R & D systems, UK. 
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Solutions & Buffers 
PBS: 5 PBS tablets into 1L d.H2O – pH 7.4, 10mM 
NaPO4, 2.7mM KCl, 127mM NaCl. 
TBS:  50mM Tris, 150mM NaCl, HCl – pH 7.6.  
RIPA buffer: 50mM Tris HCl pH7.4, 1% IGEPAL, 0.25% Na 
Deoxycholate, 150nM NaCl, 1mM EGTA, 1mM 
PMSF, 1µg/ml Aprotinin, Pepstatin, Leupeptin, 
1mM Na3VO4, 1mM NaF. 
Running buffer:  0.05% Tris, 0.384 M Glycine, 0.1% SDS. 
Sample buffer 4X: 0.04 M Tris, 4 mM EDTA, 4% SDS, 40% Glycerol, 
0.02% Bromophenol Blue. 
Transfer buffer:    190mM Glycine, 25mM Tris, 40% Methanol. 
TTBS:      0.1M Tris, 0.3M NaCl, 0.1% Tween-20 pH 7.5. 
TBARS reagent: 15% Tricholoroacetic acid, 0.09375M 2-
Thiobarbituric acid, 0.25M HCl. 
Antibiotics:  100 g/ml Streptomycin, 100 g/ml Penicillin. 
10% APS:  10% (w/v) in d.H20. 
4% Formaldehyde: 2.75mL 16% formaldehyde (methanol-free), 
8.25mL TBS. 
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Permeabilization buffer: 0.11mL Triton X-100 (10%), 11mL TBS. 
Quenching solution: 0.38mL H2O2 (30%), 11mL TBS. 
Wash buffer: 7.5mL 20X TBS, 141mL ultrapure H2O, 1.5mL 
Tween-20 (10%). 
Blocking buffer: 1mL goat serum, 9mL wash buffer.  
 
Constituent 
SDS-PAG Type 
Stacking (5%) Resolving (10%) 
d.H2O 5.6mL 11.9mL 
30% Acrylamide Solution 1.7mL 10mL 
1.5M Tris 2.5mL 7.5mL 
10% SDS 0.1mL 0.3mL 
10% APS 0.1mL 0.3mL 
TEMED 10µL 30µL 
 
 
 
 
 
 
Table 3.1 Composition of a 10% SDS-PAG for Western blotting.  
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